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3Just over a decade ago, Europe’s capacity for 
monitoring its drug problem was extremely limited. 
National approaches to the topic varied greatly and 
although some European countries had conducted 
population surveys on drug use, it was impossible to 
talk with confidence about patterns and trends in drug 
use across the EU. When the European Monitoring 
Centre for Drugs and Drug Addiction (EMCDDA) 
became operational in 1995, it built on the earlier 
pioneering work at national level and launched several 
consecutive projects to develop common European 
guidelines, while allowing flexibility for implementation 
at national level. A European expert group was 
created and it continues to meet regularly.
Now the EMCDDA is the hub of drug-related 
information in the European Union and it is widely 
acknowledged that some form of general population 
survey is necessary to develop national drug strategies. 
At present, almost all Member States have conducted 
recent surveys on drug use and in most countries they 
are being repeated on a regular basis, to track 
changes in levels and patterns of drug use and in the 
characteristics of users. This has been a remarkable 
achievement as population surveys are neither cheap 
nor easy to organise. We are aware that despite the 
considerable progress achieved, comparability across 
Member States is still far from perfect and that major 
conclusions cannot be drawn from small differences in 
prevalence. But, increasingly, observed trends and 
patterns of drug use show consistency within and 
between countries.
This report is of considerable value to highlight 
remaining differences in instruments, reporting formats 
and methodologies. And together with the authors, we 
hope the updated and extended overview presented 
here is a great leap forward in the work and progress 
to facilitate the comparison of survey practices in EU 
countries.
I would like to take this opportunity to thank all the 
governmental and non-governmental partners in 
Belgium that contributed to the funding, collection and 
preparation of this important work, as well as the 
experts from different Member States who collaborated 
with the research team.
Wolfgang Götz 
Director, EMCDDA
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9In 2001, the European Monitoring Centre for Drugs 
and Drug Addiction (EMCDDA) produced an overview 
of the general features and sampling and interviewing 
methods of 13 drug use surveys. This report presents 
an updated and more extensive meta-analysis of recent 
general population surveys in European Union Member 
States. The analysis presented here was part of a 
larger feasibility study of a repetitive drug survey 
among the general population in Belgium. This study 
was commissioned and financed by the Belgian 
Federal Science Policy, within the framework of the 
‘Research programme in support of the federal drugs 
policy document’ (see http://www.belspo.be/belspo/
fedra/prog.asp?l=en&COD=DR), a research 
programme since 2002 in response to drug problems, 
and closely linked to drug policies of public authorities. 
Although Belgium puts in a great effort to gain insight 
into the epidemiologic situation concerning drug use 
(e.g. among the school-going youth), Belgium has no 
extended research tradition. So far, the prevalence of 
drug use within the Belgian general population has 
never been studied systematically. The general aim of 
this research was to study the feasibility of a recurrent 
alcohol and drug survey among the general 
population. The research covers a detailed comparison 
of methods and designs, used in prevalence studies in 
other European countries, and the evaluation of the 
strengths, the restrictions, the preconditions and the 
costs of former studies, and includes a limited cognitive 
test of the included items with a view to the 
implementation of such study in Belgium, taking into 
account the general cultural and social practices and 
specific implications and limitations. The Belgian study 
was carried out by two research groups: the Institute 
for Social Drug Research (ISD), Ghent University, and 
the Research Centre for Longitudinal and Life Course 
Studies (CELLO), the University of Antwerp and 
performed in cooperation with the EMCDDA and key 
experts from 30 European Union Member States. 
The meta-analysis presented in this report can be seen 
as a follow-up on the previous overview produced in 
2001 by the European Monitoring Centre for Drugs 
and Drug Addiction (EMCDDA). However, the present 
report is wider in scope, now including intrinsic and 
methodological discussions and a description of 
financial sources, timetables and accessibility of the 
fieldwork and data documentation of 25 population 
surveys on drug use in Europe.
Beyond providing a useful instrument to compare 
survey practices in EU Member States, this overview is 
intended to be a reference tool for everyone planning, 
organising or executing a survey about drug use 
among the general population. The overview is a 
compilation of the intrinsic, methodological and 
financial aspects of population surveys in Europe, and 
the ways their results are disseminated. We hope this 
report is a valuable instrument to those making (policy) 
decisions; the work presented here may help them to 
clearly understand the costs and the benefits of the 
options available.
This overview is a collective endeavour and we thank 
all those who have contributed to it.
Professor Dr Tom Decorte
Professor Dr Dimitri Mortelmans
Julie Tieberghien
Sabine De Moor
Foreword
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Today, the European Union comprises 27 countries: 
Austria, Belgium, Bulgaria, Cyprus, the Czech 
Republic, Denmark, Estonia, Finland, France, Germany, 
Greece, Hungary, Ireland, Italy, Latvia, Lithuania, 
Luxembourg, Malta, the Netherlands, Poland, Portugal, 
Romania, Slovakia, Slovenia, Spain, Sweden and the 
United Kingdom (1). In many of these European 
countries one or more general population surveys have 
been carried out to get a notion of the characteristics 
of illicit drug use at the national level.
In 2001, the European Monitoring Centre for Drugs 
and Drug Addiction (EMCDDA) produced an overview 
of the general features and sampling and interviewing 
methods of 13 drug use surveys (EMCDDA, 2002; 
EMCDDA, 1997). It examined the general population 
surveys that had been conducted in France, Finland, 
Germany, Greece, the Netherlands, Ireland, Spain, the 
United Kingdom, the United States, and four Nordic 
countries (Denmark, Norway, Sweden and Finland). 
These countries were selected for practical reasons, i.e. 
availability and language accessibility to the 
researchers.
The present study provides an overview of the general 
population surveys on drug use in Europe. It focuses on 
the most recent surveys, i.e. surveys conducted since 
2001. An effort has been made to complete and 
update the 2001 EMCDDA overview, to make a 
detailed comparison of methods and designs used in 
prevalence studies in European countries, and to 
evaluate their strengths, restrictions and compliance 
with the European Model Questionnaire (EMQ). We 
are aware that some national population surveys on 
drug use have not been included, in particular those 
that have been published in native languages only 
and/or that have not been made public. Furthermore, 
some European countries have not yet developed or 
planned a general population survey on drug use.
We would like to emphasise that the 2001 EMCDDA 
overview only included the 1998 and 1999 population 
surveys in Ireland/Northern Ireland. They are omnibus 
surveys (2) and therefore not comparable with the 
results of the national population surveys on drug use 
in 2002/3 and 2006/7. So we decided to exclude 
both surveys from the updated overview. Furthermore, 
as questions about drug use have been included in the 
Belgian Health Interview Survey since 2001, the 1997 
Health Interview Survey is not incorporated in the 
overview. In Finland, population surveys focusing on 
drug use and drug attitudes (1998, 2002, 2006) have 
alternated with surveys focusing on alcohol use and 
drinking habits (2000–04). Although the surveys 
focusing on alcohol use have included some questions 
on drug use, this overview only incorporates the Finnish 
population surveys on drug use and drug attitudes.
This document discusses the intrinsic, methodological-
technical and financial components as well as 
valorisation aspects and presents them in table format 
to provide a convenient overview (EMCDDA, 2002). In 
these tables ‘year’ refers to the year in which the 
survey was conducted and ‘country’ to the country that 
is being surveyed. We have not included any local or 
regional studies. Some surveys lacked the relevant 
data; this is indicated by ‘n.a.’ (not available) in the 
table. We have indicated the data of the 2001 
EMCDDA overview in grey.
This overview of general population surveys in Europe 
is part of a feasibility study of a repetitive survey 
among the general population in Belgium (3). It 
includes a detailed comparison of methods and 
designs used in prevalence studies in European 
countries as well as evaluating the strengths, 
restrictions, preconditions and costs of former studies. It 
also contains a limited cognitive test of the included 
items with a view to implementing such a study in 
Belgium, taking into account the general cultural and 
social practices. The feasibility study was carried out 
between 1 October 2007 and 30 November 2008.
The feasibility study was commissioned and financed 
by the Belgian Science Policy Office (4) and carried out 
by the Institute for Social Drug Research (5) (Prof. Dr 
Introduction
(1)  http://europa.eu/abc/european_countries/index_en.htm
(2)  A general omnibus survey is a multi-purpose survey. The Northern Ireland Omnibus Survey provides a snapshot of the behaviour, lifestyle 
and views of a representative sample of the people of Northern Ireland.
(3)  For further information about the research project, see the website http://www.belspo.be/belspo/fedra/proj.asp?l=en&COD=DR/35
(4)  Belgian Federal Science Policy Office, Wetenschapsstraat 8, 1000 Brussels, Belgium, tel. +32 (0)22383411, website: http://www.
belspo.be/belspo/home/port_en.stm
(5)  Institute for Social Drug Research (ISD), Universiteitstraat 4, 9000 Ghent, Belgium, e-mail: Tom.Decorte@UGent.be, tel. + 32 
(0)92646962, website: http://www.law.ugent.be/crim/ISD/masternl.html
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Mravcik (the Czech Republic), Mr Ola Ekholm 
(Denmark), Mr Niels Rasmussen (Denmark), Mr Pekka 
Hakkarainen (Finland), Mrs Leena Metso (Finland), Mrs 
Sanna Rönkä (Finland), Mr Francois Beck (France), Mr 
Stephane Legleye (France), Mr Ludwig Kraus (Germany), 
Mrs Manina Terzidou (Greece), Mrs Borbala Paksi 
(Hungary), Mr Zsolt Demetrovics (Hungary), Mr Nadas 
Eszter (Hungary), Mrs Jean Long (Ireland), Mrs Sabrina 
Molinaro (Italy), Mr Marcis Trapencieris (Latvia), Mr 
Vyautas Gasperas (Lithuania), Mr Ernestas Jasaitis 
(Lithuania), Mrs Pascale Straus (Luxembourg), Mr Alain 
Origer (Luxembourg), Mrs Gerda Rodenburg (the 
Netherlands), Mr Gert-Jan Meerkerk (the Netherlands), 
Mr Sturla Nordlund (Norway), Mr Casimiro Balsa 
(Portugal), Mrs Ruxanda Iliescu (Romania), Mr Jan Luha 
(Slovakia), Mrs Eleonora Kastelova (Slovakia), Mr 
Marko Cerar (Slovenia), Mrs Mercedes Lovrecic 
(Slovenia), Mr Gregorio Barrio (Spain), Mr Borje Olsson 
(Sweden), Mr Björn Hibell (Sweden), Mrs Anna Bessö 
(Sweden), Mrs Cecilia Wadman (Sweden), Mr Mustafa 
Pinarci (Turkey), Mr Bülent Özcan (Turkey), Mrs Nicola 
Singleton (United Kingdom), as well as Mr Julian Vicente 
(EMCDDA) and Mrs Deborah Olszewski (EMCDDA) 
who contributed to discussions on how population 
surveys can be improved.
Professor Dr Tom Decorte
Professor Dr Dimitri Mortelmans
Julie Tieberghien
Sabine De Moor
Tom Decorte, Ghent University) and the Research 
Centre for Longitudinal and Life Course Studies (6) 
(Prof. Dr Dimitri Mortelmans, University of Antwerp).
The authors wish to thank the members of the Advisory 
Committee for their thoughtful input and support: Mrs 
Lieve Van Daele and Mrs Karin Hannes (Belgian Federal 
Science Policy), Dr Marc Roelands (Scientific Institute for 
Public Health), Em. Prof. Dr Jaak Billiet (K.U. Leuven, 
— Katholieke Universiteit Leuven, Faculty of Social 
Science), Mr Ruud Bless (Quinx Research), Mrs Else De 
Donder (Association for Alcohol and other Drug 
Problems), Mrs Sylvie Gerard (Federal Public Service 
Health, Food Chain Safety and Environment), Prof. Dr 
Dan Kaminski (UCL — Université Catholique de Louvain, 
Unité de recherche en criminologie), Mr Patrick 
Lambrecht (Vrije Universiteit Brussel, Dept. of 
Developmental and Life Span Psychology), Prof. Dr A. 
Lemaître (Université de Liège), Prof. Dr René Patesson 
(ULB — Université Libre de Bruxelles), Mrs Diane 
Reynders (Federal Public Service Justice), Mr Mark 
Vanderveken (Concertation Toxicomanies Bruxelles), Mrs 
Joke Rutten (Federal Public Service Justice) and Mr Peter 
Piccu — Van Speybrouck (Federal Public Service Justice).
The authors also thank all national experts who kindly 
agreed to share their experiences and concerns: Mr 
Martin Bush (Austria), Mrs Sabine Haas (Austria), Mrs 
Meropi Tzanetakis (Austria), Mrs Lidija Vugrinec 
(Croatia), Mr Hvrojka Lausic (Croatia), Mr Neoklis 
Georgiades (Cyprus), Mrs Ioanna Yiasemi (Cyprus), Mrs 
Pavla Chomynova (the Czech Republic), Mr Viktor 
(6)  Research Centre for Longitudinal and Life Course Studies (CELLO), Sint Jacobstraat 2, 2000 Antwerp, Belgium, e-mail: Dimitri.
Mortelmans@ua.ac.be, tel: +32 (0)32755535, website: http://webh01.ua.ac.be/cello/index.php?pg=2
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For a meta-analysis of the existing national prevalence 
studies in Europe, an e-mail survey was conducted 
among international experts who were responsible for 
national surveys on drug use in Europe. An e-mail 
survey (with an attached questionnaire) was chosen as 
the interviewing method because it is a fast, easy and 
inexpensive way to collect data, especially when the 
respondents are located across Europe (De Winne et 
al., 2003). The experts’ opinions and experiences on 
the content and the methodology of the respective 
national prevalence studies were taken into 
consideration. Special attention was given to the 
legitimation of the choices made as well as to (reasons 
for) any deviations from European guidelines. Also, the 
impact of a country’s social, cultural and political 
practices on the design of the study, and the specific 
implications and limitations of the national context 
were inquired into. Finally, the expert survey also dealt 
with the comparability and the valorisation of the data.
The first contact with all national experts and national 
focal points (Austria, Bulgaria, Cyprus, Croatia, the 
Czech Republic, Denmark, Estonia, Finland, France, 
Germany, Greece, Hungary, Ireland, Italy, Latvia, 
Lithuania, Luxembourg, Malta, the Netherlands, 
Norway, Portugal, Romania, Slovakia, Slovenia, Spain, 
Sweden, Turkey and the United Kingdom (Scotland, 
England and Wales)) was established in November/
December 2007. The European Monitoring Centre for 
Drugs and Drug Addiction provided the contact details 
of each expert. After explaining the aim of our 
research project, we kindly asked the experts and focal 
points to send us, if available, the reports of their 
national population surveys on drug use. At the same 
time, we announced that we would conduct an e-mail 
survey in April 2008.
Following an analysis of the EMCDDA’s survey reports 
and/or national abstracts, we contacted all experts 
and focal points a second time in April 2008. All 
experts responsible for national population surveys in 
the European Union were invited to complete a 
detailed country-specific questionnaire on their national 
general population survey on drug use. Also, the three 
countries that had not yet conducted a national 
population survey (Luxembourg, Croatia and Slovenia) 
were invited to complete a short questionnaire on their 
(concrete) plans to conduct a survey. The questionnaire 
was developed in close cooperation with the EMCDDA 
and was aimed at gaining insight into the experiences 
and know-how of the national experts, and at updating 
the overview of general populations surveys produced 
by the EMCDDA (EMCDDA, 2002). 
The questionnaire consisted of four parts. An example 
of the questionnaire is available on the EMCDDA 
website (7). Some general questions were followed by 
detailed questions about intrinsic (A.) and 
methodological aspects (B.) in order to complete the 
EMCDDA overview (2001). The questionnaire ended 
with some questions about financial (C.) and 
valorisation aspects (D.). It could be completed in an 
electronic or in a printed version. We asked the 
experts to return the questionnaire by e-mail, postal 
service or fax before 19 May 2008 at the latest. 
Shortly before the deadline, we sent a reminder to 
those who had not yet responded.
Experts from 18 countries among the 30 countries we 
approached completed the questionnaire. One country 
(Portugal) mentioned that they had had no time to 
complete the questionnaire and they sent us some 
additional information (e.g. original questionnaire, 
national abstracts). Two countries (Turkey, Luxembourg) 
that had not yet conducted a population survey on 
drug use, informed us that they had no concrete plans 
to do so, and that they were thus unable to complete 
the questionnaire. Croatia stated that it had concrete 
plans and completed the short questionnaire. Finally, 
even though we had approached each expert at the 
expert meeting in June 2008, eight countries did not 
reply to our request (EMCDDA, 2008a). 
Chapter 1
Expert survey
(7) http://www.emcdda.europa.eu
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After analysing the completed expert questionnaires, 
some (methodological or intrinsic) issues remained 
unclear. All 18 experts who were cooperating were 
contacted again (July 2008) and asked a few 
additional questions. Eleven countries responded to this 
additional request.
Table 1: Overview expert survey
Response N(= 30) Country
Completed 18 Austria, Croatia, Cyprus, the Czech Republic, Denmark, England and Wales, 
Finland, France, Hungary, Ireland, Italy, Lithuania, the Netherlands, Norway, 
Romania, Slovakia, Spain, Sweden
Not completed 8 Bulgaria, Estonia, Germany, Greece, Latvia, Malta, Poland, Scotland
No time 1 Portugal
No concrete plans to conduct a 
population survey
3 Luxembourg (2009), Slovenia (?), Turkey (2009)
NB: Countries in bold also completed the additional expert survey.
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Netherlands, Norway, Poland, Portugal, Romania and 
Spain. Others incorporate questions about drug use in 
a health survey: the Czech Republic, Denmark, 
France, Greece and Sweden. Only Scotland and 
England and Wales insert questions about drug use in 
a crime and victimisation survey. As a matter of fact, 
the context influences the specifications of the aims 
and objectives that the commissioners of the survey 
want to pursue. In most cases, general population 
surveys on drug use (and tobacco or alcohol 
consumption) aim to measure prevalence rates of drug 
use, to assess beliefs and attitudes towards drugs and 
drug users, and to evaluate the efficiency of drug 
policies (Table 2). Drug-related questions are usually 
included in a health survey in order to monitor 
perceptions concerning health and health risks, as the 
consumption of alcohol, tobacco or illicit drugs is 
regarded as risky behaviour. In addition, both crime 
surveys consider illicit drug use to be a crime-related 
topic and consequently ask about the respondents’ 
exposure to illicit drugs as victims of crime in a crime 
context. The context is discussed in more detail in the 
section on methodological focus.
This section provides an overview of the items and 
questions in the national questionnaires. Not 
surprisingly, there is wide variation in the number of 
questions and items among the countries. From surveys 
where the questions on drug use are part of a survey 
with a wider scope (e.g. health survey, crime survey), 
only the questions on drug use are analysed. The items 
and the questions are grouped around the same 
themes as in the 2001 EMCDDA overview: prevalence 
of drug use, prevalence measurements, frequency of 
drug use, quantity of drug use, other items related to 
illicit drugs, respondents’ attributes, environment, 
attitudes and opinions and lifestyle. First, the objectives 
of each general population survey are explained.
2.1 Objectives
Most countries have established national surveys that 
focus on illicit drug use, mostly in combination with the 
use of other drugs (e.g. alcohol and tobacco): Austria, 
Bulgaria, Cyprus, Germany, Hungary, Ireland/
Northern Ireland, Italy, Latvia, Lithuania, Malta, the 
Chapter 2
Intrinsic focus
Table 2: Survey objectives
Country Context Objective(s)
Austria (il)licit drug use • To measure prevalence rates of (il)licit drug use among the general population
•  To provide information about the relationship between the consumption of  
(il)licit drugs and opinions or lifestyles
• To gather information about gender-related aspects of alcohol consumption
Belgium health •  To identify health problems, health consumption and its determinants, and 
possible trends in the health status and health needs of the population
•  To analyse the prevalence and distribution of health indicators, and the social 
(in)equality in health and access to health services
Bulgaria (il)licit drug use n.a.
Croatia health • To estimate prevalence and continuation rates of (il)legal drug use
• To conduct a cross-country assessment of the general patterns of use
•  To assess relationships between particular population attributes and illicit drug 
use
Drug use: an overview of general population surveys in Europe
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Country Context Objective(s)
Cyprus (il)licit drug use • To measure the prevalence of (il)licit drug use among the general population
• To assess beliefs and attitudes towards drugs and drug users
•  To assess the relationship between particular population attributes and drug 
use
Czech Republic drugs/health •  To assess the extent and patterns of (il)licit drug use among the general 
population
• To describe the risk areas related to (il)licit drug use
• To evaluate the drug policy and to formulate effective strategies
Denmark health •  To describe the status and trends in health and the factors that influence health 
status
• To improve prevention programmes
• To investigate attitudes towards specific drug issues
England and 
Wales
crime and 
victimisation
•  To gather information about the experiences of property and personal crimes 
and about a range of other crime-related topics (e.g. exposure to illicit drugs)
•  To provide information to inform crime reduction measures and to gauge their 
effectiveness.
Estonia health n.a.
Finland (il)licit drug use • To monitor prevalence rates of (il)licit drug use
• To assess trends in (il)licit drug use and in attitudes towards drugs
France health •  To monitor behaviour, attitudes and perceptions concerning health and health 
risks 
•  To evaluate policy decisions with an eye to developing an evidence-based 
prevention policy 
Germany (il)licit drug use •  To observe trends in prevalence rates of (il)licit drug use, abuse and 
dependence
• To analyse changes in consumption patterns over time
Greece health n.a.
Hungary (il)licit drug use • To explore the extent of (il)licit drug use among the general population
• To describe trends in (il)licit drug use
• To explore the factors that have an impact on problem drug use
Ireland/
Northern 
Ireland
(il)licit drug use •  To make cross-regional comparisons on the prevalence of (il)licit drug use in the 
general population. 
•  To clearly identify the extent and nature of (il)licit drug use amongst the general 
population, specifically identifying trends amongst different segments of the 
population
Italy (il)licit drug use • To measure prevalence rates of (il)licit drug use
• To monitor risk perceptions and opinions about (il)licit drug use
Latvia (il)licit drug use •  To evaluate the drug policy and to identify a more effective approach and new 
priorities.
•  To tackle the social problems caused by (il)licit drug use and drug addiction, 
and to re-examine and redirect Latvian policies to combat illicit drug use
Lithuania (il)licit drug use • To collect and assess standardised data on (il)licit drug use 
•  To estimate the relationship between particular population attributes and (il)licit 
drug use
Malta (il)licit drug use • To monitor the drug problem from a more general perspective 
• To analyse trends over time, by regularly conducting such surveys
Netherlands (il)licit drug use •  To measure prevalence, incidence and continuation rates of (il)licit drug use 
among the national population, differentiated by age, gender and urbanisation
• To detect trends over time
Norway (il)licit drug use n.a.
Poland alcohol n.a.
Table 2 continued
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additional drugs, because other national surveys (e.g. 
health surveys, school surveys) or other national data 
(e.g. treatment and mortality statistics) show high 
prevalence rates of these drugs. Another reason to 
include additional drugs is to improve the comparability 
with, for instance, the ESPAD studies or the HBSC 
studies. These countries aim at comparing drug use 
among the general population with that among the 
youth population. In this respect, many countries (e.g. 
Austria, Scotland, Denmark, Latvia, Lithuania, Romania, 
Hungary, England and Wales, Ireland, Italy, France, 
Spain, Germany, the Czech Republic) investigate the use 
of magic mushrooms, crack, anabolic steroids (8) or 
solvents/inhalants. For the same reasons, methadone 
and/or poppers are included in both crime surveys 
(British Crime Survey and Scottish Crime and 
Victimisation Survey), the French Health survey and the 
Irish population survey on drug use. Furthermore, both 
crime surveys also include ketamine, as the expert 
survey shows that its use is becoming increasingly 
common in the club scene. For the same reason, the 
British expert intends to include methamphetamines in 
the next survey (9). Methamphetamines are already 
included in the Czech survey, because the Czech  
ESPAD study shows that in the Czech Republic use of 
this drug is more problematic than that of 
amphetamines. The most recent Finnish survey also 
assesses the use of GHB and methadone. The former 
was included because newspapers had reported on the 
use of GHB at some festivals, and as other research had 
2.2 Prevalence of drug use
2.2.1 Illicit drugs
Most countries want to include all psychoactive drugs 
that are known to be used, in order to obtain a good 
estimate of any drug use (Table 3). It is recognised, 
however, that these estimates actually underestimate 
the use of some drugs in the population as a whole 
(UNODC, 2002a).
The number of illicit drugs surveyed varies from 6 to 
16, except for the Swedish survey, which includes only 
cannabis. The Swedish expert admits that the inclusion 
of only one illicit drug makes cross-national 
comparability difficult (EMCDDA, 2008b). The other 
European questionnaires distinguish cannabis from 
other illicit drugs. The term ‘cannabis’ mostly refers to 
hashish and/or marihuana. Other illicit drugs are 
mainly ecstasy, cocaine, heroin, amphetamines and 
LSD. While the European Model Questionnaire 
considers those six drugs as a common minimum set, 
the WHO guidelines also include volatile inhalants and 
opium. The ESPAD studies cover crack, GHB, 
methadone, magic mushrooms, injected drugs and 
steroids. 
Some countries (e.g. Cyprus, Malta, Greece, Croatia) 
follow the European Model Questionnaire and select 
only cannabis, ecstasy, cocaine, heroin, amphetamines 
and LSD. However, many countries include one or more 
Table 2 continued
Country Context Objective(s)
Portugal (il)licit drug use n.a.
Romania (il)licit drug use • To remedy the lack of programmes/strategies concerning drugs
• To monitor prevalence rates of (il)licit drug use among the general population
• To detect trends in drug abuse and to evaluate the efficiency of drug policies 
Scotland crime and 
victimisation
•  To gather information about public perceptions and experiences as victims of 
crime
• To monitor the knowledge and the use of a range of legal and illegal drugs
Slovakia alcohol and tobacco • To monitor opinions on drug addiction danger, drug users, and policies 
•  To measure prevalence rates of (il)licit drug use, the availability of drugs and 
risk perceptions
Spain (il)licit drug use • To gather information about (trends in) the prevalence rates of (il)licit drug use 
• To monitor (trends in) risk perceptions
• To monitor trends of perceived availability of (il)licit drug use
• To identify determining factors of (il)licit drug use
Sweden health • To monitor (trends in) the health status among the general population
(8)  The Dutch survey includes the ‘performance enhancing drugs’ category as this illicit drug was included in the assignment by the Ministry. 
‘Performance enhancing drugs’ refer to anabolic steroids, EPO, growth hormones, etc.
(9)  The Scottish Crime Survey includes methamphetamines for the same reason as for ketamine.
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use of the bogus drug. In this respect, concerns have 
been expressed that the name of the dummy drug may 
have become too familiar. It is also put forward that 
false claims of use are less likely in general population 
surveys than in school surveys. Some countries (France, 
Norway, Ireland) have therefore decided to remove the 
dummy drug altogether. Other countries (e.g. the 
Netherlands, Romania, Spain, Latvia) did not include a 
dummy drug at all. According to the Dutch expert, data 
on the use of a dummy drug do not provide unequivocal 
cues for interpreting other data.
In most surveys (e.g. Malta, Ireland, Finland, Portugal, 
England and Wales), each drug is accompanied by 
synonyms to describe the drugs better, because a 
respondent may only know an illicit drug by one of its 
street names. As street names may be quite different in 
the cultural setting of different countries, no names or 
descriptions of drugs are included in the EMQ, the 
WHO guidelines, or the ESPAD study. It is appropriate 
to determine a list of street or slang names for various 
drugs in each country separately (UNODC, 2002b). 
Finally, the 2006/7 Irish population survey on drug 
use made a distinction between different forms of 
cannabis: grass, weed, skunk, hash oil, herb, hash, 
resin and other. Also, the British Crime Survey wants to 
collect more information on the types of cannabis, as 
there has been considerable concern that the 
increasing use of UK-grown and higher strength ‘skunk’ 
may be linked to increased health risks. Although it is 
not known how extensive its use has become, nor 
whether it is being used differently, further knowledge 
of the phenomenon is of policy importance.
reported an increase of the misuse of methadone, 
policymakers also wanted to measure the prevalence of 
methadone use. 
In some countries (e.g. France, Ireland, Finland, 
Lithuania, Norway, Portugal) an open-ended question 
is added to establish whether the respondent has used 
a drug that is not on the list. Questions such as ‘Have 
you taken any other illegal or illicit drug(s) not 
mentioned in this study?’ and ‘What is the name of the 
drug(s) that you took?’ may help to detect new drugs 
or new wordings for common drugs. However, the Irish 
expert perceives the inclusion of an open-ended 
question as less useful, as he states that these data 
were never used anyway. 
The EMQ and the ESPAD questionnaires include a 
dummy drug (Relevin) to control the reliability of the 
responses. Some surveys include a dummy drug, such 
as Relevin (e.g. Cyprus, Finland, Malta, Hungary, 
Austria, Portugal), Semeron (e.g. England and Wales, 
Scotland), Mop (e.g. France), Nubain (e.g. Ireland), or 
Cinnamon (e.g. Norway). Most countries use the name 
‘Relevin’, as this bogus drug is included in the EMQ. The 
2000 French survey preferred the name Mop because, 
according to the expert, ‘Relevin’ sounded too much like 
a pharmaceutical in French. In both crime surveys, 
‘Semeron’ was preferred as the name had to be realistic 
but not too closely resembling any actual drug name. 
Although some experts (e.g. Cyprus, Austria, Finland, 
Hungary) are of the opinion that the inclusion of a 
dummy drug may be useful as an indicator of reliability 
(it may reveal errors and identify respondents who have 
not answered properly), most highlight the difficulty in 
analysing the low number of respondents who report the 
Table 3: Prevalence of illicit drug use
Country Year
Illicit drugs
Cannabis Ecstasy Cocaine Heroin Amphetamines LSD Other Dummy
Austria 2004 Yes Yes Yes Yes Yes Yes Yes Yes
Belgium 2001 Yes Yes No No Yes No No No
2004 Yes No No No No No No No
2008 Yes Yes Yes Yes Yes Yes Yes No
Bulgaria 2005 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Croatia 2009 
(expected)
Yes Yes Yes Yes Yes Yes No No
Cyprus 2006 Yes Yes Yes Yes Yes Yes Yes Yes
Czech Republic 2004 Yes Yes Yes Yes Yes Yes Yes No
Denmark 2000 Yes Yes Yes Yes Yes Yes Yes No
2005 Yes Yes Yes Yes Yes Yes Yes No
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Country Year
Illicit drugs
Cannabis Ecstasy Cocaine Heroin Amphetamines LSD Other Dummy
2008 Yes Yes Yes Yes Yes Yes Yes No
England and 1996 Yes Yes Yes Yes Yes Yes Yes Yes
Wales 1998 Yes Yes Yes Yes Yes Yes Yes Yes
2000 Yes Yes Yes Yes Yes Yes Yes Yes
2001/2 Yes Yes Yes Yes Yes Yes Yes Yes
2002/3 Yes Yes Yes Yes Yes Yes Yes Yes
2003/4 Yes Yes Yes Yes Yes Yes Yes Yes
2004/5 Yes Yes Yes Yes Yes Yes Yes Yes
2005/6 Yes Yes Yes Yes Yes Yes Yes Yes
2006/7 Yes Yes Yes Yes Yes Yes Yes Yes
Estonia 2003 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Finland 1992 Yes No Yes No Yes Yes Yes Yes
1996 Yes Yes Yes No Yes Yes Yes Yes
1998 Yes Yes Yes No Yes Yes Yes Yes
2002 Yes Yes Yes No Yes Yes Yes Yes
2006 Yes Yes Yes Yes Yes Yes Yes Yes
France 1995 Yes No Yes Yes Yes Yes Yes Yes
2000 Yes Yes Yes Yes Yes Yes Yes Yes
2005 Yes Yes Yes Yes Yes Yes Yes No
Germany 1995 Yes Yes Yes Yes Yes Yes Yes n.a.
1997 Yes Yes Yes Yes Yes Yes Yes n.a.
2000 Yes Yes Yes Yes Yes Yes Yes n.a.
2003 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Greece 1998 Yes Yes Yes Yes Yes Yes No n.a.
2004 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Hungary 2001 Yes Yes Yes Yes Yes Yes Yes Yes
2003 Yes Yes Yes Yes Yes Yes Yes Yes
Ireland 2002/3 Yes Yes Yes Yes Yes Yes Yes Yes
2006/7 Yes Yes Yes Yes Yes Yes Yes No
Italy 2001 Yes Yes Yes Yes Yes Yes Yes No
2003 Yes Yes Yes Yes Yes Yes Yes No
2005 Yes Yes Yes Yes Yes Yes Yes No
Latvia 2003 Yes Yes Yes Yes Yes Yes Yes No
Lithuania 2004 Yes Yes Yes Yes Yes Yes Yes No
Malta 2001 Yes Yes Yes Yes Yes Yes Yes Yes
Netherlands 1997 Yes Yes Yes Yes Yes Yes Yes No
2001 Yes Yes Yes Yes Yes Yes Yes No
2005 Yes Yes Yes Yes Yes Yes Yes No
Norway 2004 Yes Yes Yes Yes Yes Yes Yes Yes
Poland 2002 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Portugal 2001 Yes Yes Yes Yes Yes Yes Yes Yes
Romania 2004 Yes Yes Yes Yes Yes Yes Yes No
Scotland 2000 Yes Yes Yes Yes Yes Yes Yes Yes
2003 Yes Yes Yes Yes Yes Yes Yes Yes
2004 Yes Yes Yes Yes Yes Yes Yes Yes
Table 3 continued
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Country Year
Illicit drugs
Cannabis Ecstasy Cocaine Heroin Amphetamines LSD Other Dummy
2006 Yes Yes Yes Yes Yes Yes Yes Yes
Slovakia 2002 Yes Yes Yes Yes Yes Yes Yes No
2004 Yes Yes Yes Yes Yes Yes Yes No
2006 Yes Yes Yes Yes Yes Yes Yes No
Spain 1995 Yes Yes Yes Yes Yes Yes Yes No
1997 Yes Yes Yes Yes Yes Yes Yes No
1999 Yes Yes Yes Yes Yes Yes Yes No
2001 Yes Yes Yes Yes Yes Yes Yes No
2003 Yes Yes Yes Yes Yes Yes Yes No
2005 Yes Yes Yes Yes Yes Yes Yes No
Sweden 2004 Yes No No No No No No No
2005 Yes No No No No No No No
2006 Yes No No No No No No No
NB: 
Adapted from the EMCDDA Handbook, p. 132 (EMCDDA, 2002).  
Data from the 2001 EMCDDA overview is indicated in grey. 
n.a.: not known/not available.
Table 3 continued
2.2.2 Licit drugs
Virtually all questionnaires include questions about 
alcohol, tobacco and pharmaceuticals (licit drugs) 
(Table 4). Most experts (e.g. Croatia, Cyprus, Finland, 
France, Lithuania, the Netherlands, Slovakia) agree that 
the inclusion of questions about licit drug use in a survey 
on (illicit) drug use is necessary because of the 
interaction between licit and illicit drug use. Questions 
about licit drug use may also serve as ‘warming up 
questions’ for questions about illicit drug use. However, 
whether questions about licit drug use are included 
depends on the survey’s objectives. Most surveys aim to 
obtain comparable and reliable information on the 
extent and patterns of the consumption of (il)licit drugs in 
the general population. Therefore, most population 
surveys on drug use and health surveys include tobacco 
as well as pharmaceuticals and alcohol. 
Both crime surveys (England and Wales, and 
Scotland) do not include questions about licit drugs. 
Although both measure the prevalence of the use of 
pharmaceuticals, questions about tobacco 
consumption are not included. Alcohol use is only 
inquired about in the British Crime Survey. These 
surveys do not (or to a lesser extent) include licit drug 
use because it is covered by several other continuous 
national surveys (e.g. General Household Survey), 
and because of lack of space. The same is true for 
the 2008 Danish drug survey.
Some countries make a distinction between different 
forms of tobacco consumption (pipe, cigarettes, cigars, 
etc.) and between different kinds of alcoholic drinks 
(beer, wine, cider, etc.). In the French and Danish Health 
surveys and the surveys in Norway, Portugal, Slovakia, 
Malta and the Netherlands, different forms of both 
tobacco and alcohol are considered. It is implied that 
many policy questions are related to various forms of 
alcohol or tobacco (e.g. ‘Has the use of snuff increased 
after the ban of smoking in bars and restaurants?’). The 
Czech and Irish surveys consider only different modalities 
of tobacco consumption, in the belief that differentiating 
between forms of tobacco consumption renders the 
questions more clear to cigar and pipe smokers. The 
Hungarian, Belgian, Lithuanian and Romanian surveys 
only ask after different forms of alcohol consumption. The 
EMCDDA guidelines make it clear that differentiating 
between alcohol drinks may influence the answers. 
Answering ‘no’ to a general question about drinking may 
turn into a ‘yes’ when the different modalities are 
presented (EMCDDA, 2002). Most experts comply with 
this guideline and underline that the inclusion of different 
modalities of alcohol consumption may be helpful both 
to determine the type of consumption and to stimulate the 
respondents’ memory.
While all countries include pharmaceuticals in the 
surveys, the interpretation of the term differs 
enormously, as most only include pharmaceuticals that 
are known to be misused or abused in their country. 
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Table 4: Prevalence of licit drug use
Country Year
Licit drugs
Alcohol Tobacco Pharmaceuticals
Austria 2004 Yes Yes Yes
Belgium 2001 Yes Yes Yes
2004 Yes Yes Yes
2008 Yes Yes Yes
Bulgaria 2005 n.a. n.a. n.a.
Croatia 2009 (expected) Yes Yes Yes
Cyprus 2006 Yes Yes Yes
Czech Republic 2004 Yes Yes Yes
Denmark 2000 Yes Yes Yes
2005 Yes Yes Yes
2008 No No No
England and Wales 1996 Yes Yes Yes
1998 Yes Yes Yes
2000 Yes Yes Yes
2001/2 Yes Yes Yes
2002/3 Yes No Yes
2003/4 Yes No Yes
2004/5 Yes No Yes
2005/6 Yes No Yes
2006/7 Yes No Yes
Estonia 2003 n.a. n.a. n.a.
Finland 1992 Yes Yes Yes
1996 Yes Yes Yes
1998 Yes Yes Yes
2002 Yes Yes Yes
2006 Yes Yes Yes
France 1995 Yes Yes Yes
2000 Yes Yes Yes
Moreover, health surveys (e.g. France, Denmark, 
Sweden) usually include the most number of 
pharmaceuticals (e.g. also anti-depressants, 
neuroleptics, hypnotics, sleeping pills, anxiolytics), 
while crime or victimisation surveys include the least. 
The British Crime Survey includes non-prescribed use of 
tranquillisers, the Scottish Crime Survey measures the 
use of temazepam and valium. In line with the EMQ, 
pharmaceuticals mostly comprise of tranquillisers and 
sedatives (e.g. Hungary, Malta, the Netherlands, the 
Czech Republic). The Austrian and Italian surveys are 
exceptions. The Austrian survey only includes 
tranquillisers and the Italian survey only sedatives. 
Some countries also include other pharmaceuticals 
than tranquillisers and sedatives: anti-depressants (e.g. 
Romania, Lithuania, Ireland), hypnotics (e.g. Portugal), 
painkillers (e.g. Finland). The Spanish population 
survey only includes sedatives and hypnotics, and the 
Cypriot survey includes hypnotics and tranquillisers. In 
the Latvian survey, different categories are 
implemented: barbiturates, benzodiazepines, 
antihistamines and other medicines.
While some surveys (e.g. Romania, Malta, the 
Netherlands, Belgium) make a distinction between 
prescription and non-prescription pharmaceuticals, 
others only focus on non-prescribed use of 
pharmaceuticals (e.g. the British and Scottish Crime 
Survey). However, the line between misuse and proper 
use of medication is difficult to draw, as some 
prescribed medications may be overused, and 
occasional use of sleeping pills might be innocuous 
(Koroleva et al., 2003). The EMQ therefore includes 
both prescribed and non-prescribed use.
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Country Year
Licit drugs
Alcohol Tobacco Pharmaceuticals
2005 Yes Yes Yes
Germany 1995 Yes Yes Yes
1997 Yes Yes Yes
2000 Yes Yes Yes
2003 n.a. n.a. n.a.
Greece 1998 Yes Yes Yes
2004 n.a. n.a. n.a.
Hungary 2001 Yes Yes Yes
2003 Yes Yes Yes
Ireland 2002/3 Yes Yes Yes
2006/7 Yes Yes Yes
Italy 2001 Yes Yes Yes
2003 Yes Yes Yes
2005 Yes Yes Yes
Latvia 2003 Yes Yes Yes
Lithuania 2004 Yes Yes Yes
Malta 2001 Yes Yes Yes
Netherlands 1997 Yes Yes Yes
2001 Yes Yes Yes
2005 Yes Yes Yes
Norway 2004 Yes Yes Yes
Poland 2002 n.a. n.a. n.a.
Portugal 2001 Yes Yes Yes
Romania 2004 Yes Yes Yes
Scotland 2000 No No Yes
2003 No No Yes
2004 No No Yes
2006 No No Yes
Slovakia 2002 Yes Yes Yes
2004 Yes Yes Yes
2006 Yes Yes Yes
Spain 1995 Yes Yes Yes
1997 Yes Yes Yes
1999 Yes Yes Yes
2001 Yes Yes Yes
2003 Yes Yes Yes
2005 Yes Yes Yes
Sweden 2004 Yes Yes Yes
2005 Yes Yes Yes
2006 Yes Yes Yes
NB: 
Adapted from the EMCDDA Handbook, p. 132 (EMCDDA, 2002).  
Data from the 2001 EMCDDA overview is indicated in grey. 
n.a.: not known/not available.
Table 4 continued
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Table 5: Prevalence measurements of illicit drugs
Country Year
Illicit drugs
LTP LYP LMP
Austria 2004 All All All
Belgium 2001 All No All
2004 Cannabis Cannabis Cannabis
2008 Yes All Cannabis
Bulgaria 2005 n.a. n.a. n.a.
Croatia 2009 (expected) n.a. n.a. n.a.
Cyprus 2006 All All All
Czech Republic 2004 All All All
Denmark 2000 All All All
2005 All All All
2008 All All All
England and Wales 1996 All All All
1998 All All All
2000 All All All
2001/2 All All All
2002/3 All All All
2003/4 All All All
2004/5 All All All
2005/6 All All All
2006/7 All All All
Estonia 2003 n.a. n.a. n.a.
Finland 1992 All All All
1996 All All All
1998 All All All
2002 All All All
2006 All All All
France 1995 All All No
2000 All All All
2005 All All All
Germany 1995 All All All
1997 All All All
2.3 Prevalence measurements
2.3.1 Illicit drugs
There is consensus about the prevalence measurement of 
illicit drugs (Table 5). In accordance with the EMQ, the 
WHO guidelines and the ESPAD study, most countries 
include three prevalence indicators (lifetime prevalence 
(LTP), last year prevalence (LYP), last month prevalence 
(LMP)) for each illicit drug included. Malta and Belgium 
are exceptions. Malta measures lifetime prevalence of 
all illicit drugs (cannabis, ecstasy, amphetamines, LSD, 
heroin and cocaine) and last year and last month 
prevalence rates of cannabis and the general category 
‘other illicit drugs’. The most recent health survey (2008) 
in Belgium measures last year prevalence of all illicit 
drugs studied and restricts lifetime prevalence 
measurement to a limited number of illicit drugs 
(cocaine, amphetamines, ecstasy and cannabis).
Measuring the prevalence of drug use yields 
information about the continuation or the 
discontinuation of use. However, some countries (e.g. 
Scotland) believe that prevalence rates of illicit drug 
use must be interpreted with a great deal of caution 
because of the low number of users among the general 
population. Continuation rates are highly sensitive to 
small changes in prevalence figures.
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Country Year
Illicit drugs
LTP LYP LMP
2000 All All All
2003 n.a. n.a. n.a.
Greece 1998 All All All
2004 n.a. n.a. n.a.
Hungary 2001 All All All
2003 All All All
Ireland 2002/3 All All All
2006/7 All All All
Italy 2001 All All All
2003 All All All
2005 All All All
Latvia 2003 All All All
Lithuania 2004 All All All
Malta 2001 All Yes Yes
Netherlands 1997 All All All
2001 All All All
2005 All All All
Norway 2004 All All All
Poland 2002 n.a. n.a. n.a.
Portugal 2001 All All All
Romania 2004 All All All
Scotland 2000 All All All
2003 All All All
2004 All All All
2006 All All All
Slovakia 2002 All All All
2004 All All All
2006 All All All
Spain 1995 All All All
1997 All All All
1999 All All All
2001 All All All
2003 All All All
2005 All All All
Sweden 2004 All All All
2005 All All All
2006 All All All
NB:
Adapted from the EMCDDA Handbook, p. 133 (EMCDDA, 2002). 
Data from the 2001 EMCDDA overview is indicated in grey.
LTP: lifetime prevalence
LYP: last year prevalence
LMP: last month prevalence
n.a.: not known/not available.
Table 5 continued
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Table 6: Prevalence measurements of licit drugs
Country Year
Alcohol Tobacco Pharmaceuticals
LTP LYP LMP LTP LYP LMP LTP LYP LMP
Austria 2004 Yes Yes Yes Yes Yes Yes Yes Yes Yes
Belgium 2001 No Yes No Yes No Yes No No Yes (3)
2004 No Yes No Yes No Yes No No Yes (3)
2008 No Yes No Yes No Yes No No Yes (2)
Bulgaria 2005 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Croatia 2009 
(expected)
n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Cyprus 2006 Yes Yes Yes Yes No No No Yes Yes
Czech Republic 2004 No Yes Yes Yes No No Yes Yes Yes
Denmark 2000 No No No Yes No No No No No
2005 No Yes No Yes No No No No No
2008 No No No No No No No No No
2.3.2 Licit drugs
The inclusion of prevalence measurements of alcohol, 
tobacco and pharmaceuticals varies widely among 
countries (Table 6). Sometimes, only lifetime prevalence 
(LTP) is measured, sometimes last year (LYP) and/or last 
month (LMP). The determinant factor seems to be the 
survey’s context. Most surveys on alcohol and drug use 
include three prevalence measurements for every licit 
drug (e.g. Malta, Romania, the Netherlands, Austria, 
Portugal). In the health and crime surveys, the inclusion 
of prevalence indicators tends to be limited.
As far as prevalence measurements of alcohol use are 
concerned, only Hungary, Lithuania, the Czech Republic 
and Latvia are compatible with the EMQ, which 
includes last year and last month prevalence. These 
experts do not regard lifetime prevalence of alcohol 
consumption as a meaningful indicator, because 
abstinence of alcohol use is quite rare. However, apart 
from Finland, France, Belgium, Denmark and England 
and Wales, many surveys include three prevalence 
measurements for alcohol consumption (e.g. Cyprus, 
Germany, Greece, Ireland, Malta, the Netherlands, 
Norway, Romania, Portugal, Spain, Slovakia). The latest 
Finnish survey only measures lifetime and last year 
prevalence of alcohol consumption. The French Health 
survey includes lifetime prevalence, last year prevalence 
and last week prevalence (prevalence of use during the 
past 7 days). The 2005 Danish Health survey and the 
Belgian Health interview surveys only measure last year 
prevalence rates of alcohol consumption. The British 
Crime Survey only measures last year and last month 
prevalence of alcohol consumption.
Cyprus, France, the Czech Republic, Denmark and 
Finland are compatible with the EMQ regarding 
tobacco use, in that they only inquire after lifetime 
prevalence. Except for both crime surveys and Greece, 
Belgium, Norway and Hungary, most other countries 
(Germany, Ireland, Latvia, Malta, the Netherlands, 
Romania, Spain, Portugal, Lithuania, Slovakia) include 
the full set of prevalence measurements for tobacco 
consumption. Greece, Belgium and Hungary measure 
lifetime prevalence and last month prevalence to 
differentiate between occasional (ever) users and 
regular users. The Norwegian survey only measures 
last year prevalence rates of tobacco consumption. 
Neither of the crime surveys (England and Wales, 
Scotland) implements questions about the prevalence 
rates of tobacco consumption. 
As for pharmaceuticals (both prescription and non-
prescription), most surveys contain three prevalence 
measurements, in addition to the EMCDDA guidelines 
that recommend only last year and last month 
prevalence. A distinction can be made between 
countries that implement prevalence measurements of 
each pharmaceutical separately and those that 
measure one or more categories. While most countries 
prefer to measure prevalence rates of each 
pharmaceutical separately, Malta opts to question 
lifetime, last year and last month prevalence of a 
general category of ‘medical drugs’. The Romanian 
survey makes a distinction between (lifetime, last year 
and last month) prevalence of prescription 
pharmaceuticals and (lifetime, last year and last month) 
prevalence of non-prescription pharmaceuticals.
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Country Year
Alcohol Tobacco Pharmaceuticals
LTP LYP LMP LTP LYP LMP LTP LYP LMP
England and Wales 1996 No (0) No No No No No (¹) Yes Yes Yes
1998 No No No No No No Yes Yes Yes
2000 No Yes Yes No No Yes Yes Yes Yes
2001/2 No Yes Yes No No Yes Yes Yes Yes
2002/3 No Yes Yes No No No Yes Yes Yes
2003/4 No Yes Yes No No No Yes Yes Yes
2004/5 No Yes Yes No No No Yes Yes Yes
2005/6 No Yes Yes No No No Yes Yes Yes
2006/7 No Yes Yes No No No Yes Yes Yes
Estonia 2003 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Finland 1992 Yes No Yes Yes No No Yes No No
1996 Yes No Yes Yes No No Yes No No
1998 Yes No No Yes No No Yes Yes Yes
2002 Yes Yes No Yes No No Yes Yes Yes
2006 Yes Yes No Yes No No Yes Yes Yes
France 1995 Yes Yes No Yes No No Yes Yes No
2000 Yes Yes No Yes No No No Yes No
2005 Yes No No Yes No No Yes Yes No
Germany 1995 Yes Yes Yes Yes Yes Yes No Yes Yes
1997 Yes Yes Yes Yes Yes Yes No Yes Yes
2000 Yes Yes Yes Yes Yes Yes No Yes Yes
2003 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Greece 1998 Yes Yes Yes Yes No Yes Yes Yes Yes
2004 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Hungary 2001 Yes Yes Yes Yes No Yes Yes Yes Yes
2003 Yes Yes Yes Yes No Yes Yes Yes Yes
Ireland 2002/3 Yes Yes Yes Yes Yes Yes Yes Yes Yes
2006/7 Yes Yes Yes Yes Yes Yes Yes Yes Yes
Italy 2001 Yes Yes Yes Yes Yes Yes Yes Yes Yes
2003 Yes Yes Yes Yes Yes Yes Yes Yes Yes
2005 Yes Yes Yes Yes Yes Yes Yes Yes Yes
Latvia 2003 No Yes Yes Yes Yes Yes Yes Yes Yes
Lithuania 2004 No Yes Yes Yes Yes Yes Yes Yes Yes
Malta 2001 Yes Yes Yes Yes Yes Yes Yes Yes Yes
Netherlands 1997 Yes Yes Yes Yes Yes Yes Yes Yes Yes
2001 Yes Yes Yes Yes Yes Yes Yes Yes Yes
2005 Yes Yes Yes Yes Yes Yes Yes Yes Yes
Norway 2004 Yes Yes Yes No Yes No No Yes No
Poland 2002 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Portugal 2001 Yes Yes Yes Yes Yes Yes Yes Yes Yes
Romania 2004 Yes Yes Yes Yes Yes Yes Yes Yes Yes
Scotland 2000 No No No No No No Yes Yes Yes
2003 No No No No No No Yes Yes Yes
2004 No No No No No No Yes Yes Yes
2006 No No No No No No Yes Yes Yes
Table 6 continued
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Country Year
Alcohol Tobacco Pharmaceuticals
LTP LYP LMP LTP LYP LMP LTP LYP LMP
Slovakia 2002 No No No No No No No No No
2004 Yes Yes Yes Yes Yes Yes Yes Yes Yes
2006 Yes Yes Yes Yes Yes Yes Yes Yes Yes
Spain 1995 Yes Yes Yes Yes Yes Yes Yes Yes No
1997 Yes Yes Yes Yes Yes Yes Yes Yes No
1999 Yes Yes Yes Yes Yes Yes Yes Yes No
2001 Yes Yes Yes Yes Yes Yes Yes Yes No
2003 Yes Yes Yes Yes Yes Yes Yes Yes No
2005 Yes Yes Yes Yes Yes Yes Yes Yes No
Sweden 2004 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
2005 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
2006 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
NB:
Adapted from the EMCDDA Handbook, p. 133 (EMCDDA, 2002).
Data from the 2001 EMCDDA overview is indicated in grey.
(0) Only ‘how often usually taken alcohol drinks?’ is included.
(1) Only current smoking (smoking at present) is assessed; this figure will be close to LMP, but lower than LMP (LMP also includes occasional 
smokers).
(2) The prevalence of use in the last two weeks and in the past 24 hours is measured. 
(3) The prevalence of use in the last two weeks is measured. 
LTP: lifetime prevalence
LYP: last year prevalence
LMP: last month prevalence
n.a.: not known/not available.
Table 6 continued
2.4 Frequency of drug use
2.4.1 Illicit drug use
There is no consensus about the measurement of the 
frequency of illicit drug use (Table 7). Cyprus, the 
Czech Republic, Lithuania, Scotland, Norway, 
Denmark, Belgium, France, Finland (since its 2002 
survey), and Ireland comply with both EMQ and 
WHO guidelines by measuring only last month 
frequency. These experts agree that last month is the 
most useful recall period. Some of these countries 
(e.g. Denmark, Belgium, France) measure last month 
frequency of cannabis use only, since they assume 
that the prevalence rates of other illicit drugs are too 
low to be estimated adequately. The French Health 
survey measures last year frequency of cannabis use 
as well.
Whereas countries such as Hungary, Romania, the 
Netherlands (2005) and Italy measure lifetime, last year 
and last month frequency, Malta includes no questions 
about frequency. The Portuguese and Spanish surveys 
only measure last year and last month frequencies. 
Because of space limitations the British crime survey is 
confined to measuring last year frequency. Moreover, 
the British expert assumes that the last year time period 
is the most relevant, as for last month frequency the 
sample size may be very small and the data not very 
robust. Finally, Slovakia intends to introduce frequency 
measurements of illicit drugs in the next survey, to 
improve the accordance with the EMQ. 
In general, the reported frequencies differ not only in 
terms of duration of drug use (lifetime, last year, last 
month), but also in terms of measurement (e.g. the 
number of times/days a drug is used). Finland and 
Hungary measure frequency of use by the number of 
times a drug is used. The German survey measures 
frequency of use by the number of times during 
lifetime and last year, and the number of days over 
the last month. The Irish population survey on drug 
use also measures last month frequency by the 
number of days on which the drug is used. The 
Portuguese survey includes two measurements. It 
measures last month frequency by both the number of 
days and the number of times, and last year 
frequency of illicit drug use by the number of times. 
In order to get an impression of lifetime frequency, a 
unique criterion is included in the Dutch surveys: 
those who have used a specific drug 25 times or 
more in their lifetime are considered ‘experienced’ 
users. 
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Table 7: Frequency of illicit drug use
Country Year
Illicit drugs
LTF LYF LMF
Austria 2004 No Yes Yes
Belgium 2001 No No No
2004 No No Cannabis
2008 No No Cannabis
Bulgaria 2005 n.a. n.a. n.a.
Croatia 2009 (expected) n.a. n.a. n.a.
Cyprus 2006 No No Yes
Czech Republic 2004 No No Yes
Denmark 2000 No No No
2005 No No Yes
2008 No No Cannabis
England and Wales 1996 No No No
1998 No No No
2000 No No No
2001/2 No No No
2002/3 No Yes No
2003/4 No Yes No
2004/5 No Yes No
2005/6 No Yes No
2006/7 No Yes No
Estonia 2003 n.a. n.a. n.a.
Finland 1992 Yes Yes Yes 
1996 Yes Yes Yes 
1998 Yes Yes Yes 
2002 No No Yes
2006 No No Yes
France 1995 No No No
2000 Yes Yes Yes
2005 No Cannabis Cannabis 
Germany 1995 Yes Yes Yes 
1997 Yes Yes Yes 
2000 Yes Yes Yes 
2003 n.a. n.a. n.a.
Greece 1998 Yes Yes Yes 
2004 n.a. n.a. n.a.
Hungary 2001 Yes (0) Yes (0) Yes (0)
2003 Yes (0) Yes (0) Yes (0)
Ireland 2002/3 No No Yes
2006/7 No No Yes
Italy 2001 Yes Yes Yes
2003 Yes Yes Yes
2005 Yes Yes Yes
Latvia 2003 No No No
Lithuania 2004 No No Yes
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Country Year
Illicit drugs
LTF LYF LMF
Malta 2001 No No No
Netherlands 1997 Yes (1) No Yes
2001 Yes (1) No Yes
2005 Yes (1) Cannabis (2) Yes
Norway 2004 No No Yes
Poland 2002 n.a. n.a. n.a.
Portugal 2001 No Yes Yes
Romania 2004 Yes Yes Yes
Scotland 2000 No No No
2003 No No No
2004 No No Yes (3)
2006 No No Yes (3) 
Slovakia 2002 No No No
2004 No No No
2006 No No No
Spain 1995 No Yes Yes
1997 No Yes Yes
1999 No Yes Yes
2001 No Yes Yes
2003 No Yes Yes
2005 No Yes Yes
Sweden 2004 No No No
2005 No No No
2006 No No No
NB:
Adapted from the EMCDDA Handbook, p. 134 (EMCDDA, 2002).
Data from the 2001 EMCDDA overview is indicated in grey.
LTF: lifetime frequency
LYF: last year frequency
LMF: last month frequency
(0) All of them illicit drugs but also injected drugs and medication + alcohol.
(1) For performance enhancing drugs, the number of cures or the number of incidental use (more or less than 25 times) is gauged.
(2) The frequency of cannabis use in the heaviest using period.
(3) To all last month users, the number of times of the drug most often taken is asked.
n.a.: not known/not available.
Table 7 continued
2.4.2 Licit drug use
Frequency rates of licit drug use are mostly measured 
by last year and last month frequency indicators 
(Table 8). Measurements of lifetime frequency of 
alcohol, tobacco or pharmaceuticals are rather rare. 
Indeed, only the Netherlands, Austria and Greece 
have measured lifetime frequency of alcohol, tobacco 
and pharmaceuticals. Just as for the frequency 
measures of illicit drug use, the Dutch survey uses a 
unique criterion (either fewer or more than 25 times 
during lifetime) to measure lifetime frequency of licit 
drug use. 
Only Cyprus, the Czech Republic, Ireland, Lithuania and 
Latvia comply with the EMQ and the WHO guidelines 
that explicitly include last month frequency of alcohol 
use. Both last year and last month frequency of alcohol 
consumption are often included (e.g. Germany, Greece, 
Malta, Spain, Portugal). The Austrian and the Italian 
survey include three frequency measurements of alcohol 
consumption, for the very reason that alcohol policy is 
high on the agenda. The frequency of alcohol 
consumption is mostly measured by the number of days 
during last year, the number of times during last month, 
or the average frequency during last month. Some 
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Table 8: Frequency of licit drug use
Country Year
Alcohol Tobacco Pharmaceuticals
LTF LYF LMF Other LTF LYF LMF Other LTF LYF LMF Other
Austria 2004 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Belgium 2001 No No No Yes No No No No No No No No
2004 No No No Yes No No No No No No No No
2008 No Yes No Yes No No No Yes No No No No
Bulgaria 2005 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Croatia 2009 
(expected)
n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Cyprus 2006 No No Yes Yes (2) No No No No No No Yes No
Czech 
Republic
2004 No No Yes Yes No No No Yes Yes Yes Yes No
Denmark 2000 No No No No No No No No No No No No
2005 No No No No No No No No No No No No
2008 No No No Yes No No No No No No No No
England 1996 No No No Yes (3) No No No No No No No No
and Wales 1998 No No No No No No No No No No No No
2000 No Yes No No No No No No No No No No
2001/2 No Yes No No No No No No No No No No
2002/3 No Yes No No No No No No No No Yes (0) No
2003/4 No Yes No No No No No No No No Yes (0) No
2004/5 No Yes No No No No No No No No Yes (0) No
2005/6 No Yes No No No No No No No No Yes (0) No
2006/7 No Yes No No No No No No No No Yes (0) No
Estonia 2003 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Finland 1992 No No No No No No No No (1) Yes No No No
1996 No No No No No No No No (1) No No No No
1998 No No No No No No No No (1) Yes No No No
2002 No No No Yes No No No No No No No No
2006 No No No Yes No No No No No No No No
countries (e.g. Hungary, Belgium, France) make a 
distinction between the frequency of drinking during the 
week and during the weekend.
Measuring the frequency of tobacco consumption is 
less common. While France and the Netherlands 
measure lifetime frequency only, Germany, Ireland and 
Spain ask about last month frequency only. Greece 
and Latvia include both lifetime and last month 
frequency. The Austrian and the Italian surveys include 
three frequency measurements for tobacco 
consumption. The national population survey of 
Portugal measures last year and last month frequency 
of tobacco consumption. The Czech and Lithuanian 
surveys measure the number of cigarettes per day to 
obtain comparative data with previous (health) surveys. 
In addition, the Belgian Health survey measures the 
frequency of tobacco consumption by questioning the 
prevalence of daily use.
Regarding the consumption of pharmaceuticals, most 
surveys (e.g. Cyprus, England and Wales, Ireland, 
Lithuania, Romania, Scotland) follow the EMQ and the 
WHO guidelines and measure last month frequency by 
the number of days/times. Some countries also include 
other frequency indicators. Malta and Germany 
measure last month as well as last year frequency. The 
Netherlands also measures lifetime frequency (either 
more or fewer than 25 times) to detect experienced 
users of pharmaceuticals. Three frequency 
measurements are included in the Austrian, the 
Portuguese and the Czech surveys.
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Country Year
Alcohol Tobacco Pharmaceuticals
LTF LYF LMF Other LTF LYF LMF Other LTF LYF LMF Other
France 1995 No No No Yes No No No No No No No Yes
2000 No Yes No Yes Yes Yes Yes Yes No No Yes No
2005 No Yes No Yes (7) Yes (6) No No Yes (5) No No No No
Germany 1995 No Yes Yes Yes (4) No No Yes No (3) No Yes (4) Yes (4) No
1997 No Yes Yes Yes (4) No No Yes No (10) No Yes (4) Yes (4) No
2000 No Yes Yes Yes (4) No No Yes No (10) No Yes (4) Yes (4) No
2003 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Greece 1998 Yes Yes Yes Yes Yes No Yes No Yes Yes No No
2004 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Hungary 2001 Yes Yes Yes No No No No Yes (8) Yes Yes Yes No
2003 Yes Yes Yes No No No No Yes (8) Yes Yes Yes No
Ireland 2002/3 No No Yes No No No Yes No No No Yes No
2006/7 No No Yes No No No Yes No No No Yes No
Italy 2001 Yes Yes Yes No Yes Yes Yes No No No No No
2003 Yes Yes Yes No Yes Yes Yes No No No No No
2005 Yes Yes Yes No Yes Yes Yes No No No No No
Latvia 2003 No No Yes No Yes (9) No Yes No No No No No
Lithuania 2004 No No Yes No No No No Yes No No Yes No
Malta 2001 No Yes Yes No No No No No No Yes Yes No
Netherlands 1997 Yes No Yes No Yes No No No Yes No No No
2001 Yes No Yes No Yes No No No Yes No Yes No
2005 Yes No Yes No Yes No No No Yes No Yes No
Norway 2004 No No No Yes No No No Yes No No No Yes
Poland 2002 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Portugal 2001 No Yes Yes No No Yes Yes No Yes Yes Yes No
Romania 2004 No No No No No No No Yes (11) No No Yes No
Scotland 2000 No No No No No No No No No No Yes (12) No
2003 No No No No No No No No No No Yes (12) No
2004 No No No No No No No No No No Yes (12) No
2006 No No No No No No No No No No Yes (12) No
Slovakia 2002 No No No Yes No No No Yes No No No No
2004 No No No Yes No No No Yes No No No No
2006 No No No Yes No No No Yes No No No No
Spain 1995 No No No No No No Yes No No No No No
1997 No Yes Yes No No No Yes No No No No No
1999 No Yes Yes No No No Yes No No No No No
2001 No Yes Yes No No No Yes No No No No No
2003 No Yes Yes No No No Yes No No No No No
2005 No Yes Yes No No No Yes No No Yes Yes No
Table 8 continued
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Country Year
Alcohol Tobacco Pharmaceuticals
LTF LYF LMF Other LTF LYF LMF Other LTF LYF LMF Other
Sweden 2004 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
2005 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
2006 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
NB:
Adapted from the EMCDDA Handbook, p. 135 (EMCDDA, 2002).
Data from the 2001 EMCDDA overview is indicated in grey.
LTF: lifetime frequency
LYF: last year frequency
LMF: last month frequency
 (0) Taking a drug more than once a month (each drug).
 (1) Regular smoker/occasional smoker/non-smoker (not operationalised).
 (2) Number of times drunk during LY and LM + during last 6 months: number of times driving after 3–6 drinks or over 6 drinks.
 (3) Average frequency, sometimes referring to a certain period.
 (4) Average frequency, sometimes referring to a certain period.
 (5) It is asked whether the respondent (current smoker or ex-smoker) ever smoked daily.
 (6) Daily, once, occasionally.
 (7) A distinction is made between drinking at weekends and during the week.
 (8) Regular or occasional use (now and earlier).
 (9) Tried/regular use/occasional use.
(10) Regular smoker/occasional smoker/non-smoker (not operationalised).
(11) Number of cigarettes daily.
(12) For all last month users, the number of times of the drug (if temazepam or valium is reported) most often taken is recorded.
n.a.: not known/not available.
Table 8 continued
2.5 Quantity of drug use
2.5.1 Illicit drug use
Questions about the quantity of illicit drug use are 
rarely included in the surveys (Table 9). Some experts 
(e.g. Finland, Spain, England and Wales, Italy, Ireland, 
Lithuania) argue that quantity measurements are not 
relevant when the prevalence rates of illicit drug use 
are too low. They further underline the difficulty of 
measuring the quantity of illicit drug use (e.g. 
measurements are difficult to determine, extensive 
training of interviewers is required). Only two 
countries, the Netherlands and France, have 
implemented questions about the quantity of illicit drug 
use. In accordance with the EMQ, WHO and ESPAD, 
no other country has implemented questions about the 
quantity of illicit drug use. The 2000 French Health 
survey asked about the quantity of use of all illicit 
drugs, but in the 2005 survey this was restricted to the 
quantity of cannabis use, as prevalence rates of other 
illicit drugs proved too low. Moreover, the French 
national survey among 17-year-olds (ESCAPAD) (Beck 
et al., 2006) found that almost half of the users had 
smoked cannabis with friends on the last occasion 
(with a decreasing proportion among high frequency 
users). Given the common practice of sharing joints, 
the French expert declares that the question should be 
modified and more detailed to improve the reliability. 
The 2005 Dutch survey included questions on the 
quantity of cannabis use in order to gain deeper 
insight into cannabis use itself. Both surveys inquire 
about the number of joints consumed on an average 
day (the Netherlands), or on the last occasion (France). 
Table 9: Quantity of illicit drug use
Country Year
Illicit drugs
Cannabis Ecstasy Cocaine Heroin Amphetamines LSD Other illicit
Austria 2004 No No No No No No No
Belgium 2001 No No No No No No No
2004 No No No No No No No
2008 No No No No No No No
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Country Year
Illicit drugs
Cannabis Ecstasy Cocaine Heroin Amphetamines LSD Other illicit
Bulgaria 2005 n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Croatia 2009 
(expected)
n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Cyprus 2006 No No No No No No No
Czech Republic 2004 No No No No No No No
Denmark 2000 No No No No No No No
2005 No No No No No No No
2008 No No No No No No No
England and Wales 1996 No No No No No No No
1998 No No No No No No No
2000 No No No No No No No
2001/2 No No No No No No No
2002/3 No No No No No No No
2003/4 No No No No No No No
2004/5 No No No No No No No
2005/6 No No No No No No No
2006/7 No No No No No No No
Estonia 2003 n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Finland 1992 No No No No No No No
1996 No No No No No No No
1998 No No No No No No No
2002 No No No No No No No
2006 No No No No No No No
France 1995 No No No No No No No
2000 Yes Yes Yes Yes Yes Yes Yes
2005 Cannabis No No No No No No
Germany 1995 No No No No No No No
1997 No No No No No No No
2000 No No No No No No No
2003 n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Greece 1998 No No No No No No No
2004 n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Hungary 2001 No No No No No No No
2003 No No No No No No No
Ireland 2002/3 No No No No No No No
2006/7 No No No No No No No
Italy 2001 No No No No No No No
2003 No No No No No No No
2005 No No No No No No No
Latvia 2003 No No No No No No No
Lithuania 2004 No No No No No No No
Malta 2001 No No No No No No No
Table 9 continued
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Country Year
Illicit drugs
Cannabis Ecstasy Cocaine Heroin Amphetamines LSD Other illicit
Netherlands 1997 No No No No No No No
2001 No No No No No No No
2005 Cannabis No No No No No No
Norway 2004 No No No No No No No
Poland 2002 n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Portugal 2001 No No No No No No No
Romania 2004 No No No No No No No
Scotland 2000 No No No No No No No
2003 No No No No No No No
2004 No No No No No No No
2006 No No No No No No No
Slovakia 2002 No No No No No No No
2004 No No No No No No No
2006 No No No No No No No
Spain 1995 No No No No No No No
1997 No No No No No No No
1999 No No No No No No No
2001 No No No No No No No
2003 No No No No No No No
2005 No No No No No No No
Sweden 2004 No No No No No No No
2005 No No No No No No No
2006 No No No No No No No
NB:
Adapted from the EMCDDA Handbook, p. 136 (EMCDDA, 2002).
Data from the 2001 EMCDDA overview is indicated in grey.
n.a.: not known/not available.
Table 9 continued
2.5.2 Licit drug use
To investigate licit drug use, most countries included 
some questions about the quantity of alcohol or tobacco 
consumption (Table 10).
Almost all countries added one or more question about 
‘binge drinking’ during a reference period: last 6 months 
(e.g. the Netherlands), last year (e.g. Belgium, Malta, 
Hungary), last month (e.g. Latvia, Ireland, Romania, 
France, England and Wales). In most European 
countries, ‘binge drinking’ is defined as consuming 6 or 
more drinks on a single occasion. As an exception, the 
Czech survey measures ‘binge drinking’ as consuming 5 
or more glasses of alcohol on one occasion in the last 
30 days. This definition is comparable with the ESPAD 
study and the WHO guidelines, which also describe 
‘binge drinking’ as consuming 5 or more drinks on one 
occasion. Furthermore, many European surveys (e.g. 
France, Belgium, Hungary, Latvia, the Netherlands, 
Germany, England and Wales) include questions about 
the number of glasses/units of alcohol consumed on an 
average (regularly or special) day or on the last 
occasion. Some countries (e.g. France, Finland, Portugal) 
measure the prevalence of drunkenness.
The quantity of tobacco consumption is measured by 
the average number of cigarettes per day (e.g. France, 
Hungary, the Netherlands, Belgium, Germany, Ireland). 
The Portuguese survey measures the quantity of 
tobacco consumption during last month and last year 
by the number of cigarettes and the number of packets 
per day. In addition, the most recent French Health 
survey measures the quantity of tobacco consumption 
by inquiring about the number of pipes, cigars and 
cigarettes smoked per day, per week, per month and 
per year.
No recent population survey measures the quantity of 
consumption of any pharmaceutical. 
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Table 10: Quantity of licit drug use
Country Year
Licit drugs
Alcohol Tobacco Pharmaceuticals
Austria 2004 Yes Yes No
Belgium 2001 Yes Yes No
2004 Yes Yes No
2008 Yes Yes No
Bulgaria 2005 n.a. n.a. n.a.
Croatia 2009 (expected) n.a. n.a. n.a.
Cyprus 2006 Yes (0) No No
Czech Republic 2004 Yes No No
Denmark 2000 Yes Yes No
2005 Yes Yes No
2008 Yes No No
England and Wales 1996 No No No
1998 No No No
2000 Yes No No
2001/2 Yes No No
2002/3 Yes No No
2003/4 Yes No No
2004/5 Yes No No
2005/6 Yes No No
2006/7 Yes No No
Estonia 2003 n.a. n.a. n.a.
Finland 1992 No No No
1996 No No No
1998 No No No
2002 No No No
2006 No No No
France 1995 Yes (1) Yes No
2000 Yes (1) Yes No
2005 Yes Yes No
Germany 1995 Yes Yes No
1997 Yes Yes No
2000 Yes Yes No
2003 n.a. n.a. n.a.
Greece 1998 Yes Yes No
2004 n.a. n.a. n.a.
Hungary 2001 Yes (2) Yes No
2003 Yes (2) Yes No
Ireland 2002/3 Yes No No
2006/7 Yes Yes No
Italy 2001 No No No
2003 No No No
2005 No No No
Latvia 2003 Yes No No
Lithuania 2004 Yes Yes No
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Country Year
Licit drugs
Alcohol Tobacco Pharmaceuticals
Malta 2001 Yes No No
Netherlands 1997 Yes No No
2001 Yes Yes No
2005 Yes Yes No
Norway 2004 Yes No No
Poland 2002 n.a. n.a. n.a.
Portugal 2001 Yes Yes No
Romania 2004 Yes No No
Scotland 2000 No No No
2003 No No No
2004 No No No
2006 No No No
Slovakia 2002 No No No
2004 No No No
2006 No No No
Spain 1995 Yes Yes No
1997 Yes Yes No
1999 Yes Yes No
2001 Yes Yes No
2003 Yes Yes No
2005 Yes Yes No
Sweden 2004 n.a. n.a. n.a.
2005 n.a. n.a. n.a.
2006 n.a. n.a. n.a.
NB:
Adapted from the EMCDDA Handbook, p. 136 (EMCDDA, 2002).
Data from the 2001 EMCDDA overview is indicated in grey.
(0) General frequency of binge drinking (6 or more glasses on the same occasion) + do you think you drink excessively?
(1) Number of glasses yesterday.
(2) An open-ended question about how much the respondent drank last time is added.
n.a.: not known/not available.
Table 10 continued
2.6  Other items related to illicit drug use
In most European surveys on drug use, other items 
related to illicit drug use are restricted to inquiries 
about the age of onset and the availability of drugs 
(e.g. Cyprus, Ireland, Latvia, Romania) (Table 11). 
However, the ESPAD study and the WHO guidelines 
also include questions on multiple drug use and the 
mode of administration. 
2.6.1 Age of onset
Almost all countries include questions about the age of 
onset of all (e.g. Cyprus, France, Denmark (10), 
Germany, Greece, Hungary, Ireland, Italy, Latvia, 
Lithuania, the Netherlands, Norway, Portugal, 
Romania, Scotland, Spain, Finland, Slovakia) or some 
(e.g. Malta, Belgium) illicit drugs in order to assess 
incidence of use and to study the time patterns of 
getting in contact with drugs. This may be useful for 
identifying target groups. Only England and Wales 
and the Czech Republic do not (or only occasionally) 
include this item. Although the British experts would 
like to gather more regular information on the age of 
first use, space limitations restrict the British Crime 
Survey to asking only occasionally about the age of 
first use. The Czech expert mentions that age of onset 
was asked in a few cases only, as relatively low 
prevalence rates of drug use were expected.
(10)  Age of onset is only included in 2005 owing to financial reasons.
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Some countries (e.g. Scotland, Finland, Slovakia) 
measure availability of illicit drugs on the basis of 
whether respondents have been offered any particular 
(illicit) drug. The Irish population survey on drug use 
measures the number of times a respondent has been 
offered a particular drug (e.g. cannabis, ecstasy, 
amphetamines, crack, cocaine, heroin, LSD, solvents, 
poppers and magic mushrooms) during the last 12 
months. 
Other countries (e.g. Cyprus, Malta, Portugal, Ireland, 
Spain) include questions about the (perceived) 
availability of illicit drugs. The perceived availability 
item refers to the ease or the difficulty to obtain a 
particular drug within 24 hours. In this respect, one 
expert (Spain) calls into question the reliability of this 
interpretation, because perceived availability may be 
influenced by the mass media. The Irish survey 
measures perceived availability for a limited number of 
drugs: cannabis, cocaine, and ecstasy. Malta measures 
how difficult or easy it is to obtain all illicit drugs, 
except for LSD. The Norwegian survey measures the 
perceived availability of illicit drugs differently, 
because the wording of the question had been used in 
surveys of adolescents and in general population 
surveys before the EMQ appeared. It has made small 
changes in the wording without destroying the 
comparability. As a result, the Norwegian survey asks 
how difficult or easy it is to obtain any of the drugs 
within 2–3 days. 
The Czech, Lithuanian and Italian surveys include both 
interpretations of the ‘availability’ item because these 
experts believe that the two interpretations measure 
different things: availability and perceived availability. 
For example, the French Health survey measures the 
availability of cannabis in a different and more 
extended way (‘been offered?’, ‘how difficult to obtain 
within 24 hours?’, ‘how obtained last time respondent 
used?’). 
Questions about the availability of illicit drugs are 
sometimes more extended. In some surveys (e.g. 
Ireland, Latvia, Portugal), the knowledge of places 
where or of the persons from whom the drug is 
obtained is investigated. The Irish survey on drug use 
asks the respondents in which of the listed places 
(street, school, office, internet, club, etc.) and from 
which person (family/friend, stranger, etc.) they have 
obtained cannabis, ecstasy or cocaine. Moreover, 
users of pharmaceuticals, anabolic steroids, magic 
mushrooms, methadone or other opiates are 
questioned on how the drug(s) were obtained on the 
last occasion of use (bought them in a shop, bought 
Some countries (e.g. Hungary and Scotland) also ask 
which illicit drug was used first, in order to either prove 
or refute the ‘gateway theory’ (Lessem et al., 2006). This 
theory assumes that the use of cannabis facilitates the 
later use of other illicit drugs such as cocaine or heroin.
The Netherlands, Finland, Portugal and Norway add a 
question on the age of last illicit or licit drug use. This 
item is considered useful as an indicator of the duration 
of drug use (length of a drug career). Uncommon in the 
surveys are questions about the place (e.g. at home, 
with friends) and the country of first use. Only the 
Portuguese survey asks after the place of first use (at a 
party, at the workplace, during a festival, at school, 
etc.) and how the drug of first use was obtained (e.g. 
friends, partner, relatives, neighbours).
Some surveys include the age of onset of licit drug use, 
such as tobacco (e.g. Romania, France), 
pharmaceuticals (e.g. Latvia), or alcohol (e.g. France). 
Malta and Portugal focus on the age of onset of all licit 
drug use (tobacco, pharmaceuticals and alcohol). The 
French Health survey measures the age of onset of 
alcohol and tobacco use. In the case of alcohol, only 
the age of first drunkenness is recorded. For tobacco, 
the age of first use and the age of first regular use (at 
least 10 times in 1 month) is measured. Other countries 
(e.g. Spain) do not include these questions because 
their experts are of the opinion that the ‘age of onset’ 
item is not reliable in the case of licit drugs.
2.6.2 Availability of drugs
The availability of drugs is also a topic of interest in 
most European surveys. Many experts argue that the 
inclusion of the ‘availability’ item is very useful for 
investigating the general perception of the drug 
phenomenon in society. Other experts believe that the 
inclusion of this item may provide information on the 
drug situation and the drug market in countries where 
prevalence rates tend to be low. However, differences 
in questions and response modalities have made 
comparisons difficult at the EU level. To remedy this, 
the EMCDDA has launched a project that develops a 
new (optional) module on drug availability to be 
included in the European Model Questionnaire. Some 
national experts (e.g. Belgium, the Czech Republic, 
Latvia) are now working actively on the development 
of drug availability questions by conducting a 
cognitive field test (EMCDDA, 2008a). The Cypriot 
and the Austrian survey do not yet include questions 
about availability of use, but intend to include the 
item in the next survey so as to be in line with the 
(new module of the) EMQ.
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life without the drug?’, ‘Have you ever felt a strong 
desire for the product?’, ‘Have you ever felt that the 
same quantity of this drug produced a weaker effect 
than before?’, ‘Have you ever had serious problems 
with your work results, with your behaviour at home 
and with your health?’. The Scottish Crime Survey 
inquires about the difficulty or ease to stop using an 
illicit drug. Finally, the Irish survey on drug use asks if 
the respondent has ever taken cannabis, alcohol, 
cocaine and ecstasy regularly, if and why he/she ever 
tried to stop taking these drugs (e.g. health reasons, 
pregnancy, rehabilitation programme).
Many countries (e.g. the Netherlands, France, the 
Czech Republic) focus on perceived health effects of 
cannabis use in relation to the high levels of cannabis 
use recorded across Europe. The 2005 Dutch survey 
inquires about (possible) emotional, psychological or 
physical complaints resulting from using cannabis. The 
survey is also interested in the effects that stopping or 
decreasing cannabis use may cause. The French 
Health survey includes questions about unpleasant 
effects of cannabis use (e.g. bad trip, hallucination), 
the difficulty of not using cannabis for one day, the 
influence of parents and friends in reducing the use of 
cannabis, etc.
2.6.5 Intravenous use
Countries are divided on the ‘intravenous use’ item. 
Some countries (e.g. Austria, Finland, England and 
Wales) do not include questions about intravenous use, 
because they believe that in a general population 
survey the prevalence of this use is extremely low. They 
are also convinced that even if some intravenous users 
were reached, they would not be willing to reply to the 
questionnaire. The former argument is confirmed by the 
Norwegian experts who included this item in their 
previous survey(s). Other countries (e.g. the Czech 
Republic, Romania) argue that the inclusion of the 
‘intravenous use’ item will make it possible to assess 
the risk patterns of use, as the use of syringes is a 
serious step in a drug career. In general, these experts 
agree that the inclusion of questions on injecting makes 
it possible to monitor problematic users and risky drug 
use, all of which is related to the dissemination of 
infectious diseases. 
Intravenous use is measured in different ways. Some 
countries (e.g. the Netherlands, Spain, the Czech 
Republic, Norway, Slovakia) explicitly elicit information 
about the respondents’ injecting behaviour while other 
countries only survey the mode of administration of one 
or more particular drugs (e.g. Ireland, France, the 
them on the Internet, got them from someone you know, 
etc.). The Portuguese survey includes questions about 
the places of use (at school, in a café, in local clubs, in 
the street, in a shopping centre, etc.), situations of use 
(alone, while studying, while working, during the 
holidays, etc.) and occasions of use (family parties, 
techno/rave parties, New Year’s Eve party, school 
parties, etc.). The respondent is further asked how he/
she obtained the drug the last time he/she used it.
Hungary and Ireland measure the availability of 
pharmaceuticals. The respondents are asked how they 
obtained them: from a doctor (with a prescription), 
from a friend, from a pharmacy (without a 
prescription). The Romanian survey gauges the 
availability of tobacco to minors. In order to evaluate 
the drug policy, respondents under 18 were asked if 
they were able to buy tobacco products.
2.6.3 Multiple drug use
Asking questions about multiple drug use is uncommon. 
Only three countries introduce a specific question 
about multiple drug use. The Maltese and the 
Hungarian surveys define multiple drug use as the 
combination of one or more illicit and one or more licit 
drugs or as the combination of different licit drugs, 
such as alcohol–medication or alcohol–tobacco, over 
a whole drug career. The Hungarian survey includes 
three prevalence indicators of the medication–alcohol 
combination, because high prevalence rates of this 
combination are expected. The Maltese survey 
interprets multiple drug use as the use of more than 
one drug in the past month. The focus lies on the 
alcohol–tobacco, and alcohol–medication 
combinations. The Scottish Crime Survey describes 
multiple drug use as the simultaneous use of several 
drugs and the combination of alcohol and drugs 
among last month users. 
2.6.4 Perceived health effects of use
Perceived health effects of use refer to whether the 
consumption of illicit drugs has influenced the 
respondent’s health (physical, psychological and social 
effects). However, the inclusion of questions about 
perceived health effects of use is uncommon, as this 
item is considered not relevant in population surveys 
with low numbers of frequent drug users. 
However, the Portuguese survey includes several 
questions about (health) effects of use. Its questions 
concern the reason for using an illicit drug, the reasons 
for not using it and dependence. Dependence is 
measured by questions such as: ‘Can you imagine your 
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and heroin among last month users. However, the mode 
of administration of amphetamines is not inquired here, 
as the Irish expert finds that the number of amphetamine 
users is too small. In the Portuguese survey, the 
respondents are asked which modes of administration 
they have already tried and how they usually consume 
the drugs (e.g. cocaine, heroin and amphetamines). The 
Italian survey includes questions about the method(s) of 
using heroin and cocaine. Next to some explicit 
questions about intravenous use, the Dutch population 
survey on drug use examines the mode of administration 
of cocaine, amphetamine, ecstasy, LSD, heroin, 
performance enhancing drugs (e.g. anabolic steroids, 
EPO, growth hormones) and cannabis. 
2.6.6 Other item: susceptibility
Susceptibility is another item that is related to illicit 
drug use. It is not introduced in this overview, but it still 
deserves some attention. ‘Susceptibility’ is measured in 
the Maltese and the Slovakian surveys. It refers to the 
extent to which respondents would try or use a drug, 
when offered. In both surveys, the respondents are 
asked whether they would take a drug when it is 
offered at a party or a social event.
Czech Republic, Italy, Portugal), or just ask which 
method has ever been used (e.g. Scotland). The Dutch 
survey explicitly inquires about lifetime prevalence of 
intravenous use and the products the respondent ever 
has injected. The Spanish survey measures lifetime and 
last year prevalence of injecting heroin or cocaine. The 
Czech survey asks the respondents if they ever have 
injected amphetamines/methamphetamines, cocaine or 
heroin. The Norwegian survey assesses the prevalence 
(never, more than one year ago, 1–12 months since, 
0–30 days since) and the last month frequency 
(number of times) of using syringes, the age of the first 
injection and the age of the last injection. The 
Slovakian survey also has questions about injecting 
behaviour of friends or relatives (e.g. using in a 
different way, using their own syringes and needles, 
new or sterilised ones, sharing syringes and needles). 
The method(s) by which a person administers a 
particular drug is a topic of interest in other European 
surveys on drug use. These general questions are also 
useful for identifying common routes as well as risk 
factors. While the French Health survey is interested in 
the method of using heroin, Ireland assesses the 
methods of using pharmaceuticals, cannabis, cocaine 
Table 11: Other items related to illicit drug use
Country Year Age of onset Multiple drug use Injecting Availability Health effects of use
Austria 2004 Yes No No No No
Belgium 2001 No No No No No
2004 Cannabis No No No No
2008 Cannabis No No No No
Bulgaria 2005 n.a. n.a. n.a. n.a. n.a.
Croatia 2009 (expected) n.a. n.a. n.a. n.a. n.a.
Cyprus 2006 Yes No No Yes No
Czech Republic 2004 No No Yes Yes No
Denmark 2000 No No No No No
2005 Yes No No No No
2008 Yes No No No No
England and Wales 1996 No No Yes No No
1998 No No No No No
2000 No No No No No
2001/2 Yes No No No (1) No
2002/3 Yes No No No No
2003/4 Yes Yes (2) No No No
2004/5 Yes No No No No
2005/6 No No No No No
2006/7 No No No No No
Estonia 2003 n.a. n.a. n.a. n.a. n.a.
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Country Year Age of onset Multiple drug use Injecting Availability Health effects of use
Finland 1992 No No Yes Yes No
1996 No No Yes Yes No
1998 Cannabis No No Yes No
2002 Yes No No Yes No
2006 Yes No No Yes No
France 1995 No No No Yes No
2000 Yes Yes Yes Yes Yes
2005 Yes No Yes Yes Cannabis (0)
Germany 1995 Yes No Yes Yes Yes
1997 Yes No Yes Yes Yes
2000 Yes No Yes Yes Yes
2003 n.a. n.a. n.a. n.a. n.a.
Greece 1998 Yes Yes Yes Yes Yes
2004 n.a. n.a. n.a. n.a. n.a.
Hungary 2001 Yes Yes Yes No No
2003 Yes Yes Yes No No
Ireland 2002/3 Yes No Yes Yes Yes
2006/7 Yes No Yes Yes Yes
Italy 2001 No No Yes Yes No
2003 Yes No Yes Yes No
2005 Yes No Yes Yes No
Latvia 2003 Yes No No Yes No
Lithuania 2004 Yes No No Yes No
Malta 2001 Cannabis Yes No Yes No
Netherlands 1997 Yes Yes Yes No No
2001 Yes No Yes Yes No
2005 Yes No Yes Performance 
enhancing 
drugs
Cannabis
Norway 2004 Yes No Yes Yes No
Poland 2002 n.a. n.a. n.a. n.a. n.a.
Portugal 2001 Yes No Yes Yes Yes
Romania 2004 Yes No No Yes No
Scotland 2000 Yes No Yes Yes n.a.
2003 Yes No Yes Yes n.a.
2004 Yes Yes Yes Yes Yes
2006 Yes Yes Yes Yes Yes
Slovakia 2002 Yes No Yes Yes No
2004 Yes No Yes Yes No
2006 Yes No Yes Yes No
Spain 1995 Yes No Yes Yes No
1997 Yes No Yes Yes No
1999 Yes No Yes Yes No
2001 Yes No Yes Yes No
2003 Yes No Yes Yes No
2005 Yes No Yes Yes No
Table 11 continued
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(owner/social renter/private renter), size (number of 
family members), age of the head of the household — 
other countries prefer to limit the number of questions. 
The ‘household type’ attribute is related to the ‘marital 
status’ item (married with/without children, divorced, 
living together, etc.). Some surveys include both 
household type and marital status (e.g. Ireland, 
England and Wales, Malta, Hungary, Belgium), others 
opt for the implementation of marital status only (e.g. 
Latvia, Scotland, Finland). The Romanian survey uses 
individual socio-demographic indicators, rather than 
‘household type’ or ‘marital status’.
Questions about ethnicity are restricted to a few 
countries (e.g. Denmark, Belgium, Greece, Ireland, the 
Netherlands, Norway, Lithuania, Slovakia). These 
countries argue that the ‘ethnicity’ item makes it 
possible to identify certain vulnerable groups. Besides, 
as immigrants are known to hardly participate in 
addiction care, a number of experts agree that it is 
important to know whether this low participation is 
related to a lower degree of drug use. The Irish surveys 
examine the ethnic origins of the respondents (e.g. 
White, Chinese, Pakistani, Indian, Black African, Black 
Caribbean, Bangladeshi, Irish traveller, Black other, 
Mixed ethnic group). In the Norwegian survey, the 
respondent is asked in which country he/she was born 
and in which country his/her mother and father were 
born. Response options are: Europe, Asia, Africa, 
North America, South America, and Australia/
Oceania. The 2005 Danish Health survey included the 
same questions as the Norwegian survey, but also 
asked respondents (who were not born in Denmark) 
when they had moved to Denmark. The Portuguese 
and Belgian surveys include questions about the 
respondents’ (double) nationality and their country of 
origin. The Lithuanian survey distinguishes four major 
(ethnic) groups: ‘Lithuanian’, ‘Russian’, ‘Polish’, and 
‘other’. The British Crime Survey assesses the 
2.7 Respondent attributes
It is quite common to report illicit drug use in relation to 
respondent attributes (socio-demographic and socio-
economic), as this makes it possible to examine the 
relationship between the attributes and the use of  
(il)licit drugs (Tables 12 and 13). However, these 
variables only refer to the present situation and 
therefore can only be related to current (last year) or 
recent (last month) patterns of drug use (EMCDDA, 
2002). Moreover, in most countries the number of 
current or recent users is too small to allow an in-depth 
analysis (e.g. the Netherlands, Latvia, British Crime 
Survey) (EMCDDA, 2002). The EMQ includes some 
socio-demographic and socio-economic attributes, 
such as age, gender, household type, level of 
education, and employment status. Income is not 
included, although one or more questions about 
(personal or family) income are found in most 
European surveys on drug use. 
2.7.1 Socio-demographic attributes
Age and gender are the most basic attributes. A few 
surveys limit their questions on drug use to particular 
age groups. The drugs module of the Scottish Crime 
Survey is only directed at respondents under 60 years 
of age. In the British Crime Survey, questions about the 
age of onset and the frequency of drug use, for those 
who had taken drugs in the last year, were only 
submitted to respondents between the age of 16 and 
24 (see also Section 3: Methodological focus). 
Household type refers to the composition of the 
household (e.g. single with/without children, two 
partners with/without children). Even though some 
countries (such as France, the Netherlands, England 
and Wales, Belgium) measure household type in great 
detail — e.g. household structure (no children, adults 
and children, single adult and children), type of tenure 
Country Year Age of onset Multiple drug use Injecting Availability Health effects of use
Sweden 2004 n.a. n.a. n.a. n.a. n.a.
2005 n.a. n.a. n.a. n.a. n.a.
2006 n.a. n.a. n.a. n.a. n.a.
NB:
Adapted from the EMCDDA Handbook, p. 137 (EMCDDA, 2002).
Data from the 2001 EMCDDA overview is indicated in grey.
(0) Health and social effects of cannabis use (to last year users).
(1) Availability is in fact measured by the ease of access to drugs (unlike availability!).
(2)  Multiple drug use is measured by ‘concurrent polydrug use’ which means the use of more than one type of drug over their careers (not 
simultaneous use).
n.a.: not known/not available.
Table 11 continued
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should be remarked that some of the countries (e.g. 
Austria, France, Denmark) that include the ‘religion’ 
item describe its inclusion as not useful. According to 
the Danish expert, the item is not useful because the 
target population consists almost exclusively of 
members of the Danish National Church.
2.7.2 Socio-economic attributes
Even though some countries (e.g. the Netherlands, 
France, Scotland, Ireland, Portugal, Belgium) measure 
the level of education and the employment status in 
great detail (e.g. employment status, type of 
organisation, type of job, total number of school 
years), other countries prefer a limited number of 
questions.
Almost all countries consider the respondent’s income 
as an item that is useful for the detection of situations 
of precarity. Drug use is expensive, and early use may 
be associated with available income. In general, a 
distinction is made between family and personal 
income. The inclusion of family/household income is 
most common (e.g. Cyprus, England and Wales, 
Denmark, Scotland, Germany, Portugal, France). Some 
countries include questions about both family and 
personal income (e.g. the Netherlands, Norway, 
Lithuania, Belgium), because family income does not 
necessarily say anything about an individual’s income.
Exceptions to this are Ireland, Finland (2006), the 
Netherlands (2005), the Czech Republic, Denmark 
(2008), Italy, Slovakia and Spain. These experts do 
not include the income item because of space/
financial limitations and because of the difficulty of 
wording the questions. Some countries (e.g. the 
Netherlands, Ireland) state that questions about 
income often meet resistance and believe that the 
level of education is a better indicator of the socio-
economic status. 
prevalence of illicit drug use across 16 different ethnic 
groups (White British, White Irish, Mixed White and 
Black Caribbean, Mixed White and Black African, 
etc.). However, the British expert regrets that the item is 
not as much used as it should be, because there are 
many groups for which the sample size is too small, 
and combining them could be misleading. 
Several countries (e.g. Austria) do not include questions 
about ethnicity because, for pragmatic reasons, it 
might stimulate xenophobic tendencies when the results 
are published. Some experts who included this item in 
their previous survey(s) (e.g. Denmark, Lithuania, 
Norway) argue that the rates in each group are too 
low to describe drug use in different ethnic groups. 
Nevertheless, these experts admit that the item may be 
used for weighting purposes because the groups are 
quite underrepresented in the sample.
The ‘religion’ item is only rarely included (e.g. France, 
Austria, Denmark, Portugal, Slovakia and Ireland). 
The Irish questionnaire makes a distinction between 
‘Catholic’ and ‘Protestant’. The Austrian survey adds 
two further categories: ‘other religion’ and ‘no 
religion’. The French Health survey also includes two 
‘other’ religions: ‘Islamic/Muslim’ and ‘Jewish’. In the 
French survey, the respondent is asked if he/she 
regards him/herself as belonging to any particular 
religion. The Danish Health surveys ask the 
respondents if they are a member of the Danish 
National Church or of any other organised religion 
(e.g. Roman Catholic, Jehovah’s Witnesses, Seventh-
Day Adventists, Judaism, Islam, Hinduism, Buddhism). 
The Portuguese survey makes a distinction among 
‘Catholic’, ‘any other religion’, ‘indifferent’, ‘agnostic’, 
‘atheist’, and ‘no definite opinion’. Some additional 
questions concern the frequency of attending church 
and other practices, such as spells or witchcraft, 
spirits, astrology, telepathy and UFOs. In addition, it 
Table 12: Socio-demographic attributes
Country Year
Socio-demographic
Age Gender Household type Marital status Ethnicity Religion
Austria 2004 Yes Yes Yes No No Yes
Belgium 2001 Yes Yes Yes No Yes No
2004 Yes Yes Yes No Yes No
2008 Yes Yes Yes Yes Yes No
Bulgaria 2005 n.a. n.a. n.a. n.a. n.a. n.a.
Croatia 2009 (expected) Yes Yes Yes No No No
Cyprus 2006 Yes Yes Yes No No No
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Country Year
Socio-demographic
Age Gender Household type Marital status Ethnicity Religion
Czech Republic 2004 Yes Yes No No No No
Denmark 2000 Yes Yes Yes No No Yes
2005 Yes Yes Yes No Yes Yes
2008 Yes Yes No No No No
England and Wales 1996 Yes Yes Yes Yes Yes No
1998 Yes Yes Yes Yes Yes No
2000 Yes Yes Yes Yes Yes No
2001/2 Yes Yes Yes Yes Yes No
2002/3 Yes Yes Yes Yes Yes No
2003/4 Yes Yes Yes Yes Yes No
2004/5 Yes Yes Yes Yes Yes No
2005/6 Yes Yes Yes Yes Yes No
2006/7 Yes Yes Yes Yes Yes No
Estonia 2003 n.a. n.a. n.a. n.a. n.a. n.a.
Finland 1992 Yes Yes No No No No
1996 Yes Yes No No No No
1998 Yes Yes No Yes No No
2002 Yes Yes No Yes No No
2006 Yes Yes No Yes No No
France 1995 Yes Yes Yes No No Yes
2000 Yes Yes Yes No Yes Yes
2005 Yes Yes Yes Yes No Yes
Germany 1995 Yes Yes Yes n.a. No No
1997 Yes Yes Yes n.a. No No
2000 Yes Yes Yes n.a. No No
2003 n.a. n.a. n.a. n.a. n.a. n.a.
Greece 1998 Yes Yes Yes n.a. Yes No
2004 n.a. n.a. n.a. n.a. n.a. n.a.
Hungary 2001 Yes Yes Yes Yes No No
2003 Yes Yes Yes Yes No No
Ireland 2002/3 Yes Yes Yes Yes Yes Yes
2006/7 Yes Yes Yes Yes Yes Yes
Italy 2001 Yes Yes No No No No
2003 Yes Yes No No No No
2005 Yes Yes No No No No
Latvia 2003 Yes Yes No Yes Yes No
Lithuania 2004 Yes Yes Yes No Yes No
Malta 2001 Yes Yes Yes Yes No No
Netherlands 1997 Yes Yes Yes No Yes No
2001 Yes Yes Yes No Yes No
2005 Yes Yes Yes No Yes No
Norway 2004 Yes Yes Yes No Yes No
Poland 2002 n.a. n.a. n.a. n.a. n.a. n.a.
Portugal 2001 Yes Yes Yes No Yes Yes
Table 12 continued
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Country Year
Socio-demographic
Age Gender Household type Marital status Ethnicity Religion
Romania 2004 Yes Yes No No No No
Scotland 2000 Yes Yes No No No No
2003 Yes Yes No No No No
2004 Yes Yes No No No No
2006 Yes Yes No Yes No No
Slovakia 2002 Yes Yes No No Yes Yes
2004 Yes Yes No No Yes Yes
2006 Yes Yes No No Yes Yes
Spain 1995 Yes Yes Yes No No No
1997 Yes Yes Yes No No No
1999 Yes Yes Yes No No No
2001 Yes Yes Yes No No No
2003 Yes Yes Yes No No No
2005 Yes Yes Yes No No No
Sweden 2004 n.a. n.a. n.a. n.a. n.a. n.a.
2005 n.a. n.a. n.a. n.a. n.a. n.a.
2006 n.a. n.a. n.a. n.a. n.a. n.a.
NB:
Adapted from the EMCDDA Handbook, p. 138 (EMCDDA, 2002).
Data from the 2001 EMCDDA overview is indicated in grey.
n.a.: not known/not available.
Table 13: Socio-economic attributes
Country Year
Socio-economic
Level of education Employment status Income
Austria 2004 Yes Yes Yes
Belgium 2001 Yes Yes Yes (family and personal)
2004 Yes Yes Yes (family and personal)
2008 Yes Yes Yes (family)
Bulgaria 2005 n.a. n.a. n.a.
Croatia 2009 (expected) Yes Yes Yes
Cyprus 2006 Yes Yes Yes (family)
Czech Republic 2004 Yes Yes No
Denmark 2000 Yes Yes Yes
2005 Yes Yes Yes
2008 Yes Yes No
England and Wales 1996 Yes Yes Yes (family)
1998 Yes Yes Yes (family)
2000 Yes Yes Yes (family)
2001/2 Yes Yes Yes (family)
2002/3 Yes Yes Yes (family)
2003/4 Yes Yes Yes (family)
2004/5 Yes Yes Yes (family)
2005/6 Yes Yes Yes (family)
2006/7 Yes Yes Yes (family)
Table 12 continued
Chapter 2: Intrinsic focus
45
Country Year
Socio-economic
Level of education Employment status Income
Estonia 2003 n.a. n.a. n.a.
Finland 1992 Yes Yes Yes (personal)
1996 Yes Yes Yes (personal)
1998 Yes Yes No
2002 Yes Yes Yes (family)
2006 Yes Yes Yes (family)
France 1995 Yes Yes Yes (family)
2000 Yes Yes Yes (family)
2005 Yes Yes Yes (family)
Germany 1995 Yes Yes Yes (family)
1997 Yes Yes Yes (family)
2000 Yes Yes Yes (family)
2003 n.a. n.a. n.a.
Greece 1998 Yes Yes Yes
2004 n.a. n.a. n.a.
Hungary 2001 Yes Yes Yes (family)
2003 Yes Yes Yes (family)
Ireland 2002/3 Yes Yes No
2006/7 Yes Yes No
Italy 2001 Yes Yes No
2003 Yes Yes No
2005 Yes Yes No
Latvia 2003 Yes No Yes (personal)
Lithuania 2004 Yes Yes Yes
Malta 2001 Yes Yes Yes
Netherlands 1997 Yes Yes Yes (family and personal)
2001 Yes Yes Yes (family and personal)
2005 Yes No No
Norway 2004 Yes Yes Yes (family and personal)
Poland 2002 n.a. n.a. n.a.
Portugal 2001 Yes Yes Yes (family)
Romania 2004 Yes Yes Yes (personal)
Scotland 2000 No Yes Yes (family)
2003 No Yes Yes (family)
2004 No Yes Yes (family)
2006 No Yes Yes (family)
Slovakia 2002 Yes Yes No
2004 Yes Yes No
Spain 1995 Yes Yes No
1997 Yes Yes No
1999 Yes Yes No
2001 Yes Yes No
Table 13 continued
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Country Year
Socio-economic
Level of education Employment status Income
2003 Yes Yes No
2005 Yes Yes No
Sweden 2004 Yes Yes Yes (family and personal)
2005 Yes Yes Yes (family and personal)
2006 Yes Yes Yes (family and personal)
NB:
Adapted from the EMCDDA Handbook, p. 138 (EMCDDA, 2002).
Data from the 2001 EMCDDA overview is indicated in grey.
n.a.: not known/not available.
Table 13 continued
2.8 Environment
The ‘environment’ item refers to whether residential 
characteristics (e.g. number of inhabitants, typology of 
places/residential area) are recorded and to whether a 
respondent is confronted with drug users (Table 14). 
This confrontation is measured by the extent of 
personal acquaintance with users of an illicit drug (e.g. 
family, friends) or the extent of seeing/observing illicit 
drug users in the neighbourhood (EMCDDA, 2002). In 
general, countries are divided on this item.
Most questionnaires include residential characteristics 
or other geographical variations, such as incivility 
scale, council/non-council houses, police force area. 
The typology of places refers to the identification 
code and the level of urbanisation. The perception of 
the level of urbanisation may differ between 
countries but, in general, it can be divided into three 
categories: urban, rural and metropolitan. The 
incivility scale refers to the perception of forms of 
neighbourhood physical disorder (e.g. street rubbish, 
vandalism). The British Crime Survey also introduces 
a ‘Classification of Residential Neighbourhoods’ 
(ACORN). This classification groups households into 
the type of social environment in which they are 
located, taking into account the demographic, 
employment and housing characteristics of the area. 
The Norwegian survey makes a distinction between 
types of housing: single family house, 2–4 
bedroomed detached house, terraced house,  
high-rise flats, lodgings, or other. A number of 
countries (e.g. Spain, the Czech Republic, Denmark, 
Portugal and Scotland) do not include questions 
about the environment, because of space limitations 
or because of a lack of interest in this item. 
Following the EMQ, many surveys (e.g. Germany, 
Greece, Hungary, Slovakia, Ireland, Italy, Latvia, 
Lithuania, Malta, Cyprus, the Czech Republic, Portugal, 
the 2008 Danish drug survey and Romania) include 
questions about ‘knowing drug users’. This item refers 
to any personal acquaintance with users of an illicit 
drug, e.g. friends or family members. ‘Do you 
personally know someone who takes a particular 
drug?’ is frequently asked as a warming-up question. 
In the Slovakian survey, respondents are asked whether 
they know anyone socially (e.g. family, friends, 
neighbourhood, working place) who is or was 
addicted to marihuana, hashish, cocaine, heroin, LSD 
or ecstasy. This question assesses the familiarity, the 
awareness and the (dis)approval of drug use(rs). 
Experts agree that the inclusion of this item is very 
useful, as it is associated with personal drug use and 
directly indicates the extent of the drug problem in a 
country. In the Slovakian survey, this item is included in 
order to study the young as a group, as it is assumed 
that they are more frequently faced with drug addicts. 
Questions about ‘knowing drug users’ are most 
common in national population surveys that only deal 
with drugs (and/or alcohol, tobacco or 
pharmaceuticals), such as Hungary, Slovakia, Finland, 
Ireland, Latvia, Malta, etc. However, other countries, 
such as France, the Netherlands, Spain, Scotland, and 
England and Wales, do not include questions about 
‘knowing drug users’, because of space limitations or 
because the inclusion of this item is considered not 
particularly relevant, taking into account the media 
coverage of drugs. 
No general population survey inquires about ‘seeing 
drug users’ (seeing or observing of users of an illicit 
drug in one’s own neighbourhood).
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Table 14: Environment
Country Year Residential characteristics
Confrontation
Personal ‘knowing drug 
users’ (1)
Neighbourhood 
‘seeing drug users’
Austria 2004 Yes Yes No
Belgium 2001 Yes No No
2004 Yes No No
2008 No No No
Bulgaria 2005 n.a. n.a. n.a.
Croatia 2009 (expected) No Yes No
Cyprus 2006 Yes Yes No
Czech Republic 2004 No Yes No
Denmark 2000 No No No
2005 No No No
2008 No Yes No
England and Wales 1996 Yes No Yes
1998 Yes No No
2000 Yes No No
2001/2 Yes No No
2002/3 Yes No No
2003/4 Yes No No
2004/5 Yes No No
2005/6 Yes No No
2006/7 Yes No No
Estonia 2003 n.a. n.a. n.a.
Finland 1992 Yes Yes No
1996 Yes Yes No
1998 Yes Yes No
2002 Yes Yes No
2006 Yes Yes No
France 1995 Yes No No
2000 Yes No No
2005 Yes No No
Germany 1995 Yes Yes No
1997 Yes Yes No
2000 Yes Yes No
2003 n.a. n.a. n.a.
Greece 1998 Yes Yes No
2004 n.a. n.a. n.a.
Hungary 2001 Yes Yes No
2003 Yes Yes No
Ireland 2002/3 Yes Yes No
2006/7 Yes Yes No
Italy 2001 Yes Yes No
2003 Yes Yes No
2005 Yes Yes No
Latvia 2003 Yes Yes No
Lithuania 2004 Yes Yes No
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Italy, the Czech Republic, 2008 Danish drug survey), or 
because of the difficulty of wording the questions 
(Lithuania). However, many countries (e.g. England and 
Wales, Hungary, Belgium, France, Malta, Portugal, the 
Netherlands, Sweden) include questions about lifestyle 
attributes because these responses clearly show the 
importance of the context in some types of drug use in 
the general population. According to many national 
experts, it may also be useful to know whether there is a 
connection between drug use and social contacts, with 
a view to developing prevention and intervention 
methods. It is generally assumed that lifestyle strongly 
correlates with drug use.
Questions about entertainment refer to amusement 
outside the home, such as visiting dance clubs, pubs, 
etc. Entertainment sometimes includes further questions 
Country Year Residential characteristics
Confrontation
Personal ‘knowing drug 
users’ (1)
Neighbourhood 
‘seeing drug users’
Malta 2001 Yes Yes No
Netherlands 1997 Yes Yes No
2001 Yes Yes No
2005 Yes No No
Norway 2004 Yes No No
Poland 2002 n.a. n.a. n.a.
Portugal 2001 No Yes No
Romania 2004 Yes Yes No
Scotland 2000 No No No
2003 No No No
2004 No No No
2006 No No No
Slovakia 2002 Yes Yes No
2004 Yes Yes No
2006 Yes Yes No
Spain 1995 No No No
1997 No No No
1999 No No No
2001 No No No
2003 No No No
2005 No No No
Sweden 2004 n.a. n.a. n.a.
2005 n.a. n.a. n.a.
2006 n.a. n.a. n.a.
NB:
Adapted from the EMCDDA Handbook, p. 139 (EMCDDA, 2002).
Data from the 2001 EMCDDA overview is indicated in grey.
(1) Refers to whether personal acquaintance with users of an illicit drug (e.g. family, friends, colleagues) was recorded.
n.a.: not known/not available.
Table 14 continued
2.9 Lifestyle attributes
In some countries, the questionnaires include questions 
about entertainment and/or social contacts (Table 15). 
‘Lifestyle’ attributes refer to the number of social contacts 
(e.g. friends, family) and to various leisure-related 
activities such as visiting pubs, sports, etc. These 
‘lifestyle’ variables are not included in the European 
Model Questionnaire, though they are commonly used 
in the ESPAD studies. Some survey questionnaires (e.g. 
Cyprus) do not include questions about lifestyle because 
they do not regard this item as essential for a drug 
survey. These surveys collect information about lifestyle 
attributes through school and special population 
surveys. Other countries do not include this item 
because of space or financial limitations (e.g. Romania, 
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social contacts (e.g. number of friends, visiting relatives). 
However, the number of questions varies a lot. The 
Danish Health surveys include three questions: ‘How 
often do you meet your family, friends and 
acquaintances?’, ‘Are you ever alone even though you 
would prefer to be with other people?’ and ‘How often 
do you participate in activities in an association or in 
other leisure activities together with other people?’. 
While Hungary includes several questions (the number 
of friends who you feel confident with, the number of 
close friends, the number of times you have had 
personal contact with friends during last month, the 
number of times e-mail/phone contact with friends 
during last month), in the Portuguese survey the 
respondent is asked how many friends he/she has and 
how often he/she meets them. The Dutch survey 
included a question about social contacts in 2001 but 
omitted it in the 2005 survey because the survey’s 
commissioner decided it was not an important question.
about the extent to which the respondent takes part in 
sports and other leisure activities (e.g. Malta, Austria). 
Questions about entertainment form part of the surveys 
of Finland, Hungary, Belgium, France, Malta, the 
Netherlands, Portugal, Sweden, Scotland and the 
British Crime Survey. The Austrian survey defines 
entertainment in terms of the frequency of practising 
sports, watching television or surfing the Internet. The 
Portuguese survey additionally questions respondents 
on the frequency of meeting people, entertaining 
friends, going for a walk, visiting friends, going to 
pubs, etc. Questions about how the respondents spend 
their nights during the week and the weekend are also 
included: staying at home, going out at night to meet 
friends, going out with no definite plans, etc.
A large proportion of surveys (e.g. France, Hungary, 
Malta, the Netherlands, Slovakia, Portugal, Sweden, 
Belgium, Danish Health surveys) include questions about 
Table 15: Lifestyle
Country Year Entertainment Social contacts
Austria 2004 No Yes
Belgium 2001 Yes Yes
2004 Yes Yes
2008 Yes Yes
Bulgaria 2005 n.a. n.a.
Croatia 2009 (expected) Yes Yes
Cyprus 2006 No No
Czech Republic 2004 No No
Denmark 2000 No Yes
2005 No Yes
2008 No No
England and Wales 1996 Yes No
1998 No No
2000 Yes No
2001/2 Yes No
2002/3 Yes No
2003/4 Yes No
2004/5 Yes No
2005/6 Yes No
2006/7 Yes No
Estonia 2003 n.a. n.a.
Finland 1992 Yes No
1996 Yes No
1998 Yes No
2002 Yes No
2006 Yes No
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Country Year Entertainment Social contacts
France 1995 Yes Yes
2000 Yes Yes
2005 Yes Yes
Germany 1995 No No
1997 No No
2000 No No
2003 n.a. n.a.
Greece 1998 No No
2004 n.a. n.a.
Hungary 2001 Yes Yes
2003 Yes Yes
Ireland 2002/3 No No
2006/7 No No
Italy 2001 No No
2003 No No
2005 No No
Latvia 2003 n.a. n.a.
Lithuania 2004 No No
Malta 2001 Yes Yes
Netherlands 1997 Yes Yes
2001 Yes Yes
2005 Yes No
Norway 2004 No No
Poland 2002 n.a. n.a.
Portugal 2001 Yes Yes
Romania 2004 No No
Scotland 2000 Yes No
2003 n.a. n.a.
2004 No No
2006 No No
Slovakia 2002 No Yes
2004 No Yes
2006 No Yes
Spain 1995 No No
1997 No No
1999 No No
2001 No No
2003 No No
2005 No No
Sweden 2004 Yes Yes
2005 Yes Yes
2006 Yes Yes
NB:
Adapted from the EMCDDA Handbook, p. 141 (EMCDDA, 2002).
Data from the 2001 EMCDDA overview is indicated in grey.
n.a.: not known/not available.
Table 15 continued
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Asking about opinions on drug addicts is common (e.g. 
the Czech Republic, Italy, Austria, Greece, Hungary, 
Ireland, Latvia, Lithuania, Malta, Romania, Portugal, 
Slovakia). Almost all countries include the question 
proposed by the European Model Questionnaire, 
which gauges the perception of a drug addict as a 
patient or a criminal. Romania and Austria extend their 
questionnaire with some questions about opinions on 
drug addicts. The Austrian survey includes two extra 
questions: ‘How would you react if a treatment centre 
was built near you?’ and ‘How would you react if a 
friend used drugs?’. The Romanian questionnaire also 
asks the respondents if they perceive drug users as 
drug dealers, if drug users should be accepted just like 
any other person, and if a person will become an 
addict when he/she tries a drug once. 
Opinions on drug policy, on legal status or interventions 
in particular, are frequently investigated. Some surveys 
(e.g. Hungary, Ireland, Greece, the Czech Republic, 
Portugal, Lithuania, Malta and Scotland) are only 
interested in opinions on the legislation of some drugs. 
These surveys gauge whether respondents (dis)agree that 
one should be permitted to take cannabis or heroin. The 
same questions are included in the European Model 
Questionnaire. Additionally, a few countries report about 
opinions on feasible interventions (e.g. Finland, 
Germany, Latvia, Romania, Austria, Norway). The 
Romanian survey questions the respondents on whether 
they (dis)agree that drug users should be punished by 
confinement. The Latvian survey is interested in the 
respondents’ opinions on several social policies for 
managing drug-related problems (e.g. drug tests, 
compulsory treatment system, criminal punishment). The 
Norwegian survey asks the respondents about their 
opinion on clean syringe distribution, injecting rooms, 
increasing the number of treatment places, etc. In 
addition, in the Slovakian survey respondents are asked 
which policies they find the most effective (e.g. economic 
and social assistance, increasing of police control, school 
preventive programmes, obligatory treatment).
2.10 Attitudes and opinions
In some general population surveys, attitudes and 
opinions concerning drugs are assessed for use by 
policymakers, politicians or prevention workers (Table 
16). Some experts (e.g. Cyprus, Croatia, Spain) 
contend that these questions are relevant because 
attitudes and opinions usually correlate inversely with 
prevalence of use and foresee the trends in drug use. 
Other experts (e.g. Italy, Hungary) argue that 
knowledge of attitudes and opinions regarding drug 
use may be useful to evaluate the impact of preventive 
campaigns. It is also stated that measuring attitudes 
and opinions may provide information about the 
causality between the image of drug use(rs) in the 
media and attitudes towards drug issues. The 
EMCDDA has also put forward some questions about 
attitudes and opinions on drug use. Most of these 
questions have been selected from the European 
School Survey questionnaire (ESPAD). A number of 
countries (e.g. England and Wales, the Netherlands, 
Scotland, Denmark) do not include questions about 
attitudes and opinions mainly because of space 
considerations and/or interpretation problems.
Risk perceptions of health and social issues are 
measured by presenting the respondent with a list of 
statements concerning the (dis)approval/tolerance of 
taking or trying one or more drugs. In other words, the 
risk perception of harming themselves is assessed. 
Most countries include questions about the perception 
of health and/or social risks. The Slovakian survey 
includes some questions concerning physical and 
mental risks for people who are experimenting with 
drugs or taking them regularly. Latvia includes two 
additional questions about the perceived use of alcohol 
and drugs to gain a better understanding of the 
reported risk perception (‘How do you perceive the use 
of alcohol and drugs in your country?’ and ‘How do 
you perceive the importance of the problem of the use 
of alcohol in Latvia?’).
Table 16: Attitudes and opinions
Country Year
Risk perception Opinion Opinion on drug policy
Health Social Drug addicts Legal status Interventions
Austria 2004 Yes No Yes Yes Yes
Belgium 2001 No No No No No
2004 No No No No No
2008 No No No No No
Bulgaria 2005 n.a. n.a. n.a. n.a. n.a.
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Country Year
Risk perception Opinion Opinion on drug policy
Health Social Drug addicts Legal status Interventions
Croatia 2009 (expected) Yes Yes No Yes Yes
Cyprus 2006 Yes Yes No No No
Czech Republic 2004 Yes Yes Yes Yes No
Denmark 2000 No No No No No
2005 No No No No No
2008 No No No No No
England and Wales 1996 No No No No No
1998 No No No No No
2000 No No No No No
2001/2 No No No No No
2002/3 No No No No No
2003/4 No No No No No
2004/5 No No No No No
2005/6 No No No No No
2006/7 No No No No No
Estonia 2003 n.a. n.a. n.a. n.a. n.a.
Finland 1992 Yes Yes Yes Yes Yes
1996 Yes Yes Yes Yes Yes
1998 Yes Yes Yes Yes Yes
2002 Yes Yes Yes Yes Yes
2006 Yes Yes No Yes Yes
France 1995 Yes No Yes Yes Yes
2000 Yes No No Yes No
2005 Yes No No No No
Germany 1995 Yes Yes No Yes Yes
1997 Yes Yes No Yes Yes
2000 Yes Yes No Yes Yes
2003 n.a. n.a. n.a. n.a. n.a.
Greece 1998 Yes Yes Yes Yes No
2004 n.a. n.a. n.a. n.a. n.a.
Hungary 2001 Yes Yes Yes Yes No
2003 Yes Yes Yes Yes Yes
Ireland 2002/3 Yes Yes Yes Yes No
2006/7 Yes Yes Yes Yes No
Italy 2001 Yes No Yes No No
2003 Yes No Yes No No
2005 Yes No Yes No No
Latvia 2003 Yes Yes Yes Yes Yes
Lithuania 2004 Yes Yes Yes Yes Yes
Malta 2001 Yes Yes Yes Yes No
Netherlands 1997 No No No No No
2001 No No No No No
2005 No No No No No
Norway 2004 No No No Yes Yes
Table 16 continued
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Country Year
Risk perception Opinion Opinion on drug policy
Health Social Drug addicts Legal status Interventions
Poland 2002 n.a. n.a. n.a. n.a. n.a.
Portugal 2001 Yes Yes Yes Yes No
Romania 2004 Yes Yes Yes Yes Yes
Scotland 2000 Yes Yes No Yes No
2003 Yes Yes No Yes No
2004 Yes Yes No Yes No
2006 Yes Yes No Yes No
Slovakia 2002 Yes Yes Yes Yes Yes
2004 Yes Yes Yes Yes Yes
2006 Yes Yes Yes Yes Yes
Spain 1995 Yes Yes No No Yes
1997 Yes Yes No No Yes
1999 Yes Yes No No Yes
2001 Yes Yes No No Yes
2003 Yes Yes No No Yes
2005 Yes Yes No No Yes
Sweden 2004 n.a. n.a. n.a. n.a. n.a.
2005 n.a. n.a. n.a. n.a. n.a.
2006 n.a. n.a. n.a. n.a. n.a.
NB:
Adapted from the EMCDDA Handbook, p. 140 (EMCDDA, 2002).
Data from the 2001 EMCDDA overview is indicated in grey.
n.a.: not known/not available.
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It follows that a simple comparison of the methodology 
of the different European population surveys is 
practically impossible. The large amount of information 
that is needed to conduct a meta-analysis is not always 
available. However, a transparent, detailed and 
standardised way of reporting on key features of the 
survey process should contribute to this analysis.
3.2 General characteristics
3.2.1 Context
The EMCDDA overview classifies surveys in three 
categories according to their context: single, general 
and multi-context. The vast majority of surveys have a 
‘single context’, which means that they deal with drugs 
(and/or alcohol and/or tobacco) prevalence only 
(Table 17). 
Drug prevalence questions are less often embedded in 
a multipurpose survey (‘general’). The context of the 
Estonian survey, for example, is relatively wide in 
comparison with the other surveys: family, work, 
leisure, economic situation, livelihood, and health, 
including drugs. Several countries piggyback drug 
prevalence measurements to another category (‘multi’) 
in their survey. Especially used are a health context 
(e.g. the Czech Republic, Belgium, Denmark, France, 
Sweden) and to a lesser degree, a crime/victimisation 
context (e.g. England and Wales, Scotland). 
The expert survey shows that the reasons for choosing 
a context vary widely. 
Validity and reliability concerns are frequently 
mentioned (e.g. Italy, Austria and the Czech Republic). 
The Austrian researchers justify the choice for a single 
context survey as follows: ‘In order to get sensible 
answers the area has to be developed step by step 
leading to specific questions. To ask suddenly if 
persons consume certain substances after e.g. asking 
them if they are satisfied with their TV-set yields 
particularly unreliable results.’ Similarly, the Czech 
This part of the meta-analysis compares and discusses 
several methodological characteristics of different 
European surveys, including survey method, sampling 
and target population. The information is mainly 
obtained from the national reports or the abstracts of the 
survey studies. However, there is a large variance 
among the available English language reports of the 
surveys: ranging from a short outline overview (e.g. 
Cyprus) to elaborated expositions with technical reports 
(e.g. Scotland). As a consequence, it was sometimes 
necessary to obtain information from the expert review.
3.1  Cross-national comparison of 
surveys
This methodological meta-analysis of the European 
population surveys was performed in two steps. First, a 
comparison of surveys of different countries had to be 
made. These countries often have their own specific 
survey traditions and climates, which are not always 
directly visible. Secondly, the meta-analysis also 
compares surveys conducted in different time periods, 
with possibly different survey climates.
Although the EMCDDA set some (intrinsic and) 
methodological guidelines to enhance comparability, 
there is still much variation between the studies for the 
simple reason that these guidelines are not binding. In 
this respect, De Heer observes that different factors 
may explain cross-national differences in survey quality 
and outcomes:
1.  General design factors: mode of data collection, 
panel versus cross-section, proxy allowed, 
substitution allowed, person or households as 
sample units, etc.
2.  Practical fieldwork strategies: length of fieldwork 
period, number of contact attempts, use of 
incentives, use of refusal conversion, etc.
3.  Factors related to survey organisation: voluntary 
participation in surveys, employment condition of 
interviewers, etc. (Stoop, 2005).
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survey. Therefore, the mere existence of a crime or 
health survey is a necessary condition for 
piggybacking, but not a sufficient one. 
Piggybacking is frequently warranted for obtaining 
more information about a related item (health and 
crime) and about the link between drugs and the 
health burden (Croatia, Sweden, France). Lower costs 
also constitute a major reason for piggybacking 
(Denmark 2005, England and Wales, Sweden). 
Piggybacking on regular surveys such as health or 
crime surveys also creates an opportunity to gather 
data on a regular and frequent basis. However, the 
experts of the British Crime Survey find that the size 
constraint associated with being piggybacked onto a 
crime survey is a clear disadvantage.
It should be noted that hardly any survey reports 
reflect on the (possible) influence of the crime and 
health-related questions on the responses to drug 
prevalence questions. Only the British Crime Survey 
(BCS) report mentions that piggybacking on a crime/
victimisation survey may lead to underestimates of 
drug use. Its experts further explain this possible bias 
in our expert survey: ‘A quick look at the difference 
between the BCS prevalence rates (a victimisation 
survey) and those from the Offending Crime and 
Justice Survey (OCJS is an offending survey) found 
that the latter were consistently higher (…). It was 
speculated that if people had already answered 
questions about offending (in the OCJS) they were 
more ready to admit illicit drug use than following 
questions about being victims of crime as in the BCS.’ 
The influence of the context was (partly) the reason 
why the Hungarian experts chose for a single survey. 
In our expert survey they argue that when comparing 
ESPAD and HBSC data, the latter always reveal lower 
prevalence rates than the former. Notwithstanding the 
awareness of the possible bias caused by the context, 
none of the piggybacking countries have explicitly 
studied the (possible) impact of the health or crime 
context. Still, the French researchers stated in our 
expert survey that ‘the bias may be relatively constant 
from one survey to another’.
The commissioners/responsible agents, the cooperating 
partners or the origin of the financial resources can 
logically also influence the choice for either a single or 
a piggybacking questionnaire. The Czech experts 
justify their single survey as follows: ‘… the survey was 
financed by the Office of the Government of the Czech 
researchers are concerned that respondents tend to 
under-report their alcohol and drug consumption when 
the main focus of the survey is on the health status.
In 1998 and 1999, Northern Ireland conducted a 
general survey, an ‘omnibus survey’ as they called it, 
about the behaviour, lifestyle and views of a 
representative sample of the people of Northern 
Ireland (11). In 2002, however, Ireland switched to a 
single drug prevalence survey in order to remedy the 
lack of knowledge about drug use in the general 
population and to meet the (non-binding) request of the 
EMCDDA to gather comparable and consistent 
information about drug use in the general population. 
Furthermore, as a shorter questionnaire results in better 
response rates, several countries (e.g. the Czech 
Republic, Finland) opted for a single questionnaire with 
fewer questions instead of a piggybacked questionnaire. 
In 2008, Denmark conducted a single drug survey for 
the first time, as the Danish Health Interview Survey (HIS) 
was already quite long and allowed only a limited 
number of questions concerning alcohol and drug use to 
be included. Hungary mentions a long questionnaire as 
a counter-argument for a piggybacked survey. Spain 
also mentions that drug surveys usually need higher 
sample sizes than health surveys. In contrast, the experts 
of the British Crime Survey justify a piggybacking design 
by pointing out that it offers a very large sample size for 
limited expenditure. In the Cypriot survey, on the other 
hand, more pragmatic reasons are given: ‘The survey 
dealt mainly with drugs and was not part of a survey 
with a wider scope, due to the limitations of 
competences and duties of the institute commissioning 
the survey’. A similar reason is given in the Lithuanian 
expert survey: there simply was no opportunity to 
piggyback. 
The first condition for piggybacking is that the survey 
must be suitable. Findings from the literature and this 
meta-analysis show that a health or a crime survey is 
appropriate. The database of the European Health 
Interview and Health Examination Surveys (12) contains 
one or more Health Interview Surveys conducted in the 
year 2000 of every country in our meta-analysis, while 
exploring the Internet on crime and victimisation 
surveys mainly gives results for England and Wales 
and Scotland only. This means that in theory every 
country has the opportunity to piggyback on a health 
survey, and to a lesser degree on a crime survey. 
Nevertheless, most countries have conducted a single 
(11)  As the results of these omnibus surveys are not comparable with the results of the first national population survey on drug use in 2002/3, 
we decided to exclude these data of the omnibus surveys from our meta-analysis.
(12)  https://hishes.iph.fgov.be/index.php?hishes=survey_search&view_mode=survey
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Some countries have only recently organised a 
population survey on drug use for the first time, with the 
intention of conducting a systematic survey (e.g. 
Romania and Austria). In this respect, the efforts of new 
EU members such as Malta, Cyprus, Hungary or Latvia 
are striking. That does not mean that nothing was known 
about substance use in those countries before. In the 
past, some drug-related questions were sporadically 
inserted into surveys on other topics (e.g. Hungary and 
Latvia), or drug use was studied among specific target 
groups, such as ESPAD school surveys (e.g. Hungary, 
Latvia and Malta). The reason those countries give for 
starting a regular general prevalence survey, is that it 
offers a more general perspective on substance use 
among the general population and as well as meeting 
the request of the EMCDDA mentioned above.
The ‘current/next survey’ column in Table 17 shows the 
recently conducted surveys or those planned for the 
near future. When no report was available yet (e.g. 
Hungary or Romania), or when the surveys were not 
yet (fully) completed (e.g. Estonia and Greece), the 
versions have not been incorporated in our meta-
analysis. This information is only offered to present a 
more complete overview. 
3.2.3 Level of analysis
The last column of Table 17 shows the aims of the 
analyses of the data obtained through general 
population surveys. The level of analysis varies from 
descriptive (‘the analysis of results primarily described 
current situations or trends’) to causal inference (more 
cross-sectional association between drug use and other 
factors such as the respondent’s characteristics) to 
explanatory (systematic explanation of drug 
prevalence based on theoretical assumptions and 
empirical observations, e.g. urbanisation) (EMCDDA, 
2002). However, some reports state that more 
profound statistics will be produced later or that more 
detailed results will be given in the report of a 
following prevalence study (e.g. Scotland, 2004).
Republic from a budgetary chapter on Expenditures on 
drug policy.’ The Slovakian expert survey makes a 
reference to the cooperating partner, the ‘General 
Secretariat of Board of Ministers for Drug 
Dependencies and Drug Control’.
3.2.2 Frequency
There is a large variety in the frequency of questioning 
the population (Table 17). Almost every survey is part 
of a continuous series that aims to identify trends 
(‘tracking’). Nonetheless, even within this category 
there is a large difference between annual surveys (e.g. 
the British Crime Survey is a continuous survey, which 
is reported on an annual basis) and those with a 
standard interval (e.g. France every 5 years). Only a 
few countries (e.g. Germany) have conducted some 
surveys before, though not as part of a continuous 
series (‘regular’). 
The reasons why a research team chooses to conduct 
the survey as frequently as indicated in Table 17 are 
similar for the different countries. Financial feasibility 
seems to be the main motive (Austria, France, Ireland, 
Norway, Cyprus, Denmark 2005, England and 
Wales). Having enough time for data collection and 
in-depth analysis (France, Denmark 2005, Italy), the 
EMCDDA recommendation to conduct a survey at least 
every 4 years (Romania) and alternating with ESPAD 
surveys (Austria, Hungary), are other reasons given in 
the expert survey. Although several countries want to 
identify trends or new developments and gather 
up-to-date information (e.g. Finland, Ireland, Austria, 
the Czech Republic, Croatia), the time period between 
two surveys can be very different (from 2 to 5 years). 
For example, in Norway every 5 years a drug survey 
is conducted because ‘most things don’t change very 
fast’, whereas in Spain drug surveys are carried out 
more frequently (every 2 years) as ‘the phenomenon of 
drug use frequently changes’.
Table 17: General characteristics
Country Year Context Frequency Current/next survey Level of analysis
Austria 2004 Single (licit and illicit 
drugs)
Tracking 2008 Descriptive –  
causal inference
Belgium 2001 Health Tracking
2012
n.a.
2004 Health Tracking n.a.
2008 Health Tracking n.a.
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Country Year Context Frequency Current/next survey Level of analysis
Bulgaria 2005 Single Single (first) 2008/9
Croatia 2009 
(expected)
Multi-health survey Single (planned survey, 
aim is to conduct every 
3 to 5 years)
n.a. n.a.
Cyprus 2006 Drugs (additional mental 
health questions)
First study (aim is to 
conduct every 3 years)
2009 Descriptive — 
causal inference
Czech 
Republic
2004 Single First study (aim is to 
conduct every 3 years)
2008 Descriptive
Denmark 2000 Health Tracking (every 5 
years)
2010/11
Descriptive —  
causal inference
2005 Multi-purpose health 
interview survey
Tracking Descriptive —  
causal inference
2008 Single First (aim is to conduct 
every 2 to 3 years)
Not decided yet Descriptive 
(primarily)
England and 
Wales
1996 Multi-crime survey Tracking
2007/8
Causal inference 
+ explanatory
1998 Multi-crime survey Tracking Causal inference 
+ explanatory
2000 Multi-crime survey Tracking Causal inference 
+ explanatory
2001/2 Multi-crime survey Tracking Causal inference 
+ explanatory
2002/3 Multi-crime survey Tracking Causal inference 
+ explanatory
2003/4 Multi-crime survey Tracking Causal inference 
+ explanatory
2004/5 Multi-crime survey Tracking Causal inference 
+ explanatory
2005/6 Multi-crime survey Tracking Causal inference 
+ explanatory
2006/7 Multi-crime and 
victimisation survey
Tracking Causal inference 
+ explanatory
Estonia 2003 Family, work, leisure, 
economic situation, 
livelihood and health 
including drugs
Tracking (3rd study, 
every 5 years)
2008 n.a.
Finland 1992 Single Tracking
2008 (drinking 
habits) 2010 
(drugs)
Causal inference
1996 Single Tracking Causal inference
1998 Single Tracking Causal inference
2002 Single (alcohol and 
drugs)
Tracking Causal inference
2004 Single (alcohol and 
drugs)
Tracking (1) Causal inference
2006 Single (alcohol and 
drugs, some questions 
about tobacco and 
pharmaceuticals)
Tracking (1) Causal inference
Table 17 continued
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Country Year Context Frequency Current/next survey Level of analysis
France 1995 Multi-health Tracking
2010
Descriptive + 
causal inference
2000 Multi-health Tracking Descriptive + 
causal inference
2005 Multi-health Tracking Descriptive + 
causal inference
Germany 1995 Single Regular
2006/9
Descriptive + 
causal inference
1997 Single Regular Descriptive + 
causal inference
2000 Single Regular Descriptive + 
causal inference
2003 Single Regular Descriptive + 
causal inference
Greece 1998 Single Regular
2009
Descriptive + 
causal inference
2004 Multi-health Tracking (with some 
exceptions, every 5 
years)
Descriptive + 
causal inference
Hungary 2001 Single (alcohol and 
drugs)
First study 
2007/11
Descriptive + 
explanatory
2003 Single (alcohol, tobacco 
and drugs)
Tracking Descriptive + 
explanatory
Ireland 2002/3 Single First study
2010/11
Descriptive + 
causal inference
2006/7 Single Tracking (aim is a 
survey every 4 years)
Descriptive + 
causal inference
Italy 2001 Single (alcohol and 
drugs)
Tracking 
2007/9
Descriptive
2003 Single (alcohol and 
drugs)
Tracking Descriptive + 
explanatory
2005 Single (alcohol and 
drugs)
Tracking Descriptive + 
explanatory
Latvia 2003 Single First study n.a. n.a.
Lithuania 2004 Single First (aim is a survey 
every 4 years)
2008 Causal inference
Malta 2001 Single First study Possibly 2011 n.a.
Netherlands 1997 Single Tracking
Probably 2009
Descriptive + 
causal inference 
+ explanatory
2001 Single Tracking Descriptive
2005 Single (web survey) 
Multi (CAPI survey)
Tracking Descriptive
Norway 2004 Single main focus on 
alcohol
Tracking (every 5 
years)
2009 Descriptive + 
causal inference 
+ explanatory
Table 17 continued
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Country Year Context Frequency Current/next survey Level of analysis
Poland 2002 Single (drugs and alcohol) First study n.a. n.a.
Portugal 2001 Single (licit and illicit 
psychoactive substances)
First study, will be 
repeated
2007 n.a.
Romania 2004 Single First study (aim is a 
survey every 3 years)
2007/10 Descriptive + 
causal inference 
Scotland 2000 Multi-crime survey Tracking 
n.a.
n.a.
2003 Multi-crime survey Tracking n.a.
2004 Multi-crime and 
victimisation survey
Tracking n.a.
2006 Multi-crime and 
victimisation survey
Tracking n.a.
Slovakia 2002 Single (alcohol and 
smoking)
Tracking (every 2 
years from 1994 
onwards)
2008
Descriptive + 
causal inference
2004 Single (alcohol and 
smoking)
Tracking Descriptive + 
causal inference
2006 Single (alcohol, tobacco 
and drugs)
Tracking Descriptive + 
causal inference
Spain 1995 Single Tracking
2007/9
Descriptive + 
causal inference
1997 Single Tracking Descriptive + 
causal inference
1999 Single Tracking Descriptive + 
causal inference
2001 Single Tracking Descriptive
2003 Single Tracking Descriptive
2005 Single Tracking Descriptive
Sweden 2004 Multi-health First study (aim is a 
bi-annual survey)
2007/8
Descriptive
2005 Multi-health Tracking Descriptive
2006 Multi-health Tracking Descriptive
NB:
Adapted from the EMCDDA Handbook, p. 124 (EMCDDA, 2002).
Data from the 2001 EMCDDA overview is indicated in grey.
(1) The 2004 and 2006 studies were also part of the alcohol panel studies conducted in 2003, 2004, 2005 and 2006.
n.a.: not known/not available.
Table 17 continued
3.3  Commissioners and responsible 
agents
Policymakers need reliable and accurate data about 
the nature and the extent of the drug phenomenon in 
their country in order to be able to define priorities, to 
plan efficient interventions, and to evaluate long-term 
policies. Therefore, it only seems rational that the 
commissioner — the authority or institute that initiates 
and commissions the population survey — is in most 
cases the national government, in particular the 
Ministry of Health (Table 18). Sometimes a research 
institute under the Ministry (e.g. STAKES in Finland or 
OKANA in Greece) commissions the survey. In 
Scotland, for example, the national research agency 
‘Scottish Executive Social Research’ is the 
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Netherlands 2001, France 2005, England and Wales). 
In Scotland and Spain, for example, a commercial 
research agency executed the survey. 
In some countries, the national focal point was the 
commissioner (e.g. Bulgaria, Croatia, the Czech 
Republic, Italy) and/or the agent responsible (e.g. 
Belgium, France 1995 and 2000, Austria, Germany, 
Greece) for the general population survey. In 
Belgium, Slovakia and Sweden, the National 
Statistical Office (Federal Public Service Economy 
— Directorate-General Statistics Belgium, Statistical 
Office of the Slovak Republic, and Statistics Sweden 
respectively) played a major part in commissioning 
and/or conducting the survey.
commissioner. In none of the studied surveys is the 
commissioner a private or commercial enterprise. 
Neither is it a Ministry of Justice, which implicitly 
confirms that drug surveys are generally conducted 
from a health point of view (‘health problem’) rather 
than from a crime point of view (‘illegal drug use’). 
The agent responsible for the survey — the body that is 
in charge of the organisation and the analysis of the 
survey — is usually a university. Given the practical 
and theoretical expertise of methodological and 
intrinsic aspects of conducting a (drug) survey, this 
seems reasonable. In several of the studied surveys, the 
responsible agent cooperated with commercial 
institutes for the data gathering (e.g. Austria, the 
Table 18: Agencies and authors of main survey reports
Country Year
Commissioned by Responsible agent
Type Name Type Name
Austria 2004 G Federal Ministry of Health and 
Women
G 
P
Federal Ministry of Health and Women 
Support in planning: Austrian Reitox focal 
point (ÔBIG) and Alcohol Coordination 
and Information Centre (AKIS) 
Execution: Market Institute 
Analysis: Ludwig Boltzmann Institute for 
Addiction Research
Belgium 2001 G Federal and regional authorities G 
 
 
A 
 
G
Scientific Institute of Public Health, 
Epidemiology Unit 
External cooperation from  
Department Biostatistics, Limburgs 
Universitair Centrum (LUC) and  
Federal Public Service Economy, 
Directorate-General Statistics Belgium
2004 G Federal and regional authorities G 
 
 
A 
 
G
Scientific Institute of Public Health, 
Epidemiology Unit 
External cooperation from  
Department Biostatistics, Limburgs 
Universitair Centrum (LUC) and  
Federal Public Service Economy, 
Directorate-General Statistics Belgium
2008 G Federal and regional authorities G 
 
 
A 
 
G
Scientific Institute of Public Health, 
Epidemiology Unit 
External cooperation from  
Department Biostatistics, Limburgs 
Universitair Centrum (LUC) and  
Federal Public Service Economy, 
Directorate-General Statistics Belgium
Bulgaria 2005 National focal point and National 
Centre for Addictions 
Financed by National Anti-Drug 
Strategy 2003–08
Centre for social strategies and initiatives, 
Sofia; National centre for investigating 
public opinion National focal point 
(methodological guidance)
Croatia 2009 
(expected)
G National focal point and 
International Relations Department – 
Office for Combating Narcotic 
Drugs Abuse of the Government of 
the Republic of Croatia
n.a. n.a.
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Country Year
Commissioned by Responsible agent
Type Name Type Name
Cyprus 2006 G Cyprus Anti-Drug Council (semi-
governmental body under the 
auspices of the Ministry of Health)
A Intercollege Research Centre and Institute 
for Social Innovation
Czech 
Republic
2004 G Czech national focal point (part of 
the Office of the Government)
G Institute of Health Information and 
Statistics (UZIS CR, part of the Ministry of 
Health) 
Czech national focal point
Denmark 2000 A 
 
G-N
National Institute of Public Health, 
University of Southern Denmark and 
Ministry of the Interior and Health 
Questions about drugs were 
financed by the National Board of 
Health
A National Institute of Public Health, 
University of Southern Denmark
2005 A National Institute of Public Health, 
University of Southern Denmark
A National Institute of Public Health, 
University of Southern Denmark
2008 G-N The National Board of Health A 
G-N
The National Board of Health National 
Institute of Public Health, University of 
Southern Denmark
England 
and Wales
1996 G Home Office G Home Office, Research and Statistics 
Directorate
1998 G Home Office G Home Office, Research and Statistics 
Directorate
2000 G Home Office G Research Development and Statistics 
Directorate (part of the Home Office)
2001/2 G Home Office G Research Development and Statistics 
Directorate
2002/3 G Home Office G Research Development and Statistics 
Directorate
2003/4 G Home Office G Research Development and Statistics 
Directorate
2004/5 G Home Office G Research Development and Statistics 
Directorate
2005/6 G Home Office G Research Development and Statistics 
Directorate
2006/7 G Home Office G 
 
P
Analysis: Research Development and 
Statistics Directorate 
Fieldwork: BMRB (British Market Research 
Bureau)
Estonia 2003 n.a. n.a. Institute of International and Social 
Studies
Finland 1992 G Ministry of Social Affairs and Health A Department of Public Health, University of 
Helsinki
1996 G Ministry of Social Affairs and Health A Department of Public Health, University of 
Helsinki
1998 G Research & Development Centre for 
Welfare and Health (STAKES) (sector 
research institute under the Ministry 
of Social Affairs and Health)
G Research & Development Centre for 
Welfare and Health (STAKES)
Table 18 continued
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Country Year
Commissioned by Responsible agent
Type Name Type Name
2002 G Research & Development Centre for 
Welfare and Health (STAKES)
G Research & Development Centre for 
Welfare and Health (STAKES)
2004 G Research & Development Centre for 
Welfare and Health (STAKES)
G Research & Development Centre for 
Welfare and Health (STAKES)
2006 G Research & Development Centre for 
Welfare and Health (STAKES)
G Research & Development Centre for 
Welfare and Health (STAKES)
France 1995 G Ministry of Social Affairs and Health P Comité Français d’Éducation pour la Santé 
(CFES) 
(private organisation dedicated to improving 
the health of the French population through 
education and research)
2000 G Ministry of Social Affairs and Health P 
 
G
Comité Français d’Éducation pour la Santé 
(CFES)  
+ Observatoire Français des Drogues et 
Toxicomanies (OFDT) 
(national focal point for the European 
Reitox network, coordinated by the 
EMCDDA)
2005 A National Institute for Prevention and 
Health Education (INPES) (academic 
institution with public funding)
A 
P
National Institute for Prevention and 
Health Education (INPES) & ATOO 
(research agency)
Germany 1995 G Ministry of Health Institut für Therapieforschung (ITF)/Institute 
for Therapy Research 
(Reitox national focal point)
1997 G Ministry of Health Institut für Therapieforschung (IFT)
2000 G Ministry of Health Institut für Therapieforschung (IFT)
2003 G Ministry of Health 
(BMGS: Bundesministerium für 
Gesundheit und Soziale Sicherung, 
Federal Ministry for Health and 
Social Security)
Institut für Therapieforschung (IFT)
Greece 1998 OKANA (Organisation against 
Drugs) 
(governed by private law and 
reporting to the Ministry of Health 
and Social Solidarity)
A University Mental Health Research 
Institute (U.M.H.R.I.) 
(Greek national focal point)
2004 OKANA (Organisation against 
Drugs)
A University Mental Health Research Institute 
(U.M.H.R.I.)
Hungary 2001 G Ministry of Youth and Sports ISM A Budapest University of Economic Sciences 
and Public Administration, Behaviour 
Research Centre
2003 National Research and Development 
Project
A 
 
 
P
Corvinus University of Budapest, Faculty 
of Social Sciences, Centre for Behaviour 
Research  
MIMIKRI Ltd
Ireland 2002/3 G National Advisory Committee on 
Drugs (NACD) in Ireland and Drug 
and Alcohol Information and 
Research Unit (DAIRU) within the 
Department of Health, Social 
Services and Public Safety in 
Northern Ireland
G 
 
P 
National Advisory Committee on Drugs 
via a research advisory committee 
MORI MRC 
(research agency)
Table 18 continued
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Country Year
Commissioned by Responsible agent
Type Name Type Name
2006/7 G National Advisory Committee on 
Drugs (NACD) in Ireland and Drug 
and Alcohol Information and 
Research Unit (DAIRU) within the 
Department of Health, Social 
services and Public Safety in 
Northern Ireland
G 
 
P 
National Advisory Committee on Drugs 
via a research advisory committee 
MORI MRC 
(research agency)
Italy 2001 Italian Observatory on Drugs and 
Drug Addiction, Ministry of Labour 
and Social Policy (the Observatory 
was formerly located in the 
Department for Social Affairs of the 
Presidency of the Council)
A Epidemiological Section of the Institute of 
Clinical Physiology, National Research 
Council
2003 Italian Observatory on Drugs and 
Drug Addiction (OIDT), Ministry of 
Labour and Social Policy
A Epidemiology Section of the Institute of 
Clinical Physiology, National Research 
Council
2005 A Italian Observatory on Drugs and 
Drug Addiction, Epidemiology 
Section of the Institute of Clinical 
Physiology, National Research 
Council
A Epidemiology Section of the Institute of 
Clinical Physiology, National Research 
Council
Latvia 2003 2000 Phare National Programme 
for Latvia
A Institute of Philosophy and Sociology, 
University of Latvia
Lithuania 2004 G National focal point Drug Control 
Department under the Government 
of the Republic of Lithuania
P Institute of Sociology; Market Analysis 
and Research company RAIT Ltd.
Malta 2001 G National Commission on the abuse 
of drugs, alcohol and other 
dependencies, Ministry for Social 
Policy
A University of Amsterdam, Bonger Institute 
of Criminology
Netherlands 1997 G Ministry of Health A Centre for Drug Research (CEDRO – 
Amsterdam University)
2001 G Ministry of Health, Welfare and 
Sports
A 
 
P
Centre for Drug Research (CEDRO – 
Amsterdam University) &  
NIPO (field work partner)
2005 G Ministry of Health, Welfare and 
Sports
A IVO (Addiction Research Institute 
Rotterdam) 
Statistics Netherlands (CBS)
Norway 2004 A Norwegian Institute for Alcohol and 
Drug Research (SIRUS)
A SIRUS 
Field work by MMI
Poland 2002 National Bureau of Drug Prevention
Portugal 2001 IPDT (Instituto Português da Droga e 
da Toxicodependência – Institute for 
Drugs and Drug Addiction)
A CEOS – Investigações Sociológicas / 
UNL (Universidade Nova de Lisboa)
Romania 2004 G National Anti-drug Agency 
(subordinated to the Ministry of 
Administration and Interior)
G National Anti-drug Agency
Scotland 2000 G Scottish Executive Central Research 
Unit
P Company MVA Ltd.
2003 G Scottish Executive Social Research P TNS Social Research + MORI Scotland 
(survey companies)
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Country Year
Commissioned by Responsible agent
Type Name Type Name
2004 G Scottish Executive Social Research P TNS Social Research + MORI Scotland 
(survey companies)
2006 G Scottish Government Social Research P BMRB Social Research (survey company)
Slovakia 2002 G Statistical Office of the Slovak 
Republic (SO SR)
G Institute for Public Opinion Research at the 
SO SR
2004 G Statistical Office of the Slovak 
Republic (SO SR)
G Institute for Public Opinion Research at the 
SO SR
2006 G Statistical Office of the Slovak 
Republic (SO SR)
G Institute for Public Opinion Research at the 
SO SR
Spain 1995 G Plan National de Drogas P EDIS/PND
1997 G Plan National de Drogas P Sigma Dos (research agency)/PND
1999 G Plan National de Drogas P Sigma Dos/PND
2001 G Plan National de Drogas 
(Ministerio del Interior)
P Sigma Dos
2003 G Plan National de Drogas 
(Ministerio de Sanidad y Consumo)
P Sigma Dos
2005 G Plan National de Drogas P Sigma Dos
Sweden 2004 G National Institute of Public Health 
(state agency under the Ministry of 
Health and Social Affairs)
G 
G
National Institute of Public Health 
Statistics Sweden 
(central government authority for official 
statistics and other government statistics)
2005 G National Institute of Public Health G 
G
National Institute of Public Health 
Statistics Sweden
2006 G National Institute of Public Health G 
G
National Institute of Public Health 
Statistics Sweden
NB:
Adapted from the EMCDDA Handbook, p. 125–126 (EMCDDA, 2002).
Data from the 2001 EMCDDA overview is indicated in grey.
Type of commissioner/responsible agent:
G: Government
A: Academic institution
P: Private/commercial company
n.a.: not known/not available.
Table 18 continued
3.4 Target population characteristics
3.4.1 Target population
a. Age restriction
The target population is mainly defined by age (Table 
19). The lower age limits vary from 12 to 19 years and 
the upper limits start at 59, which means that studies 
do not diverge much from the setting recommended by 
the EMCDDA (15–64 years). A few studies do not 
have an upper age limit (e.g. Denmark, Poland, 
Norway, and Slovakia), and the Belgian HIS has no 
age restriction at all. All inhabitants of Belgium can 
take part, although the written questionnaire, with more 
sensitive subjects such as AIDS, suicide, trauma and 
drugs, can only be completed by respondents over 15.
Most survey reports do not account explicitly for the 
specific age restriction of the target population, but 
when they do, they refer to the reasons given by the 
EMCDDA (for not questioning the elderly due to 
memory effects and/or their low prevalence rates for 
the use of prohibited drugs) or to the existence of 
school surveys (for not questioning youngsters). This is 
the case in the Hungarian survey of 2003. Further 
information about the definition of the target 
population was obtained through our expert survey. 
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same reason is given by the experts of the Netherlands 
for the introduction of 64 years as an upper age limit. 
In the 2008/9 British Crime Survey, the upper age limit 
was also extended to 69 years to conform to the 
EMCDDA standard. The British will further test 
extending the age range to include children, but it is 
not certain yet whether this younger age group will be 
interviewed about drugs, since school surveys already 
provide drug information about this age group and 
‘(…) there are recognised problems with asking 
children of this age questions about drug use in their 
homes (e.g. possible impact on response if parents see 
these questions as intrusive; possible tendency to under-
report if feel that parents might see responses). 
However, there are some possible benefits: asking 
young people at the top of the age range these 
questions would provide a way of calibrating the two 
sets of prevalence (those from school surveys being 
higher than those from household surveys); the BCS 
provides regional prevalence rates whereas the school 
survey design only provides national estimates.’
b. Other restrictions
Several countries impose other restrictions on the target 
population besides age limits. For example, Austria, 
Ireland, the Netherlands, Cyprus, the Czech Republic, 
Lithuania, Romania, Norway, Scotland, Spain, Finland, 
France, Hungary and England and Wales excluded 
institutionalised people, including people in prison, 
nursing homes or clinics. The same applies to the 
Belgian survey, although elderly people living in old 
people’s homes and (psychiatric) nursing homes were 
included in the sample, because of the main interest of 
the survey, i.e. health. Except for Romania, all these 
countries also mention that they did not interview 
homeless people. Although several countries 
recognised that those groups may be of interest for 
their potentially higher rates of drug use, they excluded 
them for practical reasons (groups are not covered by 
the sampling frame or are difficult to reach) in 
advance. Austria, France, Cyprus, the Czech Republic, 
the Netherlands, Spain and Germany limit their target 
population to native speakers, for practical and 
budgetary reasons. For obvious reasons, deaf people 
are excluded from the telephone survey in France.
c. Explicit versus implicit exclusion
A remark on the definition of the target population is 
called for. Defining or restricting the target population 
in advance is obviously only possible when the 
sampling frame contains the information that is 
needed to do so. For example, being deaf or the 
In the Austrian survey, people up to 100 years old were 
questioned, because the survey focus was on alcohol 
and tobacco use, which the researchers believe is 
relevant to the elderly also. The Norwegian, Slovakian 
and Danish expert surveys show an interest in the 
alcohol/drug habits (or health) of the whole population, 
and not just of the target population set by the EMCDDA. 
A similar rationale is offered in the Swedish expert 
survey. The Danish experts argue that the elderly is an 
interesting group to study because in Denmark they drink 
more than in other countries. The United Kingdom 
implements an upper age restriction (59 years), but only 
for the drug part of the crime survey. A similar age 
restriction is made in Scotland. In 2003, the Scottish 
Crime Survey was administered to adult respondents 
only, as this made the administration easier for the 
interviewers and as it was also felt that there are likely to 
be increasing numbers of older adults with experience of 
drug use. However, in 2006 the drug module was again 
restricted to people under the age of 60.
In the Czech survey, youngsters under 18 years old 
were excluded from the target population, because the 
researchers assumed that youngsters would  
under-report their substance consumption in face-to-face 
interviews, especially when their parents were present 
during the interview. In addition, the 15–18 age group 
had already been questioned about drugs in school 
surveys. Nevertheless, the EMCDDA recommends the 
inclusion of youngsters in the general population 
sample in order to compare the results of the general 
population survey with those of the school survey. 
However, questioning youngsters may be restricted for 
several reasons. In Germany, for example, the 
interviewing of teenagers under the age of 18 is legally 
restricted, whereas in Sweden, youngsters of 16 years 
can participate without their parents’ approval. 
Furthermore, an age restriction may have implicit social 
grounds. In Turkey, for instance, youngsters are not 
questioned about drug use, because the researchers do 
not want to incite or encourage them to use drugs. 
Some countries changed the definition of the target 
population in the course of the successive waves. Over 
three surveys Finland lowered the minimum age and 
the upper age limit from 18 to 15 years and from 74 to 
69 years respectively. The experts argue that the 15 to 
69 year age range is consistent with their alcohol 
surveys. They also state that there are no drug users 
among people over 70, whereas some 15-year-olds 
have already tried drugs. Italy, on the other hand, 
raised the upper age limit from 44 to 64 years over 
three waves to bring the age of the target population 
in line with the recommendations of the EMCDDA. The 
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In recent meetings of the EMCDDA, the oversampling 
of youngsters and inner city or urban areas has been 
recommended with a view to a more cost-effective use 
of the sample (EMCDDA, personal communication, 
2008c).
Finally, ethnic minority groups are sometimes 
oversampled. In addition to a young persons boost 
sample, the Scotland surveys contain an ethnic minority 
boost sample. Similar boost samples were drawn in the 
annual editions of the British Crime Survey (from 
2001/2 onwards) (13). As the Home Office wanted 
separate estimates for ethnic minority groups, a boost 
sample was drawn in the main black and Asian 
minority populations (14). Again, higher expected 
prevalence figures in these groups were the reason for 
introducing the two boost samples in the British Crime 
Surveys. By oversampling these groups, the progress of 
the drug strategy could be monitored more efficiently.
b. Detailed information
Besides higher expected prevalence rates, the wish to 
obtain more detailed information about a specific 
group/region may be a reason for oversampling. In the 
Austrian survey, the province of Carinthia was 
oversampled because an extra budget was available 
for a special analysis of the province. In Spain, low-
populated regions were oversampled in order to make 
more precise estimates at a regional level. The same 
applies to the Italian survey and the Irish survey of 
2006/7, which oversampled some (small) 
geographical areas. In the Netherlands, the 12–18 age 
group and big cities were oversampled because the 
researchers wanted to present outcomes per stratum of 
2 years/per city. 
c. Low response rates
Finally, low response rates in certain groups can also 
be a reason for oversampling. In the Italian survey 
youngsters were oversampled as the response rate in 
the age group below 18 years tends to be low. In the 
next Estonian survey the young urban male population 
will be over-represented, since as a rule the response 
rate among them is the lowest. On the other hand, 
elderly women will be under-represented, since the 
response rate among them is the highest. 
language the respondent speaks, are pieces of 
information that are generally not available in a 
sampling frame. For that reason, some people are 
implicitly excluded from the sample. Findings from our 
expert survey illustrate this. Even though no groups 
were intentionally excluded from the Slovakian 
sampling frame, the expert survey finds that ‘some 
marginalised or socially excluded persons (prisoners, 
homeless or hospitalised people) are difficult to 
reach’. The implicit exclusion of these groups is also 
observed in the Austrian expert survey and may 
apply to other countries as well. A better 
standardised registration of the target population and 
the sample frame could help to explain the implicit/
explicit exclusion.
3.4.2 Reasons for oversampling
a. High prevalence rates
Some specific target groups are often oversampled 
(Table 19). The main reason for oversampling is a 
higher prevalence of drug use in oversampled groups 
such as youngsters, city areas, and ethnic minorities. 
Youngsters are oversampled most often. For example, 
the 15–39 age group was oversampled in the 
Spanish survey as the researchers wanted a high 
number of respondents in a group that is 
characterised by the highest vulnerability for drug 
consumption. Similarly, in the next survey of the 
Czech Republic the 15–29 age group will be 
oversampled to gather valuable information on drug 
availability, cannabis markets and intensive cannabis 
use (new modules in the next survey). In several other 
surveys youngsters were oversampled for precisely 
that reason (e.g. Denmark 2008, Croatia, Cyprus: 
15–24 and 25–34 years, Finland: 15–34 years, 
Lithuania: 15–24 years, England and Wales, 
Hungary: 18–34 years). In Slovakia, the 15–17 age 
group was oversampled owing to the specific samples 
of 18+ and 15–29.
Furthermore, some countries oversampled city areas. 
The Romanian survey oversampled Bucharest because 
of its high prevalence of illegal drug use. For the same 
reason, the Hungarian surveys oversampled some cities 
or regions. 
(13)  The ethnic boost was discontinued in 2006/7 because the increased sample size in the previous year already resulted in a large 
enough ethnic sample in the main survey.
(14)  Drawing samples in other ethnic minority groups was evaluated as not cost-effective given their size and dispersal within the general 
population.
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Table 19: Target population characteristics
Country Year Target population Oversampling
Austria 2004 14–100 years  
Excluding non-native speakers, institutionalised 
people, homeless people and youngsters below 
14 years
Yes: province of Carinthia
Belgium 2001 All inhabitants with no restrictions for age, 
nationality or legal status, except for the 
sensitive questions only 15+ years 
Excluding institutionalised people
Yes: the regions of Antwerp, Hinaut, 
Luxembourg and Limburg
2004 All inhabitants with no restrictions for age, 
nationality or legal status, except for the 
sensitive questions only 15+ years 
Excluding institutionalised people
Yes: the elderly and the regions of 
Luxembourg and Limburg
2008 All inhabitants with no restrictions for age, 
nationality or legal status, except for the 
sensitive questions only 15+ years 
Excluding institutionalised people
Yes: the elderly 
Bulgaria 2005 18–60 years No
Croatia 2009 (expected) 15–64 years Yes: youngsters
Cyprus 2006 15–64 years 
Excluding non-native speakers and 
institutionalised people
Yes: 15–24 and 25–34 age groups
Czech 
Republic
2004 18–64 years 
Excluding non-native speakers, institutionalised 
and homeless people
No
Denmark 2000 16+ years No
2005 16+ years No
2008 16+ years Yes: youngsters
England and 
Wales
1996 16–59 years (for drug section) Yes: inner-city areas and ethnic booster 
(n=1995)
1998 16–59 years (for drug section) Yes: inner-city areas
2000 16–59 years (for drug section) 
Excluding institutionalised and homeless people
Yes: ethnic boost sample
2001/2 16–59 years (for drug section) 
Excluding institutionalised and homeless people
Yes: ethnic and youth boost samples
2002/3 16–59 years (for drug section) 
Excluding institutionalised and homeless people
Yes: ethnic and youth boost samples
2003/4 16–59 years (for drug section) 
Excluding institutionalised and homeless people
Yes: ethnic and youth boost sample
2004/5 16–59 years (for drug section) 
Excluding institutionalised and homeless people
Yes: ethnic and youth boost sample
2005/6 16–59 years (for drug section) 
Excluding institutionalised and homeless people
Yes: ethnic and youth boost sample
2006/7 16–59 years (for drug section) 
Excluding institutionalised and homeless people
Yes: youth boost sample
Estonia 2003 15–69 years n.a.
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Country Year Target population Oversampling
Finland 1992 18–74 years 
Excluding institutionalised and homeless people
No
1996 16–74 years 
Excluding institutionalised and homeless people
No
1998 15–69 years 
Excluding institutionalised and homeless people
No
2002 15–69 years 
Excluding institutionalised and homeless people
Yes: 15–34 age group
2004 15–69 years 
Excluding institutionalised and homeless people
Yes: after 500 completed surveys, the 
age group of 15–34 is oversampled
2006 15–69 years 
Excluding institutionalised and homeless people
Yes: 15–34 age group
France 1995 18–75 years No
2000 12–75 years No
2005 12–75 years, French-speaking 
(15+ for sensitive parts such as illicit drug use) 
Excluding homeless, deaf people and those 
living in institutions
No
Germany 1995 18–59 years, German-speaking No
1997 18–59 years, German-speaking No
2000 18–59 years, German-speaking No
2003 18–59 years, German-speaking No
Greece 1998 12–64 years, Aegean and Ionian Islands 
excluded
Yes: 12–24 age group
2004 12–64 years, Aegean and Ionian Islands 
excluded
Yes: 12–24 age group
Hungary 2001 18–65 years 
Excluding non-native speakers, institutionalised 
and homeless people
Yes: Budapest
2003 18–54 years 
Excluding non-native speakers, institutionalised 
and homeless people
Yes: 18–34 age group in Budapest 
and bigger cities
Ireland 2002/3 15–64 years, living in private households No
2006/7 15–64 years, living in private households Regions with smaller populations
Italy 2001 15–44 years Youngsters (<18 years)  
and urban areas (Abruzzo, Liguria, 
Veneto)
2003 15–54 years Youngsters (<18 years)  
and urban areas (Abruzzo, Liguria, 
Veneto, Sicilia)
2005 15–64 years Youngsters (<18 years)
Latvia 2003 All residents aged 15–64 years Yes: 15–24 years
Lithuania 2004 15–64 years 
Excluding institutionalised and homeless people
15–24 years
Malta 2001 18–65 years Yes
Table 19 continued
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Country Year Target population Oversampling
Netherlands 1997 12+ years Yes: age group 12–18 years and 4 
largest cities
2001 12+ years 
Excluding homeless persons and illegal 
residents
The cities of Amsterdam, Rotterdam 
(these samples were not taken in NPO 
2001 for budget reasons) + 12–19 age 
group
2005 16–64 years 
Excluding non-native speakers, institutionalised 
and homeless people (for face-to-face survey) (1) 
No
Norway 2004 15+ years No
Poland 2002 16+ years Some regions and cities
Portugal 2001 15–64 years No
Romania 2004 15–64 years, non institutionalised Bucharest 
Scotland 2000 16–59 years (drug part) 
Excluding institutionalised people
Ethnic minority ‘boost’ sample & young 
person sample (12–15 age group)
2003 16+ years 
Excluding institutionalised people
Young person sample (12–15 age 
group)
2004 16+ years 
Excluding institutionalised people
n.a.
2006 16–59 years (drug part) 
Excluding institutionalised people
n.a.
Slovakia 2002 Two specific samples: 
18+ years and 15–29 years (2)
Yes: 15–17 age group
2004 15+ years No
2006 15+ years No
Spain 1995 15+ years 
People living in institutions, community 
establishments, homeless and non-native 
speakers excluded
Yes: 15–39 age group
1997 15–65 years 
People living in institutions, community 
establishments, homeless and non-native 
speakers excluded
Yes: some regions and 15–39 years 
1999 15–65 years 
People living in institutions, community 
establishments, homeless and non-native 
speakers excluded
Yes: some regions with small 
population and 15–39 age group
2001 15–64 years 
People living in institutions, community 
establishments, homeless and non-native 
speakers excluded
Yes: some regions with small 
population and 15–39 age group
2003 15–64 years 
People living in institutions, community 
establishments, homeless and non-native 
speakers excluded
Yes: some regions with small 
population and 15–39 age group
2005 15–64 years 
People living in institutions, community 
establishments, homeless and non-native 
speakers excluded
Yes: some regions with small 
population and 15–39 age group
Table 19 continued
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Country Year Target population Oversampling
Sweden 2004 All people living in Sweden, 18–84 years No
2005 All people living in Sweden, 16–84 years No
2006 All people living in Sweden, 16–84 years No
NB:
Adapted from the EMCDDA Handbook, p. 128 (EMCDDA, 2002).
Data from the 2001 EMCDDA overview is indicated in grey.
(1) See Table 20: Survey methods applied.
(2)  As there is a growing demand for treatment in the 22–25 age group, there was a specific sample of the 15–29 age group in the 
Slovakian drug survey of 2002.
n.a.: not known/not available.
3.5 Survey methods
3.5.1 Interviewing and completion modes
Most surveys used the face-to-face interviewing mode 
with the pen and paper (P&P) questionnaire completion 
modes (e.g. Greece, Spain and Norway) (Table 20). 
No more than a few countries used computers to assist 
the interviewer: CATI (Computer Assisted Telephone 
Interviewing) in France and CAPI (Computer Assisted 
Personal Interviewing) in the Netherlands, Denmark and 
Scotland and only the UK used CASI (Computer 
Assisted Self Interviewing). However, the EMCDDA has 
the impression that nowadays the CAPI and CASI 
completion modes are used more than Table 20 
indicates (EMCDDA, personal communication, 2008c). 
Furthermore, Estonia, Italy, Sweden, Finland and 
Germany conducted a mail survey. Telephone surveys 
seem unpopular interviewing modes for drug surveys. 
Only France used a telephone survey to interview the 
general population but will consider the opportunity of 
an online survey for their next survey (in 2010). Online 
surveys are used even less. Apart from the online access 
panel in the 2005 Dutch survey, this method is never 
found to have been utilised in the analysed studies. 
Some surveys combine different interviewing and 
questionnaire completion modes (‘mixed mode design’). 
In some countries both the interviewer and the 
respondent each completed specific parts of the survey. 
For example, in the British Crime Survey, the more 
sensitive parts of the questionnaire (drugs and domestic 
violence) were completed by the respondents themselves. 
A similar questionnaire completion mode was used in 
Austria, Belgium, Spain, Scotland, Hungary, Denmark 
and Norway. In the Latvian survey the respondents only 
completed the survey by themselves when full privacy 
could not be ensured during the interview. In the German 
survey of 2006, subjects who had not completed the 
questionnaire after the third reminder, were invited to 
answer the questions by phone (15).
3.5.2 Arguments for the choice of interviewing and 
completion modes
Now and then a survey report explains the choice of a 
specific interviewing and completion mode, sometimes 
considering the experience from previous studies and 
current pilot questioning (e.g. Hungary and Norway). 
Again, our expert survey extracted some extra 
information.
a. Face-to-face surveys
Face-to-face surveys are mostly chosen for their high 
response rates and the capacity to manage the (non-)
response (Cyprus, the Czech Republic, Lithuania, 
Denmark 2005, Hungary). For example, Cyprus 
defends the choice of a (Pen & Paper) face-to-face 
survey as follows : ‘financial feasibility, completion 
control, the impact on response rate, identification of 
non-response rate and dealing with non-response 
items’. Austria justifies the use of the same method by 
referring to the support and trust the presence of an 
interviewer can create during the interview. High data 
quality of face-to-face surveys is brought forward in the 
Danish expert survey. Moreover, social or cultural 
contexts and traditions may require the researcher to 
use a (Pen & Paper) face-to-face survey, as the 
Lithuanian and Slovakian expert surveys illustrate. 
Only a few countries used computers to assist the 
interviewer during the face-to-face interviews. A lack of 
equipment or trained interviewers was the reason for 
not conducting computer assisted interviews in the 
Czech Republic, Cyprus, Norway, Spain, Hungary, 
Ireland (2002/3), Lithuania and Slovakia. In our expert 
(15)  The German general population survey of 2006 was not further studied in the meta-analysis. 
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face survey did not justify its high financial costs (Beck 
and Guilbert, 2007). A later study investigated not only 
those groups that are usually not reached by telephone 
surveys (those who are ex-directory, those who are 
difficult to reach, and those with only a mobile 
telephone), but also the (possible) differences between 
fixed and mobile phone users. The researchers came to 
the following conclusion: ‘Overall, taking into account 
“ex-directory”, “difficult-to-reach” or “mobile-only” 
respondents had only a minor impact on prevalence 
estimates. However, our results also underline the 
importance of investigating these individuals with 
particular socio-demographic profiles and lifestyles (…).’ 
(Beck et al., 2004). Moreover, by using the reverse 
directory, the addresses corresponding to the numbers 
can be identified. In this way commercial numbers can 
be deleted from the sample, as in the Baromètre Santé 
2000 and the Baromètre Santé 2005 (Beck et al., 
2004). In our expert survey the French researchers 
account for their use of Computer Assisted Telephone 
Interviewing (CATI) by referring to the absence of 
population registers on the one hand and a high level of 
(mobile) phone penetration on the other. In addition, 
financial aspects, the ease to monitor interviewers, and 
acceptable response and participation rates, were 
further reasons for opting for a telephone survey. 
Nevertheless, for its next survey France will introduce the 
internet as an alternative data collection mode for those 
who refuse the telephone survey. 
c. Mail surveys
Despite their low response rates, the lower costs of 
mail surveys may firce the researcher to choose this 
data collection method (Finland, Denmark 2008). 
Furthermore, the respondents’ privacy is more 
protected as they do not have to tell their answers to 
the interviewer. In this respect the Finnish experts state: 
‘People tend to answer sentitive questions more 
honestly in mail surveys than in personal contact in 
face-to-face or telephone surveys. (…) Despite lower 
response rates we have got higher prevalence rates of 
cannabis use in mail surveys than in face-to-face 
surveys (1992 and 2000) (16). A similar reason is given 
in the Estonian national abstract of 2008: ‘The 
response rate is below 50 %. (…) Many people simply 
refuse to answer. However, this is the only way to 
arrange a survey concerning drug use in Estonia, since 
it is impossible to ask these questions within the 
framework of an interview — there is reason to believe 
that people will fail to give honest answers.’ 
survey Cyprus, Norway, Denmark, Hungary, Lithuania 
and Slovakia are found to refer to the prohibitive costs 
of CASI or CAPI. However, the Slovakian experts are 
planning to conduct a computer-assisted survey in the 
future. The Hungarian and the Lithuanian experts also 
point out that the general population is not familiar 
enough with computers for computer-assisted 
interviews to be conducted. 
Besides, in face-to-face surveys, and irrespective of 
whether a computer or Pen & Paper is used, drug and 
other sensitive questions are frequently completed by 
the respondent himself (‘self-administered’) to safeguard 
confidentiality (e.g. Austria, Belgium, Denmark 2005, 
England and Wales, Spain, Hungary). The experts of 
the British Crime Survey illustrate this as follows: ‘The 
main survey mode is CAPI but for sensitive topics 
(drugs, domestic violence and sexual assault) CASI is 
used to encourage reporting. This is particularly 
important for young people living with their parents 
who might be reluctant to disclose activities about 
which their parents may not be aware, for fear of 
being overheard.’ Reasons why surveys are (partly) 
administered by the interviewer are the low reading 
comprehension of the target population (Austria) and 
‘to ensure that all the questions are answered and well 
understood’ (the Czech Republic). 
b. Telephone surveys
One could list several arguments against telephone 
surveys. Irrespective of the use of either a telephone 
register or random digit dialling to select the sample, 
telephone surveys often have an unknown coverage, 
as some members of the target population have no 
telephone or cannot be reached by phone (under-
coverage), while some households have more than one 
telephone (over-coverage). The spread of mobile 
phones, with unregistered phone numbers, also 
presents a challenge to telephone surveys. Finally, 
telephone numbers of companies and other institutions 
that are not part of the target population, also risk to 
be included in the sample (Beck et al., 2004). These 
arguments appear to be translated in the near absence 
of telephone surveys in our meta-analysis. 
The only country to conduct a telephone survey was 
France. To legitimate their choice of a telephone survey, 
the French researchers performed several studies. In 
1991 a pilot study comparing a computer assisted 
face-to-face survey with a telephone survey was carried 
out. Its conclusion was that the advantages of a face-to-
(16)  The surveys of 1992 and 2000 focused on alcohol use and drinking habits, but also included some drugs questions.
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authors of the 2005 report realised that because of the 
dropping response rates and the high costs of CAPI, 
other research methods should be taken into 
consideration. The self-completed online panel survey 
is a possible (low-cost) solution despite the relatively 
high self-selection and selective non-response. In a 
publication of Rodenburg et al. (2007), the researchers 
recommend using both the CAPI and the online access 
panel method for the next prevalence survey. The 
current online access panels can be used for 
identifying trends (increase or decrease of drug use). 
However, in our expert survey it is stated that only 
online access panels based on population registers will 
be used to control for selection bias. 
Financial limitations also had an impact on the data 
collection mode in the most recent Danish drug survey 
(2008). The researchers argue that a web-based 
survey is generally cheaper than mail surveys, but 
delivers generally lower response rates. Therefore, a 
mixed mode method was chosen. Compared with the 
mail survey, the web-based survey reached fewer 
elderly. Youngsters and middle-aged people were 
reached equally numerously in the mail and in the 
web based survey. Whether these different methods 
also generate different prevalence rates (and thus 
bias) had not yet been established when this report 
was written. 
It was not until 2006 that the Scottish Crime Survey 
was administered with CAPI. Previously, the P&P 
method, or as the authors call it ‘PAPI’ (Paper and Pen 
Interviewing), was used. The Scottish researchers 
concluded that the CAPI methodology yields more 
complete and accurate responses, diminishes the levels 
of (item and unit) non-response, and increases the 
proportion of people willing to admit to sensitive 
behaviours. Indeed, in the CAPI survey (2006), 37 % 
of the respondents aged between 16 and 59 admitted 
that they had taken an illegal drug at some point in 
their lives, whereas in the 2004 P&P survey this was 
only 24 %. However, it must be observed that this 
conclusion can only be drawn under the presupposition 
that the level of drug use remained stable in this period 
and that the different prevalence rates do not reflect 
any real increase in drug use. 
In the Irish drug use survey of 2006/7, the pen and 
paper interviewing technique was replaced with 
d. Online surveys
Online surveys are not a very popular way to conduct 
a general population survey on drug use, mainly 
because they lack a representative sample frame (e.g. 
the Czech Republic). Nevertheless, some countries 
have already tried out online surveys. The experience 
in the Netherlands is discussed below. Hungary 
conducted an online survey in 2007, but the response 
rate was disappointingly low. 
3.5.3  Changes in interviewing and completion 
modes
Most countries that have already conducted several 
surveys, keep applying the same interviewing and 
completion modes, mainly to avoid unpredictable 
effects on the results (e.g. Norway). However, the 
Netherlands, Denmark, Scotland and Ireland, have 
made some adjustments in their most recent surveys.
In 2001, the Netherlands conducted a pilot study with 
a Multi Method (MM) way of data collection together 
with a Computer Assisted Personal Interviewing 
method (CAPI). In this MM, respondents could choose 
between a mail questionnaire (P&P), a questionnaire 
on diskette, a questionnaire on the internet (URL), or a 
telephone interview (reminder session). The CAPI 
method generally revealed lower drug prevalence 
rates that the MM. These differences were statistically 
significant, but small. The consistently lower CAPI 
prevalence rates could indicate mode effects, such as 
socially desirable answers. The results of the logistic 
regression also suggested that the MM and CAPI 
groups were not very different. 
Because of the high costs and increasing non-response 
rates with CAPI on the one hand and a high Internet 
penetration in the Netherlands on the other, the 
Netherlands added an online access panel to the 
face-to-face survey (CAPI) in 2005 (17). The researchers 
came to the conclusion that the face-to-face survey 
offered more advantages than drawbacks. The CAPI 
method had a more representative sample, because of 
a better sample frame (18), a higher response rate, and 
fewer indications for selective non-response. Therefore, 
the researchers decided to use only the data of the 
CAPI method in the analysis, and to leave aside the 
data of the online access panel. Nevertheless, the 
(17)  In 2006, only 54 % of the households had an Internet connection in Belgium versus 80 % in the Netherlands. Source: FOD Economie, 
KMO, Middenstand en Energie — Algemene Directie Statistiek en Economische Informatie, (z.d.), Communicatiemedia en audiovisuele 
media, [WWW] http://statbel.fgov.be/figures/d75_nl.asp [17/03/2008] 
(18)  For the CAPI part of the survey, the Dutch Municipal Population Registry was used as sampling frame (known sampling frame). For the 
online survey, the sampling frame was the online access panel of SSI, a bureau for online field research. Therefore, this online sample of 
voluntary participants is drawn from an unknown sampling frame and is not representative for the general Dutch population.
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Table 20: Survey methods applied
Country Year Mode of interviewing Survey methods specifications
Questionnaire completion
Interviewer Respondent
Austria 2004 Face-to-face P&P No (1) Yes (1)
Belgium 2001 Face-to-face P&P No (1) Yes (1)
2004 Face-to-face P&P No (1) Yes (1)
2008 Face-to-face P&P No (1) Yes (1)
Bulgaria 2005 Face-to-face n.a. n.a. n.a.
Croatia 2009 (expected) Not decided yet Not decided yet Not decided yet Not decided yet
Cyprus 2006 Face-to-face P&P No Yes
Czech 
Republic
2004 Face-to-face P&P Yes No
Denmark 2000 Face to face P&P No (2) Yes (2)
2005 Face-to-face P&P No (2) Yes (2)
2008 Mail online survey n.a. No Yes
England 
and 
Wales
1996 Face-to-face CASI (1) No (1) Yes (1)
1998 Face-to-face CASI (1) No (1) Yes (1)
2000 Face-to-face CASI (1) No (1) Yes (1)
2001/2 Face-to-face CASI (1) No (1) Yes (1)
2002/3 Face-to-face CASI (1) No (1) Yes (1)
2003/4 Face-to-face CASI (1) No (1) Yes (1)
2004/5 Face-to-face CASI (1) No (1) Yes (1)
2005/6 Face-to-face CASI (1) No (1) Yes (1)
2006/7 Face-to-face CASI (1) No (1) Yes (1)
Estonia 2003 Mail P&P No Yes
Finland 1992 Mail P&P No Yes
1996 Mail P&P No Yes
1998 Mail + telephone 
(small sample)
P&P Yes Yes
2002 Mail P&P No Yes
2004 Mail P&P No Yes
2006 Mail P&P No Yes
data input is managed more efficiently, thus cutting 
costs’ (19). Moreover, the response rate is better and 
the data cleaning is supported by technological 
possibilities, still according the Irish researchers.
computer assisted personal interviewing (CAPI). The 
researchers argue that this has several advantages: 
‘interviews can be administered more quickly, human 
error is minimised yielding higher-quality data, and 
(19)  National Advisory Committee on Drugs (NACD) and Drug and Alcohol Information and Research Unit (DAIRU) 2008, Drug use in 
Ireland and Northern Ireland, first results from the 2006/7 drug prevalence survey (URL: http://www.nacd.ie/publications/survey_
Final_25thJan.pdf) (Last accessed on 30 January 2008).
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Country Year Mode of interviewing Survey methods specifications
Questionnaire completion
Interviewer Respondent
France 1995 Telephone CATI Yes No
2000 Telephone CATI Yes No
2005 Telephone CATI Yes No
Germany 1995 Self-administered mail P&P No Yes
1997 Self-administered mail P&P No Yes
2000 Self-administered mail P&P No Yes
2003 Self-administered mail P&P No Yes
Greece 1998 Face-to-face P&P Yes No
2004 Face-to-face P&P Yes No
Hungary 2001 Face-to-face P&P No (1) Yes (1)
2003 Face-to-face P&P No (1) Yes (1)
Ireland 2002/3 Face-to-face P&P Yes No
2006/7 Face-to-face CAPI Yes No
Italy 2001 Mail P&P No Yes
2003 Mail P&P No Yes
2005 Mail P&P No Yes
Latvia 2003 Face-to-face n.a. Yes No (3)
Lithuania 2004 Face-to-face P&P No Yes
Malta 2001 Face-to-face n.a. n.a. n.a.
Netherlands 1997 Face-to-face CAPI Yes No
2001 Multi method:  
open choice 
methodology 
Face-to-face
P&P, diskette & URL (CATI 
and mail in reminder 
session) 
CAPI
No 
 
 
Yes
Yes 
 
 
No
2005 Face-to-face 
 
Online access panel
CAPI & PAPI for sensitive 
subjects 
Web-based survey
Yes (CAPI) 
 
No
Yes (PAPI) 
 
Yes
Norway 2004 Face-to-face P&P No (4) Yes (4)
Poland 2002 Face-to-face n.a. n.a. n.a.
Portugal 2001 Face-to-face P&P Yes No
Romania 2004 Face-to-face P&P Yes No
Scotland 2000 Face-to-face P&P No (5) Yes (5)
2003 Face-to-face P&P No (5) Yes (5)
2004 Face-to-face P&P No (5) Yes (5)
2006 Face-to-face CAPI No (5) Yes (5)
Slovakia 2002 Face-to-face P&P Yes No
2004 Face-to-face P&P Yes No
2006 Face-to-face P&P Yes No
Table 20 continued
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frequently used as sampling frame. Such registers do 
not give a full representation of the entire population of 
a country, as they often exclude marginalised people. 
However, as most studies concentrate on people living 
in private households and exclude institutionalised or 
homeless people (e.g. Ireland, the Netherlands, 
Romania, Scotland, Finland, France and England and 
Wales), this does not present much of a problem. 
France is the only country that has conducted a 
telephone survey. Taking advantage of technological 
changes, both a fixed phone and a mobile only survey 
were conducted in 2005 in order to reach the 
increasing number of people with only a mobile phone 
(Beck and Guilbert, 2007). For the fixed phone survey, 
the researchers used a telephone register as sampling 
frame, but only as a starting point. The randomly 
selected numbers were modified by adding ‘1’ to the 
3.6 Sampling characteristics
3.6.1 Sample frame
As a sample frame must give the best possible coverage 
of the target population, including or excluding certain 
demographic groups from the target population may 
influence the choice of sampling frame. Most countries 
do not deviate much from the recommended age setting 
of the EMCDDA (15–64 years) (Table 21). Election 
registers are thus not appropriate as a sampling frame 
because they leave youngsters out of the sample. 
Therefore, the absence of election registers as sampling 
frames in Table 21, with the exception of the Czech 
Republic and Malta, seems reasonable. 
On the other hand, population registers and household 
address registries (e.g. postcode address files) are 
Country Year Mode of interviewing Survey methods specifications
Questionnaire completion
Interviewer Respondent
Spain 1995 Face-to-face P&P No (1) Yes (1)
1997 Face-to-face P&P No (1) Yes (1)
1999 Face-to-face P&P No (1) Yes (1)
2001 Face-to-face P&P No (1) Yes (1)
2003 Face-to-face P&P No (1) Yes (1)
2005 Face-to-face P&P No (1) Yes (1)
Sweden 2004 Mail n.a. n.a. n.a.
2005 Mail n.a. n.a. n.a.
2006 Mail n.a. n.a. n.a.
NB:
Adapted from the EMCDDA Handbook, p. 127 (EMCDDA, 2002).
Data from the 2001 EMCDDA overview is indicated in grey.
Survey methods specifications: 
CAPI: Computer Assisted Personal Interviewing
CASI: Computer Assisted Self Interviewing
CATI: Computer Assisted Telephone Interviewing
PAPI: Paper and Pen Interviewing
P&P: Pen & Paper
(1) Drug section/socially or legally sanctioned behaviours are completed by the respondent; other sections are completed by the interviewer.
(2)   Sensitive questions (e.g. about drugs and sexual behaviour) are collected by a self-administered questionnaire, delivered at the interview, 
and afterwards returned by mail by the respondent.
(3)  In cases where it was not possible to ensure full privacy during the interview, the most sensitive part of the questionnaire (relating directly 
to drug use) was completed by the respondents themselves.
(4)  Questions about illegal drugs were not asked, but presented on a separate sheet. The respondent could answer the questions unseen by 
the interviewer. The completed paper was put into a sealed envelope by the respondent.
(5)  For the self-completed component (about drugs and violence) only; other sections were completed by the interviewer. Adults under the 
age of 60 years are asked about their exposure to and use of drugs (and experience of domestic violence). In 2003, it was decided to 
administer the self-completion questionnaire to all adult respondents. This implies a rise of the costs for data collection, but it makes 
administration easier for the interviewers. It was also felt that there are likely to be increasing numbers of older adults with drug use 
experience. However, in 2006 the drug module was again restricted to those under the age of 60. 
The Young Person Self-Completion questionnaire was administered to all people aged 12 to 15 years resident in the respondent’s 
household where the permission of a parent or guardian was granted (‘boost sample’).
n.a.: not known/not available.
Table 20 continued
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individual. For example, when using (randomly 
generated) telephone numbers to select respondents, 
people with one or more fixed phone(s) and/or one 
or more mobile phone(s) have several opportunities of 
being selected in the sample. 
Survey reports often contain information about 
oversampling or weighting. The possible replacement 
of survey respondents is less well documented. In this 
respect, a standardisation of a detailed registration of 
the sampling method can be a valuable way to obtain 
more profound and accurate information about the 
sampling method. 
3.6.3 Weighting
The last column of Table 21 indicates whether and how 
the results were weighted. Statistical weighting may be 
needed when certain groups are under- or over-
represented in the sample carried out compared with 
the population distribution.
‘No’ indicates that no weighting was done. Only a few 
countries, including Italy or Finland, did not weight the 
survey data. This means that the responses were either 
considered representative (and no weighting was 
needed) or that the results may not accurately reflect the 
population (and no weighting was done to correct this). 
In almost every study the results were weighted 
(indicated by ‘yes’ in Table 21). Weighting corrects 
sampling and response biases and makes the survey 
results representative for the target population. For 
example, to compensate for the oversampling of the 
province of Carinthia in the Austrian survey, the results 
were weighted by province.
Weighting variables should be closely linked with the 
study’s main variables. In drug research, therefore, 
age, gender and region are relevant weighting 
variables as drug use has proven to be related to these 
variables. The findings in Table 21 (partly) confirm this. 
Especially age, gender and geographical 
characteristics (state, region or address density) are 
used as weighting variables. Kind of dwelling, 
household size, marital status, and ethnicity are used 
as weighting variables to a lesser extent. 
final digit. For the mobile only survey, all numbers were 
randomly generated. By using randomly generated 
phone numbers, people with private numbers or with 
unregistered mobile numbers can also be reached. 
However, integrating people with private numbers may 
be problematic, as that group may be the least willing 
to cooperate in a telephone survey. Furthermore, those 
people of the target group without any kind of phone 
remain out of reach.
3.6.2 Sampling method
The choice of sampling method depends on the mode 
of data collection and the availability of specific and 
accurate sampling frames (Table 21). In line with the 
recommendation of the EMCDDA, almost every 
country used a random or probability sample. Non-
probabilistic sampling methods, such as quota 
sampling in the surveys of Slovakia, are used less 
often. By contrast, the type of probability sample is 
more varied: from basic simple random sampling to 
stratified, clustered and multi-stage sampling.
A remark must be made regarding (simple) random 
sampling. Every individual in the target population 
has a known probability different from zero of being 
included in a probability sample. In simple random 
sampling, every individual in the population must 
have the identical probability of being included in the 
sample. In other random sampling methods, such as 
cluster sampling, the probability of being selected in 
the sample varies. Even though researchers may 
intend to select a (simple) random sample, it may turn 
out differently in reality. Indeed, the use of boost 
samples to select sufficient respondents among groups 
with low expected response rates or to select more 
respondents among relevant groups (youngsters, in 
the case of drug use) influences the selection 
probability of the individuals in the target population. 
Weighting of the survey data to ensure that the 
sample is representative of the general population or 
the replacement of those who refuse to cooperate or 
those who could not be contacted, also influences the 
selection probability. Furthermore, the sampling frame 
can contain one single individual several times, so 
that the selection probability is not equal for every 
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Table 21: Sampling characteristics
Country Year Sampling frame Sampling method(s) Weighting
Austria 2004 Addresses Route random approach, within 
household: last birthday method
Yes: provinces
Belgium 2001 National register Multi-stage probability sample, 
stratified by region, province and 
community 
Household as sampling unit
Yes: household, age, 
sex, date of the 
interview
2004 National register Multi-stage probability sample, 
stratified by region, province and 
community 
Household as sampling unit
Yes: household, age, 
sex, date of the 
interview
2008 National register Multi-stage probability sample, 
stratified by region, province and 
community 
Household as sampling unit
n.a.
Bulgaria 2005 Population registry Two-stage randomised sampling 
procedure
Yes: age
Croatia 2009
(expected)
n.a. n.a. n.a.
Cyprus 2006 Geographical maps Multi-stage proportionate stratified 
random sampling 
Geographical maps used for the 
selection of starting points. Selection 
and distribution of starting points based 
on area type and district, taking into 
consideration the density of population.
Yes: age, gender
Czech Republic 2004 Election registry Random stratified sampling (strata: 
age, sex, region and education)
No
Denmark 2000 Central personal register 
(population registry)
Simple random sampling Yes: country
2005 Population, single individual 
registry
Random sampling of individuals in 
the 5 main administrative regions, 
with same number of sampled 
citizens in each of the regions
Yes: region
2008 Population registry Region and age stratified random 
sample
Yes: region and age
England and 
Wales
1996 Postcode address file (PAF) Stratified face-to-face 
Within households: simple random
Yes: inner city, dwelling 
unit, individual, ethnic 
minority I, ethnic minority 
II (ethnic booster)
1998 Postcode address file (PAF) Stratified face-to-face 
Within households: simple random
Yes: inner-city areas, 
individuals living in 
households of different 
sizes
2000 Postcode address file (PAF) Cluster sampling (post code sector), 
stratified by police force area
Yes
2001/2 Postcode address file (PAF) Cluster sampling (post code sector), 
stratified by police force area 
(disproportionately) and other 
socio-demographic variables
Standard weighting + 
calibration weighting 
(designed to adjust for 
known differentials in 
response rates across 
age, gender and 
regional sub-groups)
Drug use: an overview of general population surveys in Europe
78
Country Year Sampling frame Sampling method(s) Weighting
2002/3 Idem study 2001/2 Idem study 2001/2 Idem study 2001/2
2003/4 Idem study 2001/2 Idem study 2001/2 Idem study 2001/2
2004/5 Idem study 2001/2 Idem study 2001/2 Idem study 2001/2
2005/6 Idem study 2001/2 Idem study 2001/2 Idem study 2001/2
2006/7 Idem study 2001/2 Idem study 2001/2 Idem study 2001/2
Estonia 2003 Population register Random sample Yes: by age, gender
Finland 1992 Central population register Simple random No
1996 Central population register Simple random No
1998 Central population register Simple random No
2002 Central population register Simple random Yes: age, gender, 
region
2004 Central population register Simple random sample Yes: age, gender, 
region
2006 Central population register Simple random sample of 
individuals (not households)
Yes: age, gender, 
region
France 1995 Randomised dialling 
(Telephone files)
Simple random; within household: 
birthday
Yes: age, gender, 
geographical region, 
kind of dwelling
2000 Randomised dialling 
(Telephone files)
Simple random; within household: 
birthday
Yes: age, gender, 
geographical region, 
kind of dwelling
2005 Fixed phone survey: 
telephone list 
Mobile only survey: random 
generation of mobile 
numbers
Fixed phone survey: simple 
multi-stage probability sample 
(geographical area, household, 
individual); next birthday method 
Mobile only survey: random 
generation of mobile numbers, 
stratification by operator (filter 
question excluded people with a 
fixed phone)
Yes: sex, age, region, 
urban category, 
occupation
Germany 1995 Household randomly 
selected via random route; 
questionnaires dropped off/
picked up
Multi-stage probability sample 
(1313 sampling points); stratified by 
region; household person with the 
most recent birthday
Yes: age, gender, 
federal state, 
household size
1997 Household randomly 
selected via random route; 
questionnaires dropped off/
picked up
Multi-stage probability sample 
(1313 sampling points); stratified by 
region; household person with the 
most recent birthday
Yes: age, gender, 
federal state, 
household size
2000 Household randomly 
selected via population 
registry; questionnaires sent 
and returned by mail
Multi-stage probability sample 
stratified by region
Yes: age, gender, 
federal state, 
household size
2003 Population lists in the 
community
Two stages: community-respondent, 
systematic sampling in the second 
stage
Yes: gender, age, 
region (old 
Bundesländer vs. new 
Bundesländer)
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Country Year Sampling frame Sampling method(s) Weighting
Greece 1998 Household addresses Face-to-face: town, flats, dwelling 
unit within household: random, 
using Kish selection grid 
Multi-stage probability sample
Yes: age
2004 Household addresses Multi-stage stratified probability 
sample
Yes: age, gender, 
geographical stratum
Hungary 2001 Database of the Central 
Data Processing, 
Registration and Election 
Office
Random stratified sampling: 
Budapest sub-sample: one-step 
sampling layered by districts; 
Countryside sub-sample: two-step 
sampling layered by the location 
and size of municipalities, 
individuals selected by simple 
random sampling
Yes : 
National sample by 
location; 
Budapest sample by 
age and gender
2003 Database of the Central 
Data Processing, 
Registration and Election 
Office
Random stratified sampling by 
location and size of municipalities 
and age groups
Yes: National sample: 
by age groups, 
location and size of 
municipalities;  
Budapest sample: 
18–34 age group also 
weighted by gender
Ireland 2002/3 Postcode address file (PAF) 
(N. Ireland) 
GeoDirectory ( ≈ PAF; 
Ireland)
Multi-stage sampling: stratified (by 
health board) random selection of 
primary sampling units (areas: 
electoral Divisions). Households 
selected at random from within 
each primary sampling unit. 
Individuals selected by ‘last 
birthday rule’
Yes: age, gender, area
2006/7 Postcode address file (PAF) 
(N. Ireland) 
GeoDirectory ( ≈ PAF; 
Ireland)
Multi-stage sampling: stratified (by 
health board) random selection of 
primary sampling units (areas: 
electoral Divisions). Households 
selected at random from within 
each primary sampling unit. 
Individuals selected by ‘last 
birthday rule’
Yes: age, gender, area
Italy 2001 Register of the resident 
population
Stratified random sampling from 
resident population
No
2003 Register of the resident 
population
Stratified random sampling from 
resident population
No
2005 Register of the resident 
population
Multi-stage stratified random 
sample
No
Latvia 2003 National population register Multi-stage stratified random 
sampling (regions and type of 
settlement, residential addresses, 
respondent)
Yes: age
Lithuania 2004 2001 Population and 
Housing Census, 
Department of Statistics to 
the Government of the 
Republic of Lithuania
Multi-stage stratified random 
sample
Yes: age, gender
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Country Year Sampling frame Sampling method(s) Weighting
Malta 2001 Electoral register Stratified random sampling Yes: age, gender, 
local council, marital 
status, education, 
employment and 
financial situation
Netherlands 1997 Municipal population 
registry
Two-stage stratified sample 
(municipalities, persons)
Yes: age, gender, 
marital status, address 
density
2001 Dutch Municipal Population 
Registry (GBA)
Two-stage (municipalities, persons) 
proportional stratified probability 
sample (gender, age and education 
level)
Yes: address density, 
age, gender, marital 
status
2005 Dutch Municipal Population 
Registry 
Online access panel of SSI 
(bureau for online field 
research)
Two-stage (municipalities, persons) 
stratified sampling (gender, age, 
education level, region and cultural 
origin) 
Stratified sampling (gender, age, 
education level, region and cultural 
origin)
Yes: age, gender, 
marital status, address 
density, household 
size, response month 
Yes: demographic 
variables (≈ CAPI)
Norway 2004 Household register 
(addresses)
Stratified sampling 
(stratified on geography, 
community size and community 
type), random addresses in 
communities, random person
By age, gender and 
stratum (community 
type)
Poland 2002 n.a. n.a. To balance 
overestimation of some 
regions and cities and 
additionally by 
gender, age, city-
village and 
educational level
Portugal 2001 List of statistical sections, 
National Statistics Institute
Multi-stage random sample By age, gender and 
geographical region
Romania 2004 Household registry Probabilistic, stratified and multi-
stage (stratification variables were 
the size and type of habitat)
Yes: age group, 
gender, geographical 
area, habitat type 
(size: rural, small 
urban, big urban)
Slovakia 2002 Data from Census 2001 Quota sample with randomisation 
in the last step
No
2004 Data from Census 2001 and 
Balance of Population 
Motion 2003
Quota sample with randomisation 
in the last step
No
2006 Census 2001 and Balance 
of Population Motion 2005
Quota sample with randomisation 
in the last step
No
Scotland 2000 Postcode Address File (PAF) Probability sample selected 
according to a multi-stage stratified 
design; clustered
Yes: to compensate for 
design elements of the 
survey and for 
non-response bias
2003 PAF Postcode Address File Probability sample selected 
according to a multi-stage stratified 
design; within household: random, 
using Kish selection grid; clustered
Yes: to compensate for 
design elements of the 
survey and for 
non-response bias
2004 Idem Idem Idem
2006 Idem Idem Idem
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Country Year Sampling frame Sampling method(s) Weighting
Spain 1995 Household addresses Multi-stage: electoral districts within 
autonomous communities 
Quotas and random walks
Yes: age, gender, 
region
1997 Household addresses Multi-stage: electoral districts within 
autonomous communities 
Quotas and random walks
Yes: age, gender, 
region
1999 Household addresses Multi-stage: electoral districts within 
autonomous communities 
Quotas and random walks
Yes: age, gender, 
region
2001 Household addresses Multi-stage sampling, stratified 
according to congregations, with 
previous selection of primary units 
(councils) and secondary units 
(sectors) following a proportional 
random method and the selection 
of the final units (individuals) by 
means of a systematic selection of 
the homes and then selecting 
individuals by an aleatory numbers 
table
Yes: age, gender, 
territorial habits 
(regions)
2003 Household addresses Multi-stage sampling, stratified 
according to congregations, with 
previous selection of primary units 
(census sections) and secondary 
units (autonomous) following a 
proportional random method and 
the selection of the final units 
(individuals) by an aleatory 
numbers table
Yes: age, gender, 
territorial habits 
(regions)
2005 Census sections registry and 
household registry 
Three-stage random design (census 
sections, households, individuals): 
Census sections selected by 
stratified random sampling 
(stratified by autonomous 
community) 
Households selected by non-
probabilistic method (systematic 
random routes procedure) 
Subjects selected by stratified 
random sampling (stratified by age)
Yes: age, gender, 
autonomous 
community
Sweden 2004 Population registry Random sampling Yes: country, for age, 
gender, country of 
birth, marital status, 
income, living in large 
city
2005 idem idem idem
2006 idem idem idem
NB:
Adapted from the EMCDDA Handbook, p. 129–130 (EMCDDA, 2002).
Data from the 2001 EMCDDA overview is indicated in grey.
n.a.: not known/not available.
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budget. Finally, in the Czech, Slovakian, Irish and 
Norwegian survey, a statistical rule determined the 
sample size. 
3.7.2 Response rates
a. Need for standardisation
High response rates are generally seen as a major 
quality criterion in surveys. Indeed, besides the 
selectivity of the non-response, response rates are 
important to evaluate the non-response error. Response 
measurements also serve as quality benchmarks across 
different surveys, including this meta-analysis. 
However, the EMCDDA states that ‘differences in rates 
may be due to different concepts rather than real 
differences in response’ (EMCDDA, 2002). With the 
exception of some studies with extended technical 
reports (e.g. Ireland), the information about the 
definition of (non-)response rates and the calculation of 
these rates are missing. As a result, it is not always 
clear what the concept ‘sample size’ actually refers to: 
to the sample drawn from the frame, to the sample that 
was approached or to the sample that was actually 
questioned in the field. Frame errors may be included 
or excluded, and the figures of sample size, net 
response and response rate sometimes differ slightly 
depending on the publication. In the Scottish Crime 
Survey of 2003 (McVie et al., 2005) these differences 
are explained as follows: ‘It is important to note that all 
figures presented in this report are the result of fresh 
analysis of the data, including the re-analysis of 
previous sweeps of the survey. This has resulted in 
some figures presented here being slightly different 
from previously published findings.’
Therefore, in order to use response rates as quality 
measurements and to compare response rates across 
different surveys rather than merely registering all 
response rates, it may be useful to provide standard 
tables and definitions, such as those of the American 
Association of Public Opinion Research (AAPOR). In 
2008, the AAPOR published an update of ‘Standard 
definitions, Final dispositions of case codes and outcome 
rates for surveys’, which develops specific standard 
definitions and formulas for calculating response rates 
for three different types of sampling modes (random-
digit dial telephone surveys, in-person household surveys 
and mail surveys of specifically named persons (20)) 
(AAPOR, 2008). Standardised response rates can be 
reported by following three steps:
3.7 Sample characteristics
3.7.1 Sample size
To evaluate the sample size, it is necessary to know the 
size of the target population. In a large number of 
population surveys the exact size of the target 
population was unknown or was not assessed (Table 
22). Extra information was obtained by the expert 
survey. Table 22 presents the estimated size of the 
target population. As one would expect, this size 
depends on the population figures and the delineation 
of the target population. The higher the population 
figure on the one hand and the more broadly-defined 
the target population on the other, the higher the size 
of the target population.
In addition, the sample size varies significantly among 
countries, often due to the diverse sizes of the target 
populations. However, there is no clear-cut connection 
between the (estimated) sizes of the population and the 
sample sizes. For example, in the Maltese study with a 
population of 0.2 million people, the sample size was 
2 828, while Hungary and Sweden had a similar sample 
size (respectively 2 500 and 3 000 respondents) for a 
much larger target population (respectively 7.8 million 
and 6.0 people). The evaluation of the sample size 
should also take into account the low expected 
prevalence rates of drug use and the increasingly high 
non-response rates. These latter two elements require 
higher sample sizes. In this respect, several countries 
have recently raised their sample size or indicated that 
the sample size will be increased in the next survey 
(Spain 2005, Slovakia). However, not all countries find it 
easy to raise their sample sizes. The 2003 national 
abstract of Bulgaria, for instance, states that financial 
aspects are an important problem for the sample size.
For the expert survey we asked how the sample size 
had been determined. For Austria, England and 
Wales, France, Finland, Norway, the Czech Republic, 
Denmark (2008) and the Netherlands a good 
precision of the prevalence rates, even on different 
levels (regions, age ranges, etc.) was a major factor in 
the determination of the sample size. Countries such as 
Finland and Lithuania also report that low expected 
drug prevalences require higher sample sizes. Finland, 
Italy, Norway, Spain, Romania and the Netherlands 
declare that the available financial sources were a 
decisive factor for determining the size of the sample. 
In practical terms this means that the sample size is 
lower than the ideal size because of an inadequate 
(20)  In the future, AAPOR will expand the report with modern sample modes such as internet-based surveys.
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these numbers should be based on standard 
definitions such as theses of the AAPOR (AAPOR, 
2008; Stoop, 2005).
b. Low/decreasing response rates
The net response — the number of people that actually 
participate in the population survey — and the response 
rates fluctuate greatly: from less than fifty percent to 
nearly one hundred percent of the sample. Not only do 
these numbers indicate a big variance between response 
rates of the different surveys, but also the high response 
percentage of some studies is striking. There are several 
possible explanations for the big variance in response 
rates. The mode of interviewing is one of them. Mail 
surveys tend to produce lower response rates than 
face-to-face surveys. However, a clear connection 
between the interviewing mode and the response rate 
cannot be found in this meta-analysis. For example, the 
Finnish mail survey yields response rates that are 
comparable with those of the face-to-face surveys, while 
the Italian mail surveys only reached a response rate of 
about 35 %. However, in view of the discussion 
mentioned above, comparing non-standardised response 
rates is delicate and may lead to rash conclusions.
It is important to mention that in the 2007 and 2008 
national abstracts of the EMCDDA (EMCDDA, 2007; 
EMCDDA 2008b), and in our expert survey, several 
countries bring up decreasing and/or low response 
rates as an important recurrent problem (Denmark, 
Estonia, Finland, Germany, Greece — Denmark, 
Finland, Germany — Norway, Romania, Hungary). For 
example, in the Austrian survey, no fewer than 79 % of 
the selected persons refused to cooperate. In most 
Finnish and Danish surveys (the Health Interview 
Survey as well as the Alcohol and Drug Survey), 
non-response rates were particularly high for young 
men. In the Hungarian survey, response rates were 
also the lowest in the younger age group (18–35 
years). The researchers explain this by the high 
unregistered residential mobility of this age group. On 
the other hand, in the Finnish survey of 2006 response 
rates were highest among the oldest age group 
(63–69 years). This could lead to an underestimation 
of drug use, as the prevalence of illegal drug use is 
generally the highest among young men and the lowest 
among the older age groups.
First, the survey cases must be divided into four main 
groups:
1. Interviews
 a. partial
 b. complete
2. Eligible cases that are not interviewed (non-
respondents)
 a. refusals/break-offs
 b. non-contacts
 c. other (e.g. dead, language problem)
3. Cases of unknown eligibility (no interview)
4. Cases that are not eligible (e.g. out of sample)
Second, based on these categories, outcome rates 
such as response rate (21), cooperation rate (22), refusal 
rate (23) and contact rate (24) can be calculated. 
Third, standardisation is also needed on the meta-data 
level. Comparing the outcome rates of different surveys 
will only be possible if survey-specific features like the 
sampling unit, the use of substitution (25) or proxies (26), 
and the data collection process, are well defined 
(AAPOR, 2008; De Keulenaer, 2007).
However, the use of standard definitions is not always 
very self-evident. For example, considering that the 
standards of AAPOR sometimes result in response rates 
that are much lower than what can be estimated using 
less rigorous procedures, Johnson and Owens (2003) 
conclude that ‘while a relatively high survey response 
rate alone may not be sufficient to guarantee a paper’s 
acceptance for publication, a relatively low rate may 
be enough to guarantee rejection. Consequently, the 
current lack of standards on the part of many journals, 
along with a general recognition that high survey 
nonresponse may be a barrier to publication, 
establishes an environment in which full disclosure is 
not encouraged.’ 
Nevertheless, if researchers want to monitor and 
improve the survey process and to analyse, compare 
and enhance response rates, they should report the 
following at the least: (1) the total sample size, with 
breakdowns by number interviewed, (2) the number 
eligible but not interviewed, (3) the number ineligible, 
and (4) the number with undetermined eligibility. All 
(21)  ‘The number of complete interviews with reporting units divided by the number of eligible reporting units in the sample.’
(22)  ‘The proportion of all cases interviewed of all eligible units ever contacted.’
(23)  ‘The proportion of all cases in which a housing unit or respondent refuses to do an interview, or breaks-off an interview of all potentially 
eligible cases.’
(24)  ‘The proportion of all cases in which some responsible member of the housing unit was reached by the survey.’
(25)  ‘The replacement of an originally sampled unit by another unit.’
(26)  ‘The use of one individual to report on an originally sampled person.’
Drug use: an overview of general population surveys in Europe
84
telephone (mixed mode design). Moreover, Germany is 
considering other initiatives to increase response rates 
in the future. Giving incentives and adapting the length 
of the questionnaire are possible options. Hungary 
intends to increase the response rates of their 2007 
survey by combining the face-to-face interviewing 
mode with postal and web based contacting/
interviewing modes.
Some countries have made some efforts to remedy the 
low response rates. In the 2003 survey, Germany 
conducted a short telephone survey to investigate the 
response bias introduced by non-responders. Almost 
70 % (68 %, to be precise) of the non-responders were 
reached. In the 2006 German survey, those who had 
not completed the mail survey after several reminders 
were invited to answer the survey questions by 
Table 22: Sample characteristics
Country Year
Estimated size of 
target population 
(millions)
Original sample size 
(n) (sample size minus 
frame errors) 
Net response Response rate (%)
Austria 2004 6.5 21 600 4 546 21 %
Belgium 2001 n.a. 10 000 (1) 12 050 (1) n.a.
2004 n.a. 12 600 (1) 12 945 (1) n.a.
2008 n.a. 11 000 not app. not app.
Bulgaria 2005 n.a. n.a. 1 036 n.a.
Croatia 2009 
(expected)
4.4 2 000 not app. not app.
Cyprus 2006 0.5 9 734 (5 405) 3 504 64.8 %
Czech 
Republic
2004 6.8 5 433 (5 170) 3 526 68.2 %
Denmark 2000 4.3 22 484 16 688 74 %
2005 4.3 21 832 14 566 67 %
2008 4.4 7 000 4 015 57.4 %
England 
and Wales
1996 35.0 Core sample: 19 808 
Drug section: 11 244
Core sample: 16 348 
Drug section: 10 940
Core sample: 82.5 % 
Drug section: 97.3 %
1998 35.0 Core sample: 18 983 
Drug section: 10 293
Core sample: 14 947 
Drug section: 9 988
Core sample: 78.7 % 
Drug section: 97.0 %
2000 n.a. Core sample: 26 291 
Drug section: 13 300
Core sample: 19 411 
Drug section: 13 021
Core sample: 73.8 % 
Drug section: n.a.
2001/2 n.a. Core sample: 32 797 
Drug section: 21 946
Core sample: n.a. 
Drug section: 20 1462 (2)
Core sample: 74 % 
Drug section: n.a.
2002/3 n.a. Core sample: 36 479 
Drug section: 24 604
Core sample: n.a. 
Drug section: 23 5863 (3)
Core sample: 74 % 
Drug section: n.a.
2003/4 n.a. Core sample: 37 891 
Drug section: 25 533
Core sample: n.a. 
Drug section: 24 4224 (4)
Core sample: 74 % 
Drug section: n.a.
2004/5 n.a. Core sample: 46 810 
Drug section: 29 713
Core sample: n.a. 
Drug section: 28 5095 (5)
Core sample: 75 % 
Drug section: n.a.
2005/6 n.a. Core sample: 46 810 
Drug section: 31 627
Core sample: n.a. 
Drug section: 29 9326 (6)
Core sample: 75 % 
Drug section: n.a.
2006/7 n.a. Core sample: 47 203 
Drug section: 31 130
Core sample: n.a. 
Drug section: 29 1447 (7)
Core sample: 75 % 
Drug section: n.a.
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Country Year
Estimated size of 
target population 
(millions)
Original sample size 
(n) (sample size minus 
frame errors) 
Net response Response rate (%)
Estonia 2003 n.a. 4 000 (3 982) 1 633 Below 50 %
Finland 1992 3.5 4 892 3 458 70.7 %
1996 3.5 4 429 3 009 67.9 %
1998 3.5 Mail 3 250 
Phone 550
Mail 2 143 
Phone 425
Mail 65.9 % 
Phone 77.2 %
2002 3.6 4 033 2 541 63.0 %
2004 3.6 2 207 
(panel 1 786)
1 178 
(panel 1 355)
53.2 % 
(panel 75.9 %)
2006 3.6 5 488 
(panel 989)
3 029 
(panel 885)
55.2 % 
(panel 89.5 %)
France 1995 40.0 4 116 (3 484) 1 993 75.5 %
2000 45.0 28 162 (21.803) 13 685 70.8 %
2005 46.0 67 019 fixed phone + 
34 778 mobile only  
(50 066 fixed phone 
+ 10 589 mobile only)
30 514 
(26 672 fixed phone & 
3 842 mobile only)
63.1 %
Germany 1995 48.9 12 052 7 833 65 %
1997 48.5 12 358 8 020 65 %
2000 n.a. n.a. 8 139 51 %
2003 n.a. n.a. 8 061 55 %
Greece 1998 7.5 4 960 (4 682) 3 752 80.1 %; 
22.2 % substituted
2004 n.a. n.a. n.a. n.a.
Hungary 2001 7.8 (1.2 Budapest & 
6.6 countryside)
2 500 (1 000 
Budapest & 1 500 
countryside)
2 359 (862 Budapest 
& 1 479 countryside)
94.4% (86.2 % 
Budapest & 99.8 % 
countryside)
2003 5.4 (0.96 Budapest 
& 4.4 countryside)
4 012 (854 Budapest 
& 3 158 countryside)
3 675 (604 Budapest 
& 3 071 countryside)
91.6 % (70.7 % 
Budapest & 97.2 % 
countryside)
Ireland 2002/3 3.7 (2.7 I & 1.0 N-I) 8 474 I & 8 135 N-I 
(7 037 I & 5 612 N-I)
8 434  
(4 918 I & 3 516 N-I)
70 % I & 63 % N-I
2006/7 n.a. (2.9 I & - N-I) n.a. (7 677 I & - N-I) n.a. (4 967 I & 2 002 
N-I)
65 % I & 62 % N-I
Italy 2001 24.0 7 000 2 580 37.0 %
2003 31.6 36 979 11 869 34.4 %
2005 38.6 84 004 27 995 3.3. %
Latvia 2003 n.a. 6 500 (6 162) 4 534 74 %
Lithuania 2004 2.3 7 272 (8) 4 207 56.4 %
Malta 2001 0.2 2 828 (2 569) 1 755 62.1 % (68.3 % 
corrected for frame 
errors)
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Country Year
Estimated size of 
target population 
(millions)
Original sample size 
(n) (sample size minus 
frame errors) 
Net response Response rate (%)
Netherlands 1997 13.2 41 766 (36 684) 21 959 59.9 %
2001 11.4 40 573 (37 507) 
(32 512 MM & 
8 061 CAPI)
17 655 47.1 % (48.7 % CAPI 
& 46.8 % MM)
2005 11.0 7 204 
57 125
4 516 
20 282 (12 715 
EMCDDA & 7 567 CBS)
62.7 % 
35.5 %
Norway 2004 ca 3.7 3 191 n.a. n.a.
Poland 2002 n.a. n.a. n.a. n.a.
Portugal 2001 n.a. n.a. n.a. n.a.
Romania 2004 22 3 500 n.a. 67 %
Scotland 2000 n.a. 7 760 (7 179) Core sample: 5 059 
Drug section: 2 886
Core sample: 71.0 % 
Drug section: ~ 40.2 % (9)
2003 n.a. 8 190 (7 405) Core sample: 5 041 
Drug section: 4 665
Core sample: 68.1 % 
Drug section: 63.0 %
2004 n.a. 8 485 (7 327) Core sample: 5 007 
Drug section: 4 424
Core sample: 68 % 
Drug section: 63.7 %
2006 n.a. n.a. (7 125) Core sample: 4 988 
Drug section: 4 701
Core sample: 70.0 % 
Drug section: 66.0 % (9)
Slovakia 2002 4.3 1 492 1 402 94.0 %
2004 4.4 1 600 1 526 95.4 %
2006 4.5 1 600 1 521 95.1 %
Spain 1995 31.0 10 000 9 984 80 % of people selected 
20 % after substitution
1997 27.0 9 000 12 515 n.a. (10)
1999 27.3 12 455 12 488 n.a. (10)
2001 27.9 14 113 (11) 14 113 n.a. (10)
2003 28.8 12.033 (11) 12 033 49.0 %
2005 29.6 27 934 (11) 27 934 49.9 %
Sweden 2004 6.9 20 000 12 166 61 %
2005 7.0 10 000 6 024 60 %
2006 7.0 10 000 5 995 60 %
NB:
Adapted from the EMCDDA Handbook, p. 131 (EMCDDA, 2002).
Data from the 2001 EMCDDA overview is indicated in grey.
(1)  The aim was to obtain a sample of more than 10 000 respondents. As the household is the sample unit and maximal 4 individual 
respondents per household are selected for the HIS, the net response may exceed the original sample size.
 (2)   Additional sample of 1 536 16- to 24-year-olds, response rate for the young boost was 72 %.
 (3)   Additional sample of 1 491 16- to 24-year-olds, response rate for the young boost was 75 %.
 (4)   Additional sample of 2 332 16- to 24-year-olds, response rate for the young boost was 72 %.
 (5)   Additional sample of 2 653 16- to 24-year-olds, response rate for the young boost was 74 %.
 (6)  Additional sample of 2 259 16- to 24-year-olds, response rate for the young boost was 69 %.
 (7)  Additional sample of 2 089 16- to 24-year-olds, response rate for the young boost was 75 %.
 (8)  Valid gross sample size is not available. Field work agency did not count frame errors.
 (9)   The drug questions in the self completion module were only asked of respondents aged 16–59; thus not everyone who participated in 
the survey completed this module.
(10)  Before 2003, the response rate was not well known.
(11)  One can consider that the original sample size is the same as the net sample, because with random route sampling it is not easy to know 
the frame errors.
n.a.: not known/not available.
not app.: not applicable.
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of living in the different countries must be borne in 
mind. For instance, wages in Hungary or Romania 
are undoubtedly much lower than in Belgium. 
Therefore, as personnel costs are a substantial part of 
the cost of a survey, especially face-to-face surveys, 
the absolute figures may be misleading. It may be 
more effective to establish what percentage of the 
total national research budget is spent on drug 
research. Of course, this is beyond the scope of this 
meta-analysis.
Comparing surveys from different countries may 
therefore be difficult. However, one constant element to 
emerge from this meta-analysis is that data collection is 
not only a very expensive phase in the survey process 
(Table 24), but also requires a large number of staff 
(Table 25). 
The EMCDDA 2007 and 2008 national abstracts 
(EMCDDA, 2007; EMCDDA 2008b) show that several 
countries consider the funding of the survey to be a 
serious concern (Bulgaria, the Czech Republic, Italy, 
Malta, Greece, and Austria respectively). This comes 
as no surprise, as general population surveys are 
expensive and repetitive surveys require sustained 
funding. As our expert survey shows, this sometimes 
leads to restrictions on the length of the questionnaire 
and the sample size (Netherlands, Norway and 
Romania).
About the finances there is a more general consensus. 
Almost every population survey was funded by the 
national or the regional government. Academic 
institutions and private or commercial enterprises 
hardly play any financial part. 
We reviewed the financial sources and the timetable 
of the European general population surveys (Tables 
23, 24 and 25). Most of the (technical) reports in the 
surveys contained no financial data and only limited 
time data. Neither are these aspects assessed by the 
EMCDDA. It was thus difficult to collect sufficient 
information, and in the expert survey additional 
information was requested. As this information can be 
very detailed and of a sensitive nature, we only asked 
for the financial data of the most recent survey we 
studied and we left the experts free not to reveal the 
exact financial information in this report (27). As ‘time’ 
and ‘money’ are interrelated, the analysis of the 
timetable was also restricted to that same survey. 
4.1 Financial sources
Table 23 gives an overview of the financial resources 
of the surveys. Most of this information had to be 
requested by our expert survey. Somehow, finances 
remain a taboo topic. Many countries asked not to 
release their financial information in this meta-analysis 
or simply did not reply to the financial questions. 
Drawing conclusions is therefore not easy.
Information about the survey method and the 
(standardised) sample size is crucial when the size of 
a survey budget is evaluated. A face-to-face survey 
with a large sample size is generally more expensive 
than a mail survey with an equally large sample size. 
However, our meta-analysis does not reveal any clear 
relationship between sample size and sample method 
on the one hand, and the survey budget on the other. 
Furthermore, when comparing budgets, the standard 
Chapter 4
Financial focus and timetable
(27) See questionnaire expert survey at http://www.emcdda.europa.eu/publications/thematic-papers/gps/questionnaire
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Table 23: Financial sources
Country Year
Financer Budget (EUR)
Type Name Type Amount
Austria 2004 G-N 
G-R
Ministry of Health and Women 
Local government of Carinthia
- -
Belgium 2008 G Federal authorities, Flemish Community, 
French Community, Walloon Region, 
Brussels Capital Region
G 1 414 266
Bulgaria 2005 n.a. n.a. n.a. n.a.
Croatia 2009 
(expected)
- - - -
Cyprus 2006 G-N Cyprus Antidrugs Council 
(Ministry of Health)
G-N 50 000
Czech 
Republic
2004 G-N Office of the Government of the Czech 
Republic, within the budgetary chapter on 
Expenses on Drug Policy
G-N 38 800 
(only field data collection 
and data entry into a 
database, 
other costs are n/a)
Denmark 2005 G-N The National Institute of Public Health, 
University of Southern Denmark and the 
Ministry of Welfare
-
2008 G-N National Board of Health -
England and 
Wales
2006/7 G-N Home Office - -
Estonia 2003 n.a. n.a. n.a. n.a.
Finland 2006 G-N STAKES n.a. n.a.
France 2005 A National Institute for Prevention and Health 
Education INPES (public funds)
G-N 870 000 (for the fieldwork)
Germany 2003 n.a. n.a. n.a. n.a.
Greece 2004 n.a. n.a. n.a. n.a.
Hungary 2003 G 
G
National Research and Development Project 
Ministry of Youth and Sport
58 000
Ireland 2006/7 - - - (2002/3: ca 650 000 )
Italy 2005 G-N Presidenza del Consiglio dei Ministri and 
National Research Council
G-N 300 000
Latvia 2003 n.a. n.a. n.a. n.a.
Lithuania 2004 - - - -
Malta 2001 n.a. n.a. n.a. n.a.
Netherlands 2005 G-N Ministry of Health, Welfare and Sports G-N 330 000
Norway 2004 G-N 
 
G-N 
 
SIRUS 
 
State Alcohol Monopoly (Vinmonopolet, a 
government institution, under the same 
department as SIRUS)
SIRUS: 100 000 (excl. VAT) 
for fieldwork 
Vinmonopolet: ca 100 000 
 
Poland 2002 n.a. n.a. n.a. n.a.
Portugal 2001 n.a. n.a. n.a. n.a.
Romania 2004 G 
O
Government 
The Global Found Project in Romania
O 30 000
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Country Year
Financer Budget (EUR)
Type Name Type Amount
Scotland 2006 n.a. n.a. n.a. n.a.
Slovakia 2006 - - - -
Spain 2005 G-N Government Office for the National Plan on 
Drugs
G-N 
G-R
691 500  
81 154 
Sweden 2006 G Swedish National Institute of Public Health - -
NB:
Type of financer:  
G-N: Government, national level
G-R: Government, regional level
A: Academic institution
P: Private/commercial company
O: Other 
n.a.: not available/do not know.
-: no reply given, reply not to be released in this report.
Table 23 continued
Table 24: Average costs per activity in EUR
Country Year Data collection One single interview Data analysis and data set Whole study
Austria 2004 - - - -
Belgium 2004 631 103 n.a. 278 077 n.a.
Bulgaria 2005 n.a. n.a. n.a. n.a.
Croatia 2009 (expected) 40 000–80 000 - - -
Cyprus 2006 - - - 49 123
Czech Republic 2004 38 800 n.a. n.a. n.a.
Denmark 2005 - n.a. n.a. n.a.
2008 - - - -
England and Wales 2006/7 - - - -
Estonia 2003 n.a. n.a. n.a. n.a.
Finland 2006 - - - -
France 2005 870 000 30 n.a. n.a.
Germany 2003 n.a. n.a. n.a. n.a.
Greece 2004 n.a. n.a. n.a. n.a.
Hungary 2003 44 000 12 8 000 ca 60 000
Ireland 2006/7 - - - -
Italy 2005 200 000 2.5 100 000 300 000
Latvia 2003 n.a. n.a. n.a. n.a.
Lithuania 2004 - - - -
Malta 2001 n.a. n.a. n.a. n.a.
Netherlands 2005 134 000  
(66 000 CAPI, 
62 000 online and 
6 000 miscellaneous)
22 180 000 315 000
Norway 2004 ca 200 000 ca 63 n.a. n.a.
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Country Year Data collection One single interview Data analysis and data set Whole study
Poland 2002 n.a. n.a. n.a. n.a.
Portugal 2001 n.a. n.a. n.a. n.a.
Romania 2004 - - - -
Scotland 2006 n.a. n.a. n.a. n.a.
Slovakia 2006 - - - -
Spain 2005 n.a. 27.66 n.a. n.a.
Sweden 2006 - - - -
NB:
n.a.: not known/not available.
-: no reply given, reply not to be integrated in the report.
Table 24 continued
Table 25: Average staff requirements 
Country Year
Senior researchers Junior researchers Interviewers Other (secretary, etc.)
FTE Time (months) FTE
Time 
(months) FTE
Time 
(months) FTE
Time 
(months)
Austria 2004 1 6 0 0 512 - 0 0
Belgium 2008 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Bulgaria 2005 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Croatia 2009 (expected) - - - - - - - -
Cyprus 2006 1 2 3 1/2 31 2 (1) 1 1
Czech Republic 2004 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Denmark 2005 3 27 (1) 4 30 (1) 175 n.k. 1 3
2008 n.a. - n.a. - 0 0 n.a. -
England and Wales 2006/7 - - - - - - - -
Estonia 2003 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Finland 2006 2 4 0 0 - - 1 2
France 2005 25 2 15 4 150 5 1 3
Germany 2003 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Greece 2004 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Hungary 2003 1 18 1 8 285 1,5 2 5
Ireland 2006/7 - - - - - - - -
Italy 2005 2 12 3 12 - - 10 12
Latvia 2003 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Lithuania 2004 - - - - - - - -
Malta 2001 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Netherlands 2005 0.2 
0.8 
0.1 
0.2
10 
9 
10 
9
0 not app. - - 0.1 
0.1 
0.05
10 
9 
9
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Country Year
Senior researchers Junior researchers Interviewers Other (secretary, etc.)
FTE Time (months) FTE
Time 
(months) FTE
Time 
(months) FTE
Time 
(months)
Norway 2004 n.a. n.a. n.a. n.a. n.a. 1 n.a. n.a.
Poland 2002 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Portugal 2001 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Romania 2004 - - - - - - - -
Scotland 2006 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Slovakia 2006 - - - - - - - -
Spain 2005 0.2 12 0.5 12 n.a. 5 0.2 12
Sweden 2006 - - - - - - - -
NB:
(1) Time period the entire research staff worked on it.
n.a.: not known/not available.
not app: not applicable.
-: no reply given, reply not to be released in the report.
Table 25 continued
4.2 Timetable
Although data gathering is an important element in 
the timetable of a survey, other elements such as 
instrument development, sampling and selecting, 
training or supervising staff, must also be taken into 
consideration. As inquiring about all of these elements 
separately was too detailed for our expert survey, we 
confined ourselves to the time scope of the entire 
survey, the duration of the data gathering and the 
average duration of the administration of one 
questionnaire (Table 26). 
There proves to be much variation between the time 
scope of the various surveys: from a half year 
(Slovakia) to two years (Ireland). As a result, some 
studies were at variance with the WHO 
recommendation for completing a survey within about 
one year. 
The data collection period mainly depends on the 
interviewing mode and the sample size. Face-to-face 
surveys require a longer data collection period than 
mail surveys. This is certainly the case with large 
sample sizes. Most of the studies in this meta-analysis 
are face-to-face administered, a very time consuming 
method. The sample size, on the other hand, is more 
varied (Table 26). For example, in the 2005 French 
study, data of a sample of roughly 102 000 
respondents were gathered in about four months. 
Whereas in the 2004 Scottish study, only about 
8 500 respondents were questioned over the same 
time period. However, the data in France were 
gathered by telephone and in Scotland through 
face-to-face interviews. But even when the same 
survey method is applied, the data collection period 
may fluctuate significantly. For instance, in the Scottish 
studies only about half as many respondents were 
questioned as in the 2002/3 Irish survey, even though 
the data were gathered in about the same time 
period and with the same survey method (face-to-face 
interview). Of course, various other factors (e.g. the 
number of interviewers and the length of the 
questionnaire) have an impact on the length of the 
data collection period.
In the literature it is found that in holiday periods the 
respondents’ drug use may be untypical and their 
willingness to cooperate may also be lower. This may 
also influence the validity of the data, although this 
may be offset by (nearly) continuous data gathering, 
as in the United Kingdom (England and Wales) and 
Belgium, or by interrupting the data collection during 
holiday periods. In Spain, for example, the data were 
collected between November 2005 and April 2006, 
but no surveys were administered in January, to avoid 
any influence a holiday season might have on the drug 
consumption in the past 30 days. 
The average duration of the administration of one 
questionnaire depends on the interviewing mode and 
its length. However, the general rule is ‘the shorter, the 
better’, as a lengthy questionnaire may have a 
negative impact on both the response rate and the 
Drug use: an overview of general population surveys in Europe
92
As for the timetable findings in our expert survey, some 
final remarks must be made. As with the report on 
response rates, the concepts of ‘whole survey’, ‘data 
collection period’ and ‘average duration of one 
questionnaire’ may have been interpreted differently by 
the different experts. To allow us to draw any 
conclusions, this should perhaps have been examined in 
more detail in our expert survey. Moreover, when the 
study is conducted for the first time, the preparation of 
the survey (defining target population, selecting sampling 
frame, sampling method and data collection method, 
etc.) and conceivably even data collection and data 
analysis will take more time than in a practised survey.
quality of the answers. For example, in the French 
expert survey it is mentioned that the duration of the 
questionnaire (45’ for the fixed phone survey and 20’ 
for the mobile phone survey) is very long for a 
telephone interview. This is confirmed by Amelia 
Roman, researcher at the Institute for Labour Studies of 
Tilburg University. She argues that similar lengthy 
telephone surveys are not possible in the Netherlands, 
because people drop out. The Norwegian experts 
mention that the length of the questionnaire was 
adapted to the capabilities of the respondents (and 
thus mainly to obtain higher response rates) but also to 
reduce costs. 
Table 26: Timetable
Country Year Time scope whole study Duration data collection Average duration one questionnaire
Austria 2004 24 months 
(January 2004  
December 2005)
2 July  19 October 2004 60’
Belgium 2008 48 months 12 months n.a.
Bulgaria 2005 n.a. n.a. n.a.
Croatia 2009 (expected) not app. not app. not app.
Cyprus 2006 9–10 months 2–3 months 20’
Czech Republic 2004 12 months 2 weeks n.a.
Denmark 2005 36 months 12 months 50’ face-to-face 
25’ self-administered
2008 12 months 2 months 12’
England and 
Wales
2006/7 - April 2006  March 2007 50’  
(44’ non-victim, 66’ 
victim)
Estonia 2003 n.a. n.a. n.a.
Finland 2006 - September–October -
France 2005 36 months 4 months 
(14 October 2004   
12 February 2005)
45’ fixed phone survey 
20’ mobile phone 
survey
Germany 2003 n.a. n.a. n.a.
Greece 2004 n.a. n.a. n.a.
Hungary 2003 18 months 1.5 months 69’
Ireland 2006/7 24 months 8 months -
Italy 2005 24 12 20’
Latvia 2003 n.a. n.a. n.a.
Lithuania 2004 - 1 month 
(19 November–3 
December)
40’
Malta 2001 n.a. n.a. n.a.
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Country Year Time scope whole study Duration data collection Average duration one questionnaire
Netherlands 2005 20 months 6 months n.a.
Norway 2004 Unlimited About 1 month n.a.
Poland 2002 n.a. n.a. n.a.
Portugal 2001 n.a. n.a. n.a.
Romania 2004 12 months 2 months 60’ with abuse history, 
32’ without abuse 
history
Scotland 2006 n.a. June  December 2006 n.a.
Slovakia 2006 6 months 1 month 90’
Spain 2005 12 months 3–5 months 
(November 2005  April 
2006)
45’
Sweden 2006 9 months  
(January  September)
5 months 
(March  June)
-
NB:
n.a.: not known/not available.
not app.: not applicable.
-: no reply given.
Table 26 continued
94
or presented at international conferences. Clearly, all 
countries have made efforts to improve the 
accessibility of the survey report(s).
The fact remains, however, that the acquisition of 
legible survey reports (translations or summaries) for 
our meta-analysis has proven to be a time consuming 
and sometimes frustrating process, which caused some 
delay in the meta-analysis. It is also clear that the 
survey reports are hardly accessible to the wider 
public. To improve the valorisation of data, it is 
recommended to report in a common international 
language, e.g. English. It is striking that countries such 
as Italy, Austria and Spain fail to publish their results in 
English, in contrast with some new European Member 
States (e.g. Latvia, Hungary and Romania). 
5.1.2 Content
The EMCDDA guidelines recommend that the survey 
report must be clear about the topic and objectives of 
the research, the methods used, the research findings, 
and its (policy) recommendations. However, the 
survey reports of the different countries vary widely. 
Most reports give a proper and clear description of 
the study design (objectives of the survey, sampling 
design, non-response data, etc.) and the drug 
prevalence data. In some cases references, contact 
details of the experts, or a copy of the original 
questionnaire(s) are added (e.g. Ireland, Hungary, 
Scotland, England and Wales). As mentioned above, 
a detailed survey report is sometimes available only 
in the national language, with the consequence that 
non-native speakers have to resort to the summaries 
of the survey reports (e.g. Malta). On the other hand, 
some countries present elaborate research reports. 
Findings from the drug part of the British Crime 
Survey, for example, are published in a separate 
report and even contained a statistical bulletin. The 
Irish population survey on drug use publishes not only 
several bulletins with findings, but also an extensive 
The distribution of documentation about the fieldwork 
and the data on the one hand and the original data 
set on the other, is necessary to valorise the results. In 
this respect, data must be easily available and 
accessible to interested people (e.g. researchers, 
companies, general public). The meta-analysis of 
existing general population surveys and the expert 
questionnaire enabled us to evaluate the degree of 
accessibility to all survey data (Table 27).
5.1  Accessibility of the fieldwork and 
data documentation
5.1.1 Publication form and language
To collect the information for our meta-analysis, we 
first used the Internet to look up the survey reports of 
the population surveys. Detailed reports on the drug 
situation on the national level, compiled by each 
Reitox focal point, have been available on the 
EMCDDA website since 2000 (28). These reports 
describe the new developments, trends and in-depth 
information on selected drug issues, and present 
summary accounts of drug use in the general 
populations. This made it easy for us to find the 
references of the most relevant studies. However, it 
remained hard to find (legible) national prevalence 
studies on drug use. Many websites and survey 
reports are available in the native language only. 
Conversely, when the website (and the report) was 
available in English, it was usually confined to the 
general results. The technical reports and the original 
questionnaire were hardly accessible. When the 
report was not available in English and when the 
technical report or questionnaire was not obtainable, 
the national expert was contacted. Many experts 
responded positively and sent us the requested 
information, if available. Further, some survey reports 
have been published in a book or in scientific articles, 
Chapter 5
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In the first case, access to the full data set is restricted. 
For example, the data of the Belgian HIS can be 
consulted by the general public via an interactive 
web-based application on the following website: 
http://www.iph.fgov.be/EPIDEMIO/hisia/index.htm. 
The application does not require any knowledge of the 
statistical package, and interested users have access 
after simple registration. The data cover the three 
tied-up Belgian Health surveys (1997, 2001 and 
2004). However, only limited descriptive analyses can 
be made and any analysis is restricted to a number of 
indicators (prevalence, frequency, age of onset, etc.), 
distributed by several parameters (geographical level, 
gender, age, level of education, etc.). The user can 
directly generate tables, figures or graphs online for 
different variables. On the other hand, several 
countries in our meta-analysis make the data set 
available for analysis on micro/individual level. Table 
27 gives an overview of several features of the data 
sets. As this information was acquired by our expert 
survey itself, only those countries that cooperated are 
represented in the table. 
In Belgium, Denmark, France, Italy, Norway, Spain and 
Sweden data sets are released by the drug researchers 
themselves, while in England and Wales they are 
distributed by an archive. The data are mostly provided 
in well known formats, such as SPSS or SAS. Other 
formats are STAT and ASCII (Belgium). Most academics 
and students have access (1) after signing an agreement 
with some standard conditions for using data sets and 
their documentation, (2) after signing an agreement with 
specific conditions set out by the depositor or (3) after 
obtaining a written permission from the depositor. 
Except for academics, ministerial officers, and students, 
access is usually not free. In most cases the users of the 
data sets are obliged to specify their use of the data 
and to mention the original source of the data set in 
their publications. All data sets guarantee the privacy of 
the respondents, for instance, by not entering names 
and addresses in the database.
technical report including methodological aspects of 
the survey design, instructions for the interviewer and 
the questionnaire. 
5.1.3 Time
Another problem that may have a negative impact on 
accessibility is the distribution of the documentation 
long after finishing the study. Some countries do not 
manage to finish the survey report in a short period of 
time (e.g. France, Ireland, the Czech Republic). Results 
of the French and Irish survey were not published until 
two years after finishing the study. The publication of 
the Czech survey results took about 18 months. Most 
countries publish the survey report within one year 
after finishing the survey: Austria (1 year), Norway (8 
months), Denmark (9 months), Spain (6–10 months), 
Italy (6 months), Cyprus (2–3 months), etc. 
Of course, the whole time scope of the survey must be 
taken into consideration. A survey report may be 
published in a reasonable time period after finishing 
the data analysis, but the survey preparation or the 
fieldwork each may have taken more than a year.
5.2 Accessibility of data set
The availability of original data gives a surplus value to 
scientific research. However, our expert survey shows 
that many countries, including Austria, Cyprus, 
Hungary and the Netherlands, do not release the data 
set to interested people other than the data managers 
themselves. Sometimes access is restricted to the 
national focal point and the EMCDDA (Ireland and 
Romania). Other countries give more open access to 
the data set. 
The released data sets can be explored or analysed on 
an aggregate level (data can be analysed for both 
sexes, different social classes, etc.) or on micro/
individual level (data can be analysed for every single 
respondent). 
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EMQ and thus possess a long survey tradition, they 
do not wish to interrupt this in any major way. The 
extent of compatibility with the European Model 
Questionnaire also depends on the survey context. 
Many surveys that include their questions on drug use 
in a crime and health survey only include a limited 
number of items, due to space limitations. In general, 
we may conclude that the number of questions and 
the number of items vary widely among the countries. 
Furthermore, declining and low response rates 
sometimes force the countries to modify their survey 
design so that comparability with previous surveys on 
the one hand and those of other countries on the 
other decreases. The same is true when difficulties 
with (repetitive) funding occur. Face-to-face surveys 
are known to be a very costly data collection method. 
Finally, differences in the interpretation of concepts 
discussed in this meta-analysis — and thus also the 
report on those concepts — (response rate, sampling 
design, etc.) may hamper the comparability of 
European surveys. Therefore, a standardisation of the 
report on at least the intrinsic and methodological 
information would be helpful. 
Many countries decided to follow the intrinsic and 
methodological EMCDDA guidelines in order to 
improve the cross-national comparability. Most 
countries (e.g. Lithuania, Austria, France, Cyprus, 
Finland, Denmark, the Czech Republic, Spain, and 
Hungary) describe their national population survey(s) 
as highly compatible with the European Model 
Questionnaire. However, in many cases additional 
items (lifestyle attributes, age of onset, etc.) are 
included because of extended information needs. 
Most of these countries aim to obtain comparative 
data through other surveys (Health surveys, ESPAD 
surveys, etc.) carried out in their country. The wording 
of some questions and the spectrum of drugs is 
frequently based on these surveys. In particular, the 
ESPAD surveys serve as an important source of 
information on the use of new drugs. Besides, in some 
countries (e.g. Italy, Norway, Finland), the 
commissioner of the national population survey on 
drug use is also responsible for the national ESPAD 
survey. Some surveys describe themselves as 
moderately comparable with the EMQ (e.g. England 
and Wales). As most of these surveys pre-date the 
Conclusion
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